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Melina Dritsaki ,1 Lucy Cureton ,2 Susan J Dutton ,1 Helen Dakin ,3
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1Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and
Musculoskeletal Sciences, University of Oxford, Oxford, UK
2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of
Oxford, Oxford, UK
3Nuffield Department of Population Health, University of Oxford, Oxford, UK
4College of Medicine and Health, University of Exeter, Exeter, UK
5Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK
6Manchester Metropolitan University, Manchester, UK
*Corresponding author sally.hopewell@csm.ox.ac.uk
Background: Rotator cuff-related shoulder pain is very common, but there is uncertainty regarding
which modes of exercise delivery are optimal and the long-term benefits of corticosteroid injections.
Objectives: To assess the clinical effectiveness and cost-effectiveness of progressive exercise
compared with best-practice physiotherapy advice, with or without corticosteroid injection, in adults
with a rotator cuff disorder.
Design: This was a pragmatic multicentre superiority randomised controlled trial (with a 2 × 2
factorial design).
Setting: Twenty NHS primary care-based musculoskeletal and related physiotherapy services.
Participants: Adults aged ≥ 18 years with a new episode of rotator cuff-related shoulder pain in the
previous 6 months.
Interventions: A total of 708 participants were randomised (March 2017–May 2019) by a centralised
computer-generated 1 : 1 : 1 : 1 allocation ratio to one of four interventions: (1) progressive exercise
(n= 174) (six or fewer physiotherapy sessions), (2) best-practice advice (n = 174) (one physiotherapy
session), (3) corticosteroid injection then progressive exercise (n = 182) (six or fewer physiotherapy
sessions) or (4) corticosteroid injection then best-practice advice (n = 178) (one physiotherapy session).
Main outcome measures: The primary outcome was Shoulder Pain and Disability Index (SPADI) score over
12 months. Secondary outcomes included SPADI subdomains, the EuroQol 5 Dimensions, five-level version,
sleep disturbance, fear avoidance, pain self-efficacy, return to activity, Global Impression of Treatment and
health resource use. Outcomes were collected by postal questionnaires at 8 weeks and at 6 and 12 months.
A within-trial economic evaluation was also conducted.The primary analysis was intention to treat.
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Results: Participants had a mean age of 55.5 (standard deviation 13.1) years and 49.3% were female.
The mean baseline SPADI score was 54.1 (standard deviation 18.5). Follow-up rates were 91% at
8 weeks and 87% at 6 and 12 months. There was an overall improvement in SPADI score from baseline
in each group over time. Over 12 months, there was no evidence of a difference in the SPADI scores
between the progressive exercise intervention and the best-practice advice intervention in shoulder
pain and function (adjusted mean difference between groups over 12 months –0.66, 99% confidence
interval –4.52 to 3.20). There was also no difference in SPADI scores between the progressive exercise
intervention and best-practice advice intervention when analysed at the 8-week and 6- and 12-month
time points. Injection resulted in improvement in shoulder pain and function at 8 weeks compared with
no injection (adjusted mean difference –5.64, 99% confidence interval –9.93 to –1.35), but not when
analysed over 12 months (adjusted mean difference –1.11, 99% confidence interval –4.47 to 2.26), or
at 6 and 12 months. There were no serious adverse events. In the base-case analysis, adding injection
to best-practice advice gained 0.021 quality-adjusted life-years (p = 0.184) and increased the cost by
£10 per participant (p = 0.747). Progressive exercise alone was £52 (p = 0.247) more expensive per
participant than best-practice advice, and gained 0.019 QALYs (p = 0.220). At a ceiling ratio of £20,000
per quality-adjusted life-year, injection plus best-practice advice had a 54.93% probability of being the
most cost-effective treatment.
Limitations: Participants and physiotherapists were not blinded to group allocation. Twelve-month
follow-up may be insufficient for identifying all safety concerns.
Conclusions: Progressive exercise was not superior to a best-practice advice session with a physiotherapist.
Subacromial corticosteroid injection improved shoulder pain and function, but provided only modest
short-term benefit. Best-practice advice in combination with corticosteroid injection was expected to
be most cost-effective, although there was substantial uncertainty.
Future work: Longer-term follow-up, including any serious adverse effects of corticosteroid injection.
Trial registration: Current Controlled Trials ISRCTN16539266 and EudraCT 2016-002991-28.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 48. See the NIHR Journals Library website for further project information.
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The rotator cuff is a group of muscles and tendons that stabilise the shoulder and allow it to move.Problems with the rotator cuff are very common. Symptoms include pain, which can affect a
person’s ability to work, sleep well or perform daily tasks. It is not known which treatments work best
for shoulder pain, how exactly they should be delivered and whether or not people do better if they
are given a steroid injection.
The GRASP (Getting it Right: Addressing Shoulder Pain) trial tested whether or not people with a rotator
cuff disorder would do better after a progressive exercise programme (supervised by a physiotherapist
over six appointments spread out over 16 weeks) compared with a one-off best-practice advice session
with a physiotherapist. The trial also tested whether or not giving a corticosteroid injection in the
shoulder before starting either regime would help people recover more. We assessed the cost of
delivering these treatments to the NHS.
We recruited 708 people from 20 NHS-based musculoskeletal centres in the UK. People were allocated
to one of four treatment groups at random: (1) progressive exercise (six or fewer physiotherapy sessions),
(2) best-practice advice (one physiotherapy session), (3) corticosteroid injection then progressive
exercise (six or fewer physiotherapy sessions) or (4) corticosteroid injection then best-practice advice
(one physiotherapy session). Trial participants were asked to complete a questionnaire that asked about
their level of shoulder pain and their ability to perform basic daily tasks before treatment, and then
again at 8 weeks and at 6 and 12 months.
Participants’ shoulder pain and function improved over time in each of the four treatment groups.
The GRASP trial showed that there was no difference between the best-practice advice session with a
physiotherapist and the more comprehensive exercise programme. Corticosteroid injection improved
people’s shoulder pain and function, but only by a small amount and in the short term. No serious side
effects were observed during the 12-month follow-up period. Best-practice advice in combination with
corticosteroid injection is likely to be most cost-effective to the NHS.
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Shoulder pain is very common, with around 70% of cases due to rotator cuff-related shoulder pain.
Despite the widespread use of physiotherapy, there is uncertainty regarding which type of exercise
therapy is associated with the best outcomes. There is also uncertainty about the long-term benefits
and harms of corticosteroid injection therapy, which is often used in addition to physiotherapy.
Objectives
The GRASP (Getting it Right: Addressing Shoulder Pain) trial assessed (1) if an individually tailored
progressive home exercise programme prescribed and supervised by a physiotherapist provided
greater improvement in shoulder pain and function over 12 months compared with a best-practice
advice session with a physiotherapist supported by high-quality self-management materials; and (2) if
subacromial corticosteroid injection provided greater improvement in shoulder pain and function over
12 months compared with no injection.
Methods
Design
This was a pragmatic multicentre superiority randomised controlled trial using a 2 × 2 factorial design.
Participants and physiotherapists were not blinded to group allocation.
Setting
Participants were recruited from 20 NHS primary care-based musculoskeletal and related
physiotherapy services.
Participants
Adults aged ≥ 18 years with a new episode of shoulder pain (i.e. in the previous 6 months) attributable
to a rotator cuff disorder (e.g. cuff tendonitis, impingement syndrome, tendinopathy or rotator cuff
tear), as per British Elbow & Shoulder Society guidelines, not currently receiving physiotherapy or
being considered for surgery.
Interventions
Participants (n = 708) were randomised (March 2017–May 2019) using a centralised computer-
generated 1 : 1 : 1 : 1 allocation ratio to one of four interventions: (1) progressive exercise (n = 174)
(six or fewer physiotherapy sessions), (2) best-practice advice (n = 174) (one physiotherapy session),
(3) corticosteroid injection then progressive exercise (n = 182) (six or fewer physiotherapy sessions)
or (4) corticosteroid injection then best-practice advice (n = 178) (one physiotherapy session).
Participants randomised to the progressive exercise intervention received up to six individual face-to-face
sessions with a physiotherapist over 16 weeks. Participants were provided with a folder containing an
advice booklet, an exercise action planner and diary, and instructions on their exercise programme,
which was set up in collaboration with their physiotherapist. A resistance band was issued as required.
The progressive exercise programme was highly structured, but could be tailored to the needs and
preferences of participants.
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Participants randomised to the best-practice advice intervention received a single individual face-to-face
session with a physiotherapist. Participants were given an advice booklet. The content of the advice in
the booklet was the same as that provided for the progressive exercise group, with the exception of a
different exercise programme. Participants were given a simple set of self-guided exercises, at least one
level of resistance band and access to an exercise video (available on a website and a digital versatile
disc), which could be progressed and regressed, depending on their capability. The exercises were
designed using similar concepts to the progressive exercise intervention, such as increased resistance,
but these were a simpler range. An exercise diary was provided in addition to an exercise action planner
that was simpler than the one provided to those in the progressive exercise group.
Follow-up
Measurements for the primary and secondary outcomes were collected by postal questionnaires at
8 weeks and at 6 and 12 months after randomisation. Telephone follow-up was used to contact those
who did not respond or fully complete the returned questionnaire.
Clinical outcomes and analysis
The primary outcome was the mean difference in Shoulder Pain and Disability Index (SPADI) total score
over 12 months. The scale is from 0 to 100, with higher values representing worse pain. Secondary
outcomes were the pain and function SPADI subdomains, health-related quality of life (assessed using
the EuroQol-5 Dimensions, five-level version), sleep disturbance, fear avoidance, pain self-efficacy,
return to activity, global impression of treatment, health resource use, out-of-pocket expenses and
work disability. Prespecified subgroup analyses included age, sex, smoking status, higher baseline
SPADI score (≥ 50) and higher baseline pain self-efficacy score (≥ 8). The planned sample size was 704
participants, assuming 20% loss to follow-up at 12 months, and based on 90% power and 1% two-sided
statistical significance to detect a minimally clinically important difference of eight points on the SPADI
total scale. The primary analysis was intention to treat. The two main effect comparisons for this
2 × 2 factorial trial were (1) progressive exercise compared with best-practice advice to determine the
efficacy of progressive exercise and (2) subacromial corticosteroid injection compared with no injection
to determine the efficacy of subacromial corticosteroid injection. The presence of an interaction effect was
formally investigated before testing their effects on the primary outcome. The difference in SPADI score
between the two intervention groups was estimated overall and at each data collection time point using a
repeated measures linear mixed-effects regression model adjusted for baseline and other covariates.
Economic analysis
The cost–utility of interventions was evaluated from an NHS and Personal Social Services perspective,
using a within-trial intention-to-treat analysis. Quality-adjusted life-years were estimated from data
collected from the EuroQol-5 Dimensions, five-level version, at baseline, 8 weeks and 6 and
12 months. Costs were estimated for each participant over 12 months of follow-up based on patient-
reported use of health-care services attributable to their rotator cuff disorder. The cost of delivering
each intervention, including physiotherapists’ training, materials, delivery of the progressive exercise
and advice sessions, and corticosteroid injections, was also estimated.
Results
The mean age of participants was 55.5 (standard deviation 13.1) years, 49.3% of participants were
female and the mean duration of symptoms was 4 (interquartile range 3–6) months. Intervention groups
were well matched in terms of demographic data and clinical and generic health-related quality-of-life
measures. Overall, 92% (324/352) of participants randomised to the best-practice advice intervention
and 95% (339/356) of participants allocated to progressive exercise either partially or fully completed
the intervention. High levels of protocol adherence were achieved across all intervention groups.
Follow-up data were obtained for 87% (618/708), 87% (615/708) and 91% (641/708) of participants
at 12 months, 6 months and 8 weeks, respectively.
SCIENTIFIC SUMMARY
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The overall mean baseline SPADI score was 54.1 (standard deviation 18.5), with higher baseline levels of
shoulder pain (mean SPADI pain subscale score 63.9; standard deviation 17.1) than impaired function
(mean SPADI function subscale score 44.3; standard deviation 22.1). There was an overall improvement in
SPADI score in each of the four groups from baseline over time, representing a 32.2-point improvement
(standard deviation 23.9 points) on the SPADI scale [with a SPADI score of 21.9 (standard deviation 23.4)
at 12 months]. There was no evidence of an interaction effect and so results were analysed for the two
main effect comparisons.
Clinical results
Over 12 months, there was no evidence of a difference in the SPADI scores between the progressive
exercise intervention and best-practice advice intervention (adjusted mean difference between groups
over 12 months –0.66, 99% confidence interval –4.52 to 3.20); nor was there evidence of a difference
when analysed at the 8-week and 6- and 12-month time points (adjusted mean difference at 12 months
–3.10, 99% confidence interval –7.85 to 1.64). There was also no difference between groups for secondary
outcome measures, with the exception of progressive exercise, which resulted in an improvement in
patient-reported global impression of treatment over the 12 months (adjusted mean difference over
12 months 0.38, 95% confidence interval 0.10 to 0.66) and at the 6- and 12-month time points.
Over 12 months, there was also no evidence of a difference in SPADI scores between the injection
and the no injection groups (adjusted mean difference over 12 months –1.11, 99% confidence interval
–4.47 to 2.26). There was a small difference in SPADI scores at 8 weeks (adjusted mean difference at
8 weeks –5.64, 99% confidence interval –9.93 to –1.35) in favour of the injection group, but not at the
6- and 12-month time points (adjusted mean difference at 12 months 1.93, 99% confidence interval
–2.41 to 6.27). There was no difference between groups for secondary outcome measures, with the
exception of the injection group at 8 weeks, which resulted in a small improvement in shoulder pain,
shoulder function, sleep disturbance, return to desired activities and global impression of treatment.
Prespecified subgroup analysis showed that the effect of injection was stronger at 8 weeks in people
with a higher baseline SPADI score (adjusted mean difference at 8 weeks –9.67, 99% confidence
interval –15.37 to –3.97) than in those who received injections but had a lower baseline SPADI score
(adjusted mean difference at 8 weeks –0.36, 99% confidence interval –8.87 to 6.16). No differences
were observed for other prespecified subgroup analyses. No serious adverse events were associated
with treatment interventions.
Economics results
The base-case cost-effectiveness analysis showed that, over the 12-month period, participants in the
best-practice advice treatment group gained, on average, 0.74 quality-adjusted life-years (95% confidence
interval 0.710 to 0.763) and an NHS cost of £195. Adding progressive exercise to best-practice advice
resulted in a gain of an additional 0.019 quality-adjusted life-years (p = 0.220), compared with best-practice
advice alone, at an additional cost of £52 (p = 0.247). Adding corticosteroid injection to best-practice
advice resulted in a gain of 0.021 quality-adjusted life-years (p = 0.184), compared with best-practice
advice alone, and increased the cost by £10 per participant (p = 0.747). At a £20,000 per quality-adjusted
life-year ceiling ratio, best-practice advice plus injection was found to have a 54.93% probability of being
best value for money of the four treatments evaluated in the trial. Best-practice advice plus injection cost
£475.59 per quality-adjusted life-year gained compared with best-practice advice alone, and strongly
dominated progressive exercise alone and progressive exercise plus injection, being less costly and
accruing more quality-adjusted life-years. Sensitivity analyses assuming additive effects, taking a societal
perspective and varying the cost of training physiotherapists, confirmed the base-case conclusion that
best-practice advice plus injection is expected to be best value for money at a ceiling ratio of £20,000 per
quality-adjusted life-year, although there was substantial uncertainty around this conclusion in all analyses.
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Conclusion
Implications for health care
The GRASP trial shows that the progressive exercise intervention was not superior to a best-practice
advice session with a physiotherapist. Subacromial corticosteroid injection improved shoulder pain
and function at 8 weeks, but provided modest short-term benefit only, with the greatest benefit being
in those with higher levels of pain and functional impairment. Best-practice advice in combination
with corticosteroid injection has a 54.93% probability of being the most cost-effective intervention
for the NHS.
Recommendations for research
There is a case to extend follow-up to assess long-term outcomes, as some participants still reported
ongoing pain and impaired shoulder function at 12 months. There is a need to better understand the
natural history of rotator cuff disorders, including whether symptoms resolve over an extended period or
persist in the longer term. Longer-term follow-up would also address concerns regarding later surgery
and corticosteroid injection, and potential long-term harm due to its possible effects on tendon structure.
Trial registration
This trial is registered as ISRCTN16539266 and EudraCT 2016-002991-28.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 48.
See the NIHR Journals Library website for further project information.
SCIENTIFIC SUMMARY





Shoulder pain is common. Annually, around 1% of adults aged > 45 years in primary care present
with a new episode of shoulder pain, accounting for 2.4% of all general practitioner (GP) consultations
in the UK.1 This is most commonly attributed to the rotator cuff, which causes around 70% of cases.2
The rotator cuff is a group of four muscles and their tendons/attachments. The rotator cuff actively
moves and stabilises the shoulder joint, enabling a wide range of efficient movements at the shoulder.
Disorders of the rotator cuff can be associated with substantial, persistent disability (e.g. being unable
to dress independently) and pain. Rotator cuff disorders can persist for long periods. Up to half of
those who present for treatment, particularly older people, continue to have pain and/or functional
disturbance for up to 2 years.3
The majority of shoulder pain is managed in primary care or in musculoskeletal interface services by
physiotherapists and GPs. Musculoskeletal interface services are led by specialist practitioners who
manage patients with musculoskeletal disorders through assessment, treatment, investigation and by
referring to appropriate health-care professionals. Musculoskeletal interface services aim to promote
more community-based management options for patients, rather than traditional hospital-based secondary
care, and provide a more efficient, cost-effective and sustainable model for dealing with high-volume
conditions. Treatments for rotator cuff disorders aim to improve pain and function. Standard primary
care options include rest, advice, analgesia, non-steroidal anti-inflammatory drugs, physiotherapy and
corticosteroid injections.4,5 However, usual care can be highly variable and there are no National
Institute for Health and Care Excellence (NICE) clinical guidelines.
A diagnostic algorithm2 has been developed as part of the NICE-accredited standards developed by
the British Elbow & Shoulder Society (BESS) and other professional bodies (e.g. the Royal College of
Surgeons, the Chartered Society of Physiotherapy and the British Orthopaedic Association) to confirm
when a diagnosis of rotator cuff disorder is highly likely, based on a patient’s history and simple shoulder
tests4 (see Appendix 1, Figure 13). The recommended tests have been selected with primary care application
in mind,6 although they do require a reasonable degree of clinical skill. Imaging is not recommended
in primary care because of the poor fit between structural change and symptomatic presentation.7
We have used the BESS algorithm (see Appendix 1, Figure 13) to define the entry criteria for the GRASP
(Getting it Right: Addressing Shoulder Pain) trial, thereby ensuring that the trial is consistent with
national guidance.
Explanation of rationale
Problems associated with rotator cuff disorders can seriously affect patient health and well-being.
The prevalence of shoulder complaints in the UK is estimated at around 14%,8 increasing with age1 and
highest in those aged ≥ 60 years. Shoulder problems are a significant cause of morbidity and disability
in the general population and have a significant socioeconomic burden, as they affect an individual’s
capacity to work and ability to perform daily tasks and social activities. They have a significant impact
on primary care services. The average cost per patient with a musculoskeletal condition in the NHS is
£461.13 per head per year,9 with wide geographical variability. The estimated cost to the UK economy
is £7.4B per year.
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The NHS currently invests considerable amounts of money in unproven therapies and corticosteroid
injections. One common treatment prescribed for rotator cuff disorders is corticosteroid injection,
which typically costs £47–332, depending on the mode of delivery (the cheapest of which is by a
physiotherapist without ultrasound guidance). In comparison, a set of six physiotherapy sessions costs
approximately £206 and an assessment and advice session costs £45 (see Chapter 5). It is important
for the NHS to develop cost-effective, pragmatic methods for dealing with high-volume conditions.
Rotator cuff disorders may be self-limiting if they are managed effectively in primary care, as patients
can regain function and pain can be reduced. However, the consequences of poor initial management
are an increased likelihood of recurrent or persistent problems in older age and the need for surgical
intervention.4
We planned to conduct a large, well-powered randomised controlled trial, using a factorial design, to
co-test two interventions commonly used in the management of rotator cuff disorders in primary care:
(1) progressive exercise delivered by a physiotherapist and (2) corticosteroid injection. We used a best-
practice advice session with a physiotherapist and no injection as the respective comparators. The
interventions tested used current patient pathways for people with a rotator cuff disorder. We wanted
to assess which of these interventions, or combination of interventions, are most clinically effective
and cost-effective for the NHS. The primary outcome for the trial is shoulder pain and function, which
is assessed using the well-validated Shoulder Pain and Disability Index (SPADI).10,11 The SPADI is a tool
that was developed to measure current shoulder pain and disability in an outpatient setting.
Choice of comparators
Exercise interventions
In designing the trial, we looked at existing evidence regarding the choice of comparator interventions.
There is promising evidence from small, short-term trials that physiotherapist-prescribed exercise
is effective.12–14 However, there is a lack of evidence regarding its long-term clinical effectiveness and
cost-effectiveness,12–14 despite the widespread provision of physiotherapy for these conditions. There is
also uncertainty about which types of exercise and delivery mechanisms (e.g. supervised or home based)
are associated with the best outcomes.12,13,15–17 This evidence is limited by problems in study design and
choice of comparators.13 There are also competing ideologies around which exercise programmes should
be considered to ensure a worthwhile trial. Resistance training to improve muscular strength, whether
supervised or home based, has been identified as a core component of exercise for rotator cuff disorders,
although there is no evidence that any specific programme is superior.18,19 Manipulation of the exercise
volume and intensity is achieved by varying the frequency, load, number of sets, repetitions and rest
intervals.20 A trial of strength training found that duration, specificity of exercises, progression criteria
and individualisation (i.e. adjusting the programme to suit each participant) were also important.21 We
did not consider other forms of physiotherapy-led interventions, such as electrotherapy, acupuncture,
soft tissue mobilisation, manipulation or stratified care, because of the lack of evidence of their efficacy.22,23
Little attention has been paid to the need for behavioural frameworks to enhance adherence to
advice and exercise programmes and to tackle pain beliefs and behaviour in this context.24 Non-adherence
to physiotherapy treatment is estimated to be up to 70%.25 In a large trial of exercise for lower back pain
that did not include a behavioural component to increase exercise adherence, only half of the participants
attended the minimum number of treatment sessions.26 Risk factors for low adherence include low levels
of physical activity, low self-efficacy, depression, anxiety, poor social support and greater perceived barriers
to exercise.24 Some of these risk factors are modifiable in the context of a physiotherapy intervention.
We have previous expertise in this area27 and planned to include a behavioural component as part of
the progressive exercise intervention.
INTRODUCTION
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Corticosteroid injection
There is systematic review evidence that, in comparison with placebo, corticosteroid injections have a
short-term benefit in the shoulder, as in other areas of the body. However, there are some concerns
about the longer-term benefits and harms of corticosteroid injections.28–30 The combination of injection
and physiotherapy has intuitive appeal, with some evidence of an additive, but not interactive,
effect in the short term (3–4 months).30–33 The longer-term benefits of injections require further study.
We planned to use a no-injection comparison, as finding an inert robust placebo is challenging and,
given the existing evidence,28–30 we believed that it was unethical and undesirable to progress a placebo
arm in a large Phase III trial. In our study based in NHS musculoskeletal services, extended-scope
physiotherapists typically deliver the corticosteroid injections. This is increasingly common practice in
the NHS, where therapists undertake additional post-registration training to deliver injections, working
within a local Patient Group Direction and/or becoming qualified non-medical independent prescribers.34
Although the use of ultrasound to guide injections in primary care has become increasingly common,
evidence from the SUPPORT (SUbacromial imPingement syndrome and Pain: a randomised controlled
trial Of exeRcise and injecTion) trial35 and other trials3 have demonstrated that it is no more effective
than standard injection practice. Ultrasound guidance also substantially increases the cost and reduces
the practicality of injection therapy. Therefore, we planned to deliver injections without the use of
ultrasound guidance.
Objectives
The aim of the GRASP trial was to assess the clinical effectiveness and cost-effectiveness of
individually tailored progressive exercise compared with best-practice advice, with or without
corticosteroid injection, in patients with a new episode of a rotator cuff disorder. The primary
objectives were to assess the following:
l whether or not an individually tailored progressive exercise programme, including behavioural
change strategies and led by a physiotherapist, provides greater improvement in shoulder pain and
function over the 12 months post randomisation compared with a best-practice advice session with
a physiotherapist supported by high-quality materials
l whether or not subacromial corticosteroid injection provides greater improvement in shoulder pain
and function over the 12 months post randomisation compared with no injection.
The secondary objectives of the GRASP trial were to investigate if there were any differences at 8 weeks
and at 6 and 12 months in shoulder pain, shoulder function, health-related quality of life, fear avoidance,
pain self-efficacy, sleep disturbance, return to desired activities (RDA) (including work, social life and sport
activities), patients’ global impression of change, adherence to exercises, use of medication (prescribed
and over the counter), time off work, health resource use (consultation with primary and secondary care)
and additional out-of-pocket expenses.
A parallel within-trial health economic analysis was also conducted.
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Parts of this chapter have been reproduced with permission from Hopewell et al.36 This is an OpenAccess article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/. The text below includes minor additions and formatting changes to the original text.
Parts of this chapter have been reproduced with permission from Marian et al.37 This article is licensed
under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are included in the article’s Creative
Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in
the article’s Creative Commons licence and your intended use is not permitted by statutory regulation
or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
Trial design
The GRASP trial protocol36 and the statistical analysis plan (SAP) have been reported previously.37
The GRASP trial is a 2 × 2 factorial trial, which was used to test the following four physiotherapy-led
interventions:
1. Progressive exercise programme (i.e. an individually tailored, progressive, home exercise programme
prescribed and supervised by a physiotherapist, involving up to six face-to-face sessions over
16 weeks).
2. best-practice advice (i.e. one face-to-face session with a physiotherapist and a home exercise
programme supported by high-quality self-management materials).
3. Progressive exercise programme (as described above) preceded by a subacromial
corticosteroid injection.
4. best-practice advice session (as described above) preceded by a subacromial corticosteroid injection.
A parallel within-trial health economic analysis was also conducted.
The factorial design allowed two primary comparisons, based on the assumption that there was no
interaction effect: (1) progressive exercise programme compared with best-practice advice session and
(2) subacromial corticosteroid injection compared with no injection.
Internal pilot
An internal pilot was included as an integral part of the GRASP trial design, which mirrored the
procedures and logistics undertaken in the main GRASP trial. The purpose of the internal pilot was to
test and refine the recruitment process and explore treatment acceptability. The decision to progress
to the main trial was made in collaboration with the Trial Steering Committee (TSC) and the National
Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme based on a
predefined progression criterion: reaching the target recruitment rate (42 participants) within the
specified time frame (4 months). Data from the internal pilot trial contributed to the final analysis,
as there were no substantive changes in design or delivery of the trial interventions.
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Study setting
The GRASP trial was conducted across 20 primary care-based musculoskeletal services and their related
physiotherapy services in the NHS. These services treat people with a range of musculoskeletal
conditions and are run by specialist practitioners, including extended-scope physiotherapists, GPs
with a specialist interest in musculoskeletal conditions, clinical nurse specialists and, in some instances,
rheumatologists and orthopaedic consultants. Sites were chosen so that they reflected a range of
settings (urban and rural) and were able to deliver the trial interventions. The local principal investigator
was responsible for the conduct of the research at their site.
Participants
Participants were recruited if referred by their GP or physiotherapist for treatment of a new, but
not necessarily first, episode of shoulder pain attributable to a rotator cuff disorder. Participants
were predominantly seeking treatment for one shoulder. People who self-referred directly to the
musculoskeletal service were also assessed for eligibility, as the typical route of referral varied across
services. The participants did not routinely undergo diagnostic imaging, such as magnetic resonance
imaging or ultrasound, as a requirement of the trial, as this is generally not recommended in primary care.
Inclusion criteria
l Men and women aged ≥ 18 years.
l A new episode of shoulder pain (i.e. within the previous 6 months) attributable to a rotator cuff
disorder (e.g. cuff tendonitis, impingement syndrome, tendinopathy or rotator cuff tear), using the
diagnostic criteria set out in the BESS guidelines4 (see Appendix 1, Figure 13).
l Not currently receiving physiotherapy.
l Not being considered for surgery.
l Able to understand spoken and written English.
Exclusion criteria
l Participants with a history of recent significant shoulder trauma (e.g. dislocation, fracture or
full-thickness tear requiring surgery).
l Those with a neurological disease affecting the shoulder.
l Those with other shoulder disorders (e.g. inflammatory arthritis, frozen shoulder or glenohumeral
joint instability) or with red flags consistent with the criteria set out in the BESS guidelines.4
l Those who had received corticosteroid injection or physiotherapy for shoulder pain in the
previous 6 months.
l Those with contraindications to corticosteroid injections.
Recruitment
Recruitment of participants, screening and eligibility assessment
Potentially eligible participants were identified by clinicians in NHS musculoskeletal services. People
attended their clinic appointments in accordance with standard NHS procedures. The treating practitioner
in the musculoskeletal services undertook a clinical assessment according to their usual practice.
If a patient fulfilled the criteria for a rotator cuff disorder, they were assessed to see whether or not
they met the GRASP trial eligibility criteria. Patients were provided with a copy of the participant
information sheet and asked if they wished to be considered for the trial. Those who met the eligibility
criteria and wanted to participate were approached for informed consent. Participants who did not
meet the eligibility criteria or who did not wish to participate received standard NHS treatment.
We recorded anonymous information on the age and sex of those who declined to participate so that
we could assess the generalisability of those recruited. Reasons for declining were also recorded.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Informed consent and baseline assessment
After participants had been assessed for eligibility, informed consent for participation in the GRASP
trial was obtained by a research facilitator at the site who was trained in Good Clinical Practice (GCP).
The following was explained to the participant: the exact nature of the study; what it would involve for
the participant, including expectations that the participant would be willing and able to attend sessions
to receive the study intervention; and any risks involved. The potential participant was provided with a
patient information sheet and was given the opportunity to discuss issues and ask questions. In most
cases, the process of obtaining informed consent took place during the initial musculoskeletal clinic
appointment. Some participants required a second research appointment because they required more
time to consider the study or because of local resources at site. Participants were then asked to
complete a baseline assessment questionnaire that recorded simple demographic information and
baseline measurements for the primary and secondary outcomes (Table 1).
TABLE 1 Outcomes measured and time points assessed
Outcome Measurement Time point
Demographic Age, sex, height, weight, ethnicity, marital status, smoking, date of
rotator cuff diagnosis, duration of symptoms, hand dominance,
affected shoulder, current work status, level of education, place
of residence, household income and state benefits
Baseline
Primary
Pain and function SPADI10,11 13-item total scale Baseline, 8 weeks,
6 months, 12 months
Secondary
Pain SPADI10,11 five-item subscale Baseline, 8 weeks,
6 months, 12 months
Function SPADI10,11 eight-item subscale Baseline, 8 weeks,
6 months, 12 months
Health-related quality life EQ-5D-5L score38 Baseline, 8 weeks,
6 months, 12 months
Psychological factors FABQ-PA five-item subscale39 and PSEQ-240 Baseline, 8 weeks,
6 months, 12 months
Sleep disturbance ISI41 Baseline, 8 weeks,
6 months, 12 months
GIT Patient-rated Likert scale42 8 weeks, 6 months,
12 months
RDA Patient-reported RDA, including work, social life and
sport activities
Baseline, 8 weeks,
6 months, 12 months
Exercise adherence Patient-reported adherence to exercise 8 weeks, 6 months,
12 months
Medication usage Prescribed and over-the-counter medications, additional
steroid injection
8 weeks, 6 months,
12 months
Work disability Sick leave (days) 8 weeks, 6 months,
12 months
Health-care use NHS outpatient and community services (e.g. GP, additional
physical therapy), NHS inpatient and day case (e.g. radiography,
MRI) and private health-care services
8 weeks, 6 months,
12 months
Out-of-pocket expenses Patient-related out-of-pocket expenses recording form 8 weeks, 6 months,
12 months
EQ-5D-5L, EuroQol 5 Dimensions, five-level version; FABQ-PA, Fear Avoidance Belief Questionnaire – Physical
Activity; GIT, Global Impression of Treatment; ISI, Insomnia Severity Index; MRI, magnetic resonance imaging;
PSEQ-2, Pain Self-Efficacy Questionnaire, two-item version.
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Randomisation
Consented participants were randomised to one of the four physiotherapy-led intervention groups
(1 : 1 : 1 : 1) (see Trial design), using a centralised computer randomisation service RRAMP (Registration/
Randomisation and Management of Product; URL: https://rramp.octru.ox.ac.uk) provided by the Oxford
Clinical Trials Research Unit (OCTRU). This was undertaken directly by the research facilitator at the site or
by the research facilitator contacting the central randomisation centre by telephone, who then accessed
the system on their behalf, depending on the facilities available at the study sites. Randomisation was
computer generated and stratified by centre, age (18–35 years, > 35 years) and sex, using a variable block
size to ensure that participants from each study site had an equal chance of receiving each intervention.
Blinding
Both the physiotherapists delivering the intervention and the study participants were informed of
treatment allocation at the initial appointment. Because of the nature of the interventions being
tested, it was not possible to blind them to the treatment allocation once treatment allocation was
revealed. Where practical, team members were blinded until after data analysis was complete. Trial
statisticians had access to treatment assignment during the study for the purposes of data monitoring
and safety. Data entry personnel entered data from anonymised questionnaires, which included some
details on treatments received.
Interventions
Full details of the exercise interventions are described in Chapter 3 and have been reported
previously.43 A summary is provided here for continuity.
Subacromial corticosteroid injection
The subacromial corticosteroid injection was delivered prior to the progressive-exercise or best-practice
advice intervention. The injections were predominantly carried out by extended-scope physiotherapists
with appropriate post-registration qualifications in injection therapy who worked within a local patient
group directive or as non-medical independent prescribers.34 This reflects an increasingly common
practice in the NHS and ensured that the injections were delivered in the most cost-effective manner
possible. The corticosteroid injection was given as per its marketing authorisation and in accordance
with its normal indication and therapeutic dosage.44
The corticosteroid and local anaesthetic were given together in one injection or separately in two injections,
depending on local treatment protocols at sites. The corticosteroid injected was either methylprednisolone
acetate (Depo-Medrone®, Pfizer Ltd,Walton Oaks, UK; up to 40 mg) or triamcinolone acetonide (Kenalog™,
Bristol-Myers Squibb, Mulhuddart, Ireland; up to 40mg), as per local treatment protocols. These are the
two routinely injected corticosteroids for shoulder pain.There is no clear evidence that either corticosteroid
is more effective than the other.30 The local anaesthetic was either 1% lidocaine (up to 5 ml) or 0.5%
bupivacaine hydrochloride (up to 10 ml).We selected sites that adhered to these prescribing boundaries.
The choice and dose of corticosteroid, local anaesthetic (including volume) and the injection site were
recorded for each participant on a trial injection data collection form (see Appendix 2, Figure 14).
Participants were advised to take care and avoid heavy lifting for 24–48 hours after the injection.
Appointments were co-ordinated so that participants typically received their injection within 10 days of
randomisation. Very occasionally, a second injection was given after 6 weeks in accordance with the trial
protocol (but within 16 weeks of the patient being randomised), but this injection was administered to
only those patients who received good initial benefit from their first injection and who requested further
pain relief to facilitate their exercises. Any participants who received a second injection had the dose,
drug and date of administration recorded on a trial injection data collection form.
METHODS
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Progressive-exercise intervention
Participants randomised to the progressive-exercise intervention received up to six individual face-
to-face sessions with a physiotherapist over 16 weeks. These sessions included a behavioural component
to encourage adherence to the exercises. A similar rationale has been used to good effect in other
trials.21,45 We chose the number of sessions, spread over this time, to enable progression of the intensity
of exercise and provide a sufficient amount of time for a physiological response in the neuromuscular
system.46 Appointments were co-ordinated so that participants typically started their first exercise
session within 14–28 days of randomisation, as per local appointment availability. The initial session
lasted up to 60 minutes for assessment and setting up the home exercise programme, followed by up to
five 20- to 30-minute follow-up sessions. Participants were provided with a folder containing an advice
booklet, an exercise action planner and diary, and instructions on their exercise programme set up in
collaboration with their physiotherapist. A resistance band was issued as required. The physiotherapists
recorded the number of treatment sessions attended by each participant. The intervention was designed
to support participants through a progressive dose of exercises and optimise adherence to the home
exercise plan. The progressive-exercise programme was highly structured, but could be tailored to the
needs and preferences of participants, with the aim of helping them achieve their rehabilitation goals.
Importantly, the intervention could be delivered within the current NHS commissioning paradigm.47
Best-practice advice intervention
Participants randomised to the best-practice advice intervention received a single, individual face-
to-face session with a physiotherapist, lasting up to 60 minutes. Again, appointments were co-ordinated
so that participants typically started their exercise session within 14–28 days of randomisation, as per
local appointment availability. After a comprehensive shoulder assessment, participants were given an
advice booklet. The content of the advice in the booklet was the same as that provided for the progressive-
exercise group, with the exception of the different exercise programme. An exercise diary was also
provided, along with a simplified version of the exercise action planner (see Chapter 3). Tailored
education, reassurance and self-management exercise advice, including advice on pain management and
activity modification, was offered. Participants were also given a simple set of self-guided exercises,
including at least one level of resistance band and an exercise video [available on a website and digital
versatile disc (DVD)], which could be progressed and regressed, depending on their capability. The exercises
were designed using similar concepts to those of the progressive-exercise intervention, such as increased
resistance, but with a simpler range of exercise options that were not supervised.
The best-practice advice intervention was selected as the comparator because it is consistent with
current clinical practice guidelines regarding the self-management advice that should be provided to
people with rotator cuff disorders.4,5 In addition, people may find a single advice session and DVD
preferential to a course of face-to-face physiotherapy sessions, as they do not have to come back to
the hospital or clinic, take time off work or make carer arrangements.
Concomitant care
All participants were advised that they could take over-the-counter analgesia as required (e.g.
paracetamol with or without codeine, or an oral non-steroidal anti-inflammatory drug) in accordance
with the BESS guidelines.4 Participants could seek other forms of treatment during the follow-up
period, but were informed that they should use usual routes (predominantly NHS referral) to do so.
Additional treatments, including contact with their GP or other health professional, changes in
medication, use of physical treatment and alternative therapies, were recorded as a treatment outcome
through the patient questionnaires at 8 weeks, 6 months and 12 months post randomisation.
Training and monitoring of intervention delivery
All physiotherapists delivering study interventions, progressive exercise and best-practice advice had
access to a comprehensive intervention manual and were required to have undertaken trial-specific
training by a GRASP trial research physiotherapist. A rigorous quality control programme was also
conducted to ensure intervention fidelity (see Chapter 3).
DOI: 10.3310/hta25480 Health Technology Assessment 2021 Vol. 25 No. 48
Copyright © 2021 Hopewell et al. This work was produced by Hopewell et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.




The primary outcome was shoulder pain and function over the 12 months post randomisation measured
using the SPADI,10,11 which was developed to measure current (i.e. in the last week) shoulder pain and
disability in an outpatient setting. The SPADI scale is based on 13 questions, all scored on a 0–10 scale,
on which 10 is the worst score. In addition, the SPADI scale has a five-item pain subscale and an eight-item
disability subscale. The subscale items are summed and converted to a 0–100 scale, where a higher value
denotes more pain and/or disability. A systematic review of outcome measurement sets for shoulder pain
trials showed that SPADI is the most commonly used measure to assess pain and disability.48 The SPADI
scale has good psychometric properties, is used widely in the field and can be completed using a
postal questionnaire.
Secondary outcomes
Secondary outcomes (see Table 1) were subdomains of the SPADI, which are pain measured using the
SPADI five-item pain subscale10,11 and function measured using the SPADI eight-item disability subscale;10,11
health-related quality of life, measured using the well-validated EuroQol 5 Dimensions, five-level version
(EQ-5D-5L) score;38 psychological factors, measured using the Fear Avoidance Belief Questionnaire –
Physical Activity (FABQ-PA) five-item subscale39 and the Pain Self-Efficacy Questionnaire, two-item
version (PSEQ-2);40 sleep disturbance, measured using the Insomnia Severity Index (ISI);41 patient global
impression of change;42 RDA, including work, social life and sport activities; patient adherence to
exercise; any serious adverse events (SAEs); health resource use, including consultation with primary
and secondary care, prescribed and over-the-counter medication use, additional physiotherapy or
injection use, and hospital admission; additional out-of-pocket expenses; and work absence (i.e. number
of sickness days).
The EQ-5D-5L38 is a validated, generic health-related quality-of-life measure comprising five dimensions,
each with a five-level answer possibility and a health thermometer scale. The EQ-5D-5L can be used to
report health-related quality of life in each of the five dimensions and each combination of answers can
be converted into a health utility score, where 1 represents perfect health and 0 indicates health states
equal to death. The health thermometer scale (EuroQol visual analogue scale) takes values between
0 and 100, where 0 represents worst imaginable health and 100 best imaginable health. It has good
test–retest reliability and gives a single preference-based index value for health status that can be used
for broader cost-effectiveness comparative purposes.
The Fear Avoidance Belief Questionnaire (FABQ)39 is a validated measure of fear-avoidance
behaviour. The FABQ-PA is a subscale of the FABQ that measures fear-avoidance beliefs about
physical activity using five items scored on a 0 (strongly disagree) to 6 (strongly agree) scale.
The total score range for FABQ-PA is 0–24, with higher scores representing greater levels of
fear-avoidance behaviour.
The PSEQ40 is a well-established 10-item measure of pain self-efficacy (i.e. a belief in one’s ability
to carry out activities despite pain). PSEQ-2 is a two-item, short measure of pain self-efficacy.40
The two items reflect the confidence in ability to work and lead a normal life despite the pain, on a
0 (not at all confident) to 6 (completely confident) scoring scale. The total PSEQ-2 score is summed
from the two items, giving a range from 0 to 12, with higher values representative of higher confidence
levels despite the pain.
The ISI41 is a brief self-report measure of a patient’s perception of their insomnia, targeting the subjective
symptoms and consequences of insomnia, as well as the degree of concerns or distress caused by those
difficulties. The ISI has seven items rated on a 0–4 scale and the total score is a summation of these
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items, with a value ranging from 0 to 28. Higher scores are suggestive of more severe insomnia.
A detailed interpretation of the ISI total score is as follows:
l A score of 0–7 indicates no clinically significant insomnia.
l A score of 8–14 indicates subthreshold insomnia.
l A score of 15–21 indicates clinical insomnia of moderate severity.
l A score of 22–28 indicates severe clinical insomnia.
The Global Impression of Treatment (GIT)42 is a simple method of measuring change in health status,
with respect to shoulder problems, by charting self-assessed clinical progress on an 11-point scale that
ranges from –5 (very much worse) to 5 (completely recovered). Psychometric properties include a
minimum detectable change of 0.45 points and a minimally clinically important difference (MCID) of
2 points.
Return to desired activities is a self-reported outcome that aims to measure physical function
during social life, recreational activities and work. RDA is an adapted version of the Disabilities of the
Arm, Shoulder and Hand (QuickDASH), using three questions with a five-point Likert scale answer
option, with lower scores indicating better function.
Other secondary outcomes (including medication usage, work disability, health-care use and out-of-pocket
expenses) are analysed separately as part of a health economics analysis (see Chapter 5).
Adverse events
Expected adverse events occurring as a result of the trial intervention(s) were not recorded as part
of the trial. Participants were provided with information on the potential adverse events resulting
from exercise and corticosteroid injection (if applicable) as part of their treatment, including what they
should do if they experienced an adverse event, as would happen as part of standard NHS procedures.
SAEs (defined as any medical occurrence that could result in death, is life-threatening or results in
hospitalisation or incapacity) were considered highly unlikely to occur as a result of either the exercise
or the corticosteroid injection therapy delivered in this trial. However, if a SAE arose in the period
from the participant’s enrolment in the trial to their final visit for their allocated intervention, standard
procedures for recording and reporting SAEs applied.
Follow-up data collection
Measurements for the primary and secondary outcomes were all patient reported and collected
using postal questionnaires at 8 weeks, 6 months and 12 months after randomisation (see Table 1).
Participants were asked to complete the questionnaire and return it to the GRASP study team in the
prepaid envelope. For those who did not respond to the initial questionnaire, at least one postal reminder
was sent. A web-based version of the questionnaire, and telephone and e-mail follow-up were used to
contact those who did not respond to the postal questionnaire. Telephone and e-mail follow-up was also
used to collect a core set of questionnaire items if these had not been fully completed on the returned
questionnaire. To maximise response rates for the 12-month follow-up, a small monetary incentive (in the
form of a gift voucher) was sent to all participants along with their 12-month follow-up questionnaire as a
thank you for the time and effort involved.
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Data management
All data were processed according to the General Data Protection Regulation 2018 and all documents
were stored safely in confidential conditions.49 All trial-specific documents, except for the signed
consent form and follow-up contact details, referred to the participant using a unique study participant
number/code and not by name. Participant identifiable data were stored separately from study data
and in accordance with local procedures. All trial data were stored securely in offices that were
accessible using a swipe card by the central co-ordinating team staff and authorised personnel only.
Statistical methods
Sample size
The target sample size for the trial was 704 randomised participants (176 in each treatment arm).
This sample size was based on 90% power and 1% two-sided statistical significance to detect a minimally
clinically important between-group difference of 8 points on the SPADI total scale,10 assuming a baseline
standard deviation (SD) of 24.3 (chosen as representative of the patient population50). This difference
is the equivalent of a standardised effect size of 0.33, which required a sample size of 550 participants
[Power Analysis and Sample Size 13 NCSS Statistical Software Kaysville, UT, USA; URL: www.ncss.com
(accessed 20 May 2021)]. Allowing for a potential loss to follow-up of 20% at 12 months inflated the
sample size to 688. We further inflated the sample size to take into account the potential for a small
clustering by physiotherapist effect in the progressive-exercise intervention group.We used an interclass
correlation (ICC) of 0.001, based on our experience with individually tailored physiotherapy interventions51
and the expectation that each physiotherapist would treat approximately 20 participants in the progressive-
exercise intervention group. This lead to an inflation of:
f = 1 + (m –1) × ICC = 1 + (20 –1) × 0:001 = 1:019, (1)
and increased the sample size to the total of 704 participants.
This sample size was based on the assumption that there was no interaction effect and was powered
for the two main effect comparisons: (1) progressive exercise compared with best-practice advice
and (2) corticosteroid injection compared with no injection. However, this number of participants also
provided 80% power and 5% two-sided significance to detect an interaction standardised effect size
of 0.35, if an interaction effect did exist. The interaction effect was tested before the main effect
comparisons were undertaken. It should be noted that a non-significant interaction effect did not
preclude a smaller interaction that this study was not powered to detect. We chose 90% power and
1% two-sided significance to provide more convincing evidence of any treatment effects discovered.
No further adjustments to the sample size were made because of multiple testing. The Data Monitoring
and Ethics Committee (DMEC) reviewed the sample size assumptions after 338 participants were
recruited and no changes were made to the final sample size.
Statistical analysis
A separate SAP37 provides full details of all planned statistical analyses and was finalised prior to any
primary outcome analysis. A summary is provided below.
The SAP was reviewed and received input from the TSC and DMEC. Any changes or deviations from
the original SAP are described and justified in Chapter 4 and any additional publications, as appropriate.
All statistical analyses were undertaken using Stata® (StataCorp LP, College Station, TX, USA).
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The primary statistical analysis was carried out on the basis of intention to treat (ITT), with all randomised
participants included and analysed according to their allocated treatment group, irrespective of which
treatment they actually received or their compliance with the proposed interventions. The two main effect
comparisons for this 2 × 2 factorial trial were (1) progressive exercise compared with best-practice advice
to determine the efficacy of progressive exercise [group A (progressive exercise) + group C (progressive
exercise + injection) vs. group B (best-practice advice) + group D (best-practice advice+ injection)] and
(2) subacromial corticosteroid injection compared with no injection to determine the efficacy of subacromial
corticosteroid injection (A+ B vs. C+D). This ‘factorial analysis’ was conducted ‘at the margins’ of the table
(Table 2). The sample size for this type of analysis was calculated under the assumption that there will be no
intervention interaction effect (i.e. that progressive exercise would not interact with the steroid injection,
such that it would work, work better or work worse only when used together rather than used alone). If a
substantial interaction between the two interventions was present, the factorial analysis of the groups
would lead to biased results and, therefore, the efficacy of each intervention would need to be drawn from
comparisons within the intervention groups (i.e. ‘inside-the-table’ comparisons). Regardless of being able to
detect a significant interaction effect, the results of the trial for the primary outcome, SPADI, meant
that estimates were to be presented both ‘inside the table’ and ‘at the margins’, together with the size
of the interaction.52 The success or otherwise of the interventions would be evaluated from the analysis
results conducted based on evidence for presence/absence of a treatment interaction.
Interaction
An interaction between the two main effect comparisons was not expected, but the trial was powered
to identify a moderate standardised interaction effect of 0.35. The presence of an interaction between
the two interventions was formally investigated before testing their effects on the primary outcome.
An initial regression model was fitted for the primary outcome to predict the outcome of interest and
included the two effects of interest [i.e. (1) individually tailored progressive-exercise programme
compared with best-practice advice and (2) subacromial corticosteroid injection compared with no
injection] and their interaction.
In the presence of a non-statistically significant treatment interaction (i.e. p ≥ 0.05), a factorial analysis
was planned to determine the success of the trial. The effects for the individually tailored progressive-
exercise programme and corticosteroid injection were determined separately from this model as mean
differences (MDs) with associated 99% confidence intervals (CIs), as appropriate, adjusted for the
relevant covariates. The model used did not include an intervention interaction term.
If a statistically significant treatment interaction (i.e. p < 0.05) had been detected then the effect of the
individually tailored progressive-exercise programme and corticosteroid injection would have been
evaluated from comparisons within the intervention groups, referred to as ‘inside-the-table’ comparisons
(i.e. group A vs. group B to test the effect of the individually tailored progressive exercise programme and
group B vs. group D to test for the effect of the corticosteroid injection) (see Table 2). The main effects
and their interaction terms would have been included in the analysis model, their regression coefficient
with corresponding 95% CI for the interaction terms presented and the reduced statistical power of
this model noted.
TABLE 2 Factorial 2 × 2 analysis diagram
No corticosteroid injection Corticosteroid injection
Effect of ProgEx
intervention
ProgEx intervention Group A (ProgEx) Group C (ProgEx + injection) A +C vs. B+D
BPA intervention Group B (BPA) Group D (BPA+ injection)
Effect of corticosteroid injection A + B vs C+D
BPA, best-practice advice; ProgEx, progressive exercise.
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Primary outcome analysis
The difference in SPADI between the two intervention groups was estimated overall and at each data
collection time point using a repeated measures linear mixed-effects regression model.53 The model
was adjusted for the fixed effects of age, sex and baseline SPADI, and random intercepts by centre
and observations within participants. Robust standard errors (SEs) for treatment effects from all time
points were reported. Clustering by physiotherapist in the progressive-exercise group was accounted
for using cluster-robust SEs as part of the mixed-effects model. The final trial results were based on
the adjusted model. A non-parametric statistical test (e.g. Mann–Whitney test for comparison of
means) with no adjustment and medians and interquartile ranges (IQRs) were reported where
approximate normality for the model residual terms was not established. Statistical significance was
set at the 1% level and corresponding 99% CIs were reported for the primary outcome. Flooring effects
in the SPADI outcome over the 12 months were explored and reported for each treatment group.
Secondary outcome analyses
The intervention effects on secondary outcomes were analysed following the analysis method described
for the primary outcome on the basis that the outcomes are clinically similar. If there was no statistically
significant evidence of an interaction effect for the primary outcome, then no interaction effect would be
assumed for the secondary outcomes. Likewise, if a statistically significant interaction effect was identified
for the primary outcome, then the secondary outcomes would be analysed, assuming an interaction effect
was present. Continuous secondary outcomes analyses were conducted following similar methods to the
outline for the primary outcome analysis, using linear regression for continuous outcomes and logistic/
multinomial logistic regression (i.e. logit, mlogit or ologit, as appropriate) for binary and ordinal outcomes.
Statistical significance for secondary outcomes was set at 5% and 95% CIs were reported.
Missing data
Missing data were reported and summarised by treatment group. Item-level imputation for the primary
outcome SPADI was carried out for items where no more than two out of five items in the pain subscale
were missing and no more than three out of eight items in the function subscale were missing, given
that no more than 10% of cases had missing data.54,55 Missing continuous primary and secondary outcomes
were handled as part of the likelihood-based estimation of the repeated measures mixed-effects model,
assuming the data were missing at random.56 This method took account of missing observations owing
to missed visits or a participant leaving the study prematurely. The distribution of missing data was
explored to assess the assumption of data being missing at random. Full details are provided in the SAP.37
Sensitivity analysis
Sensitivity analyses were used to assess the robustness of the trial results in the light of the
assumptions made about the underlying missing data mechanism. Most analyses assume data to
be missing at random or missing completely at random. The sensitivity analysis, therefore, assumed
missing not at random, such that missing outcomes were assumed to be worse or better than the
observed outcomes.
Prespecified subgroup analysis
Subgroup effects in the following prespecified subgroups were analysed for the primary outcome,
utilising subgroup-by-treatment interactions:
l Age: ≤ 64 years vs. ≥ 65 years. (Rationale: increasing age has been shown to be associated with
poorer outcome.57,58)
l Sex: male vs. female. (Rationale: prevalence is higher in males than in females.1)
l Smoking status: never smoked vs. former smoker or current smoker. (Rationale: smoking has been
shown to be associated with a negative effect on tendon healing.59)
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l Higher SPADI score at baseline. (Rationale: higher pain and functional disability at baseline may be
associated with poorer outcome. We defined a higher SPADI score as ≥ 50 at baseline when the
SPADI is converted to the 0 to 100 scale.19,57)
l Higher pain self-efficacy (PSEQ-2) score at baseline. (Rationale: higher belief in one’s ability to carry
out activities despite pain may be associated with better outcome. We define a higher PSEQ-2 score
as ≥ 8 at baseline when the PSEQ-2 is converted to the 0–12 scale.)
Supplementary/additional analyses
A complier-average causal effect (CACE) analysis was used to investigate the role of compliance in the
treatment effect, given the CACE assumptions described in the SAP. Compliance with intervention was
defined in the SAP37 as follows. For the progressive exercise intervention, participants were considered
compliant with treatment if they had been signed off for completing treatment or if they receive all
six physiotherapy sessions. For corticosteroid injection intervention, participants were considered
compliant if they received at least one injection. If no evidence of a statistically significant interaction
between the two treatments was identified, then this analysis was planned to be conducted ‘at the
margins’ and using a similar mixed-effects model. If a statistically significant treatment interaction for
the primary outcome was identified, the CACE analysis would be conducted ‘inside the table’.
Cost-effectiveness analysis
An economic evaluation was integrated within the GRASP trial design. Full details are described in
Chapter 5 and a summary is described here for continuity.
The economic evaluation, in the form of a cost–utility analysis, was conducted from the recommended
NHS and Personal Social Services (PSS) perspective.60 Individual patient data on the use of health and
social services were collected at 8 weeks, 6 months and 12 months post randomisation as part of the
follow-up data collection process (see Table 1). The cost of delivering each intervention, including
physiotherapists’ training, materials, delivery of the progressive exercise and advice sessions, and
corticosteroid injections, were also estimated. Participants’ health-related quality of life was captured
through the EQ-5D-5L at baseline and at 8 weeks, 6 months and 12 months post randomisation.
Patient and public involvement
Patient and public involvement (PPI) was central to the design of the GRASP trial and was maintained
throughout the trial set-up, implementation and dissemination. PPI representatives were involved in a
number of ways. First, as part of the initial trial design, we held a PPI study development meeting,
supported by the Research Design Service South Central (Oxford, UK), where the proposed research
was presented and discussed with attendees. The views expressed by the patients contributed to the
trial design and subsequent trial protocol. In particular, an outcome looking at sleep disturbance was
included, as this was deemed to be very important to patients. The PPI representatives also advised
keeping the number of self-reported outcomes to a minimum to avoid an undue burden on the participants
and recommended using diaries so that the patients could record and monitor their own progress.
Patient and public involvement representatives also attended the GRASP intervention development
meeting (see Chapter 3) and provided valuable practical input regarding delivery and acceptability of
the progressive-exercise and best-practice advice interventions. In addition, PPI representatives were
involved in reviewing the participant information sheets and participant questionnaires to ensure that
they were accessible and user-friendly. Two PPI representatives were formal members of the GRASP
TSC and attended and actively contributed to these meetings, including the final results meeting where
data were shared and interpreted. As part of the dissemination process, the PPI representatives also
reviewed and advised on the wording of the letter to trial participants, advising them of the GRASP
trial results.
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Ethics approval and monitoring
Ethics committee approval
The GRASP trial protocol and all related documentation (e.g. informed consent forms, participant
information leaflets, patient questionnaires and any proposed advertising material) was approved
by the Berkshire B Research Ethics Committee (reference 16/SC/0508) and Integrated Research
Application System (ID 199243). The trial was also approved by the UK competent authority the
Medicines and Healthcare products Regulatory Agency, as it was classified as a clinical trial of an
investigational medicinal product (EudraCT number 2016-002991-28). The trial was conducted
in accordance with the principles of the Declaration of Helsinki61 and the Medical Research Council’s
GCP guidelines.62
Trial Management Group
A Trial Management Group, consisting of the core trial team, chief investigator and co-applicants, was
responsible for the day-to-day running of the trial and met monthly to report on progress and ensure
that milestones were met. A trial manager oversaw all aspects of the day-to-day trial management.
Trial Steering Committee
A TSC was responsible for monitoring the trial’s progress and providing independent advice. The TSC
comprised an independent clinician, two specialist physiotherapists, a statistician, a health economist
and two patient representatives.
Data Monitoring and Ethics Committee
A DMEC was responsible for monitoring the trial’s progress and providing independent advice. It
advised the chairperson of the TSC if, at any time, in its view, the trial should be stopped for ethics
reasons, including concerns about participant safety. The DMEC comprised an independent clinician,
health service researchers, a specialist physiotherapist and a statistician.
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Chapter 3 Intervention description and
rationale
Parts of this chapter have been reproduced with permission from Keene et al.43 This is an OpenAccess article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/. The text below includes minor additions and formatting changes to the original text.
Developing the GRASP trial exercise interventions
The GRASP trial interventions were developed using Medical Research Council guidance for developing
and evaluating complex interventions.63 We took into account clinical guidelines, research evidence,
current practice variation, deliverability in the NHS (in terms of staffing, resources and time), expert and
patient opinion, acceptability to clinicians and patients, and the need to ensure consistency in delivery and
reproducibility. The intervention development and descriptions have been reported previously.43
Intervention development
In Chapter 1, the lack of evidence for particular exercises, treatment intensities or durations were outlined.
With no clear evidence or clinical consensus, advice from clinicians, patient and public representatives
and other experts was crucial to the development of the GRASP trial interventions. Twenty-six clinicians,
researchers, patients and public representatives attended a GRASP intervention development meeting
(June 2016). Delegates discussed and evaluated a comprehensive list of 22 exercise types commonly
used in clinical practice and/or reported in trials of shoulder pain treatments (see Appendix 3, Table 26).
The delegates categorised the exercises into essential exercises, optional exercises or exercises considered
not important for managing rotator cuff disorders.
Those selected as essential exercises generally strengthen the posterior rotator cuff muscles (i.e.
supraspinatus, infraspinatus and teres minor) and load the shoulder into an elevated position, consistent
with current trial evidence.17,64 The GRASP trial, therefore, included these exercise types as an essential
component of both the progressive-exercise and best-practice advice exercise interventions. Delegates
agreed that both exercise interventions should be as practical and simple as possible. Some exercises
were considered important for patients with specific presentations or in particular circumstances. These
were included as optional exercises in the progressive-exercise intervention. They were not incorporated
into the best-practice advice intervention, which prioritised a simple, progressive set of exercises that were
likely to benefit most patients and could be easily understood and performed at home without supervision.
Delegates agreed that stretching was not a priority target in rotator cuff disorders and that range of
motion could be incorporated into other active exercises. A posterior capsule/soft tissue stretch for
the shoulder was included as an option in the progressive-exercise intervention as we recognised that
these stretches feature in many exercise programmes evaluated in other clinical trials.14 Isolated
exercises to correct posture towards a theoretical ideal were not included, as there is limited evidence
for this approach.65 Experts disagree on whether exercises can or should provoke symptoms or should
be symptom-free. There is limited evidence for these alternatives, although evidence is building for
the acceptability of mild-to-moderate pain symptoms during exercise.66,67 The participant information
booklet, which was included as part of the GRASP trial intervention materials, and treating physiotherapists
advised participants that some pain during the exercises is acceptable, provided that they found it
manageable and symptoms resolved to an acceptable level within a few hours.
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After the meeting, we developed detailed intervention manuals for the treating physiotherapists that
described the key components of the progressive-exercise and best-practice advice interventions.
We also developed patient-facing materials, which were reviewed by patient representatives.
Internal pilot
As part of the GRASP trial, we ran an internal pilot from February to June 2017 at three sites, recruiting
42 participants. One of the aims of the internal pilot was to test and refine the recruitment process and
explore treatment acceptability. The physiotherapists delivering the GRASP exercise interventions were
also asked to provide feedback on the delivery of the intervention. The exercise intervention manuals
and training materials were subsequently refined to clarify identified misconceptions. The interventions
did not require significant modifications.
The GRASP trial interventions
Table 3 summarises the key components of the GRASP exercise interventions. The interventions were
delivered face to face and one to one by UK-registered physiotherapists based at physiotherapy and
musculoskeletal services across England.
TABLE 3 Overview of GRASP trial exercise interventions, as per Template for Intervention Description and Replication
criteria
TIDieR items68 Progressive exercise Best-practice advice
Brief name GRASP
Why Physiotherapy-led exercise and advice are commonly used to manage rotator cuff disorders;
however, evidence is lacking in terms of how exactly it should be delivered and whether or
not patients do better if they receive a corticosteroid injection before starting an exercise
programme
What Home exercise and advice programme
overseen by physiotherapist over six or fewer
sessions within 16 weeks
Home exercise and advice programme
initiated during a single face-to-face session
with a physiotherapist, and then performed
unsupervised by participant at home
Materials: participants Participant information booklet (see Table 4)
and exercise instruction sheets with photos
Action planner and exercise diary
(see Appendix 3, Figure 15)
Resistance bands (if applicable)
Participant information booklet
(see Table 4), incorporating exercise
instructions with photos
Action planner and exercise diary
(see Appendix 3, Figure 22)
Resistance bands




Therapist manuals detailing all aspects of the
trial and the progressive-exercise intervention,
and a quick reference guide for use in the
clinic
Training, including 1 full day (at least
4–5 hours) of face-to-face training delivered
by GRASP trial research physiotherapists
A therapist manual detailing all aspects
of the trial and the best-practice advice
intervention
At least half a day of training
Procedures Initial appointment
Assess participant as per normal
physiotherapy practice
Single face-to-face appointment
Assess participant as per normal
physiotherapy practice
INTERVENTION DESCRIPTION AND RATIONALE
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TABLE 3 Overview of GRASP trial exercise interventions, as per Template for Intervention Description and Replication
criteria (continued )
TIDieR items68 Progressive exercise Best-practice advice
Issue folder containing the progressive-
exercise participant information booklet
Agree level of exercise that is most
appropriate for the participant initially
(see Figures 1 and 2)
Advice should address barriers to exercise
identified during assessment
Provide education regarding pain during and
after exercise
Help participant to complete exercise





Reassess as per normal physiotherapy practice
Assist participant to progress/regress
exercises
Reassure the participant and reinforce key
messages from the advice and education
Review home exercise programme using the
exercise diary
Discuss return to functional activities
Review action planner
Complete treatment log (after every session)
Issue best-practice advice participant
information booklet
Explain exercise ladder (see Appendix 3,
Figure 21) and agree with participant what
level of the ladder is most appropriate
initially
Educate participants on how to progress and
regress their exercises
Ensure that the participant knows how to
access the exercise videos online or issue
DVD (or both)
Advice should address barriers to exercise
identified during assessment
Provide education regarding pain during and
after exercise
Help participant to complete exercise
documentation (i.e. the exercise diary and
action planner)
Strategies to encourage adherence to
exercise were less extensive than in the
progressive-exercise intervention, as they
need to be feasible to deliver within a
single session
Discharge participant with advice/
encouragement to continue with the self-
management exercise programme for at least
16 weeks
Complete treatment log
Who provides Physiotherapists already working in NHS
musculoskeletal services who have attended
the progressive-exercise intervention training
The GRASP trial does not exclude
physiotherapists based on number of years
qualified or experience in treating shoulder
conditions
Physiotherapists already working in NHS
musculoskeletal services who have attended
the best-practice advice intervention training
The GRASP trial does not exclude
physiotherapists based on number of years
qualified or experience treating shoulder
conditions
How Participants receive up to six sessions with a
physiotherapist over 16 weeks
The initial session lasts up to 60 minutes for
assessment. It is then followed by up to five
20- to 30-minute sessions
Participants receive a single face-to-face
session with a physiotherapist lasting up to
60 minutes
Where Physiotherapy sessions are in outpatient
clinics based in the NHS
The exercise programme is performed by the
participant at home
Same as progressive-exercise intervention
continued
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Research physiotherapists from the GRASP trial team provided 1 full day (at least 4–5 hours) of face-
to-face training on the progressive-exercise intervention and at least half a day of face-to-face training
on the best-practice advice intervention to the relevant delivering physiotherapists. Details on who
provided the interventions are provided in Chapter 4. Physiotherapists were trained to deliver either
the progressive-exercise intervention or the best-practice advice intervention (not both) to reduce
the risk of contamination. Training included the trial background, how to deliver the intervention,
TABLE 3 Overview of GRASP trial exercise interventions, as per Template for Intervention Description and Replication
criteria (continued )
TIDieR items68 Progressive exercise Best-practice advice
When and how much The initial appointment is co-ordinated within
14–28 days of randomisation, as per local
appointment availability
Up to five follow-up sessions arranged within
16 weeks
Can be fewer than six sessions if participant
has met rehabilitation goals and is self-
managing condition
Volume of exercise described in Figure 2
Same as progressive exercise, but without
any follow-up appointments
Tailoring Education and advice
Focus of education and advice are
individualised and based on assessment
Exercises
Selection, manipulation of sets, repetitions
and/or load is a joint decision-making process
Range of motion and position may be modified
to accommodate the patient’s comfort and
preferences
Education and advice
Focus of education and advice are
individualised and based on assessment
Exercises
The range of motion through which an
exercise is performed, and the load and
volume, may be increased or decreased
Modifications Quick reference guides for each intervention were produced after the pilot phase and
contained all key operational procedures for each intervention to supplement the
comprehensive manuals
Intervention fidelity
How well: training All aspects of training delivery, content, structure, duration and therapists’ confidence to




Intervention fidelity is monitored centrally using treatment logs and during site monitoring
and quality assurance visits. If performance is found to be below the required standard of
protocol adherence, further measures (e.g. further training) will be instituted after discussion
with the Trial Management Team and the site
How well: participants Exercise adherence
Physiotherapists review the exercise diary at
each subsequent session
Participants asked to report exercise
frequency in postal follow-up questionnaires
at 8 weeks, 6 months and 12 months
Exercise adherence
Participants asked to report exercise
frequency in postal follow-up questionnaires
at 8 weeks, 6 months and 12 months
How well: reporting Intervention fidelity is reported with main trial results
TIDieR, Template for Intervention Description and Replication.
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the exercises permitted within the trial protocol, behavioural techniques to improve adherence, trial
reporting and paperwork, and practical examples using case studies. Physiotherapist manuals were
provided, which detailed all aspects of the trial and interventions. GRASP trial team members were
available post training to provide support and answer queries.
GRASP trial exercise interventions
Assessment and advice
Appointments were co-ordinated so that participants typically started their first exercise session
within 14–28 days of randomisation. The physiotherapist carried out an initial assessment, as per their
usual practice, to identify which shoulder movements, in relation to the rotator cuff, were particularly
problematic in terms of pain, weakness and restriction, and the associated functional deficits. All GRASP
trial participants received a participant information booklet, which contained education and advice
relevant to people with a rotator cuff disorder (Table 4). All parts of the booklet contained the same
information in the progressive-exercise and best-practice advice intervention groups, with the exception
of the specifics of the exercise guidance. Advice included use of over-the-counter analgesia, as per BESS
guidance.69 The treating physiotherapist reinforced the education and advice aspects relevant to that
participant. All participants were advised to perform the exercises for at least 4 months and to continue
to do so for longer if they were still improving or finding them helpful. Physiotherapists delivering the
interventions were trained in questioning techniques based on cognitive–behavioural models70 to elicit
and address unhelpful beliefs about shoulder pain or exercise that can impede exercise adherence.71
TABLE 4 Contents of the GRASP trial participant information booklet
Section Content
Introduction Summary of common treatments for rotator cuff disorders
What is the rotator cuff? Description of rotator cuff muscles
What does the rotator cuff do? Function of rotator cuff muscles
What can go wrong with the rotator cuff? Possible mechanisms and common symptoms of rotator cuff disorders
What can I do to help my rotator cuff
problem?
Introduction to role of self-management advice, includes simple pain
education, pain management (including use of heat and cold, medication
and pacing)
Maintaining physical fitness Importance of staying active
Return to usual physical activities Fear avoidance and deconditioning, and how to address these
Modifying activities Modifying rather than avoiding activities
Work Advice on returning to work activities
Sleeping Sleep positions, pacing to lessen night-time pain
Looking after your mental well-being Activities to maintain a positive mood and when to seek medical advice
Coping with flare-ups Planning exercise and activity for times when pain is more severe
Exercise guide Benefits of exercise and how long to continue with exercise
Pain during and after exercise
Guidance on doing GRASP trial exercises with full instructions (e.g. colour
photographs and text explaining technique and modifications that can be made)
Note
Exercise details were specific to the progressive-exercise or best-practice advice intervention.
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Progressive-exercise intervention
Participants received up to six sessions with a physiotherapist over 16 weeks. The initial session was
set to last up to 60 minutes for assessment and treatment initiation, followed by up to five 20- to
30-minute follow-up sessions. The physiotherapist and participant decided how frequently to schedule
the review appointments within the 16-week time frame. Six sessions over 16 weeks was set to allow
the exercise intensity to be progressed and because it was a volume of physiotherapy within the range
of feasible delivery in the NHS. It was also deemed to be a sufficient time for a physiological response
in the neuromuscular system.46 The participant information booklet was provided in a file so that
instructions on the progressive exercises selected could be inserted, including detailed guidance and
photos for each exercise. The physiotherapist and participant jointly chose one to three exercises
to address the problems identified during the assessment (Figure 1). We anticipated participants
presenting with different problems and pain irritability and, therefore, the exercises were categorised
into three difficulty levels (level 1, 2 and 3 exercises), with progressions within each level and different
aims and guidelines to match indications for use.
Assessment
Agree level of exercise – can advise to
















Review at next appointment
• Check conf idence level
• Issue/review exercise diary
• Issue/review action planner














FIGURE 1 Process map of the GRASP trial progressive exercise intervention.
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Level 1 exercises: simple shoulder movements
Level 1 exercises aimed to reduce fear, encourage normal movement, improve shoulder mobility and
build confidence in exercising independently at home (see Appendix 3, Figure 17). The exercises were
considered appropriate for participants with irritable and/or severe shoulder pain and/or fear
avoidance. The frequency and the number of sets and repetitions for each exercise were agreed
between the physiotherapist and participant. Depending on symptom severity, it was recommended
that some participants could reasonably move straight to level 2 exercises.
Level 2 exercises: progressive structured resistance training
Level 2 exercises included the essential exercises that target strengthening of the posterior rotator
cuff muscles and other optional exercises (see Appendix 3, Figure 18). The essential exercises focused
on movements commonly affected by a rotator cuff disorder (i.e. resisted external rotation, flexion
and abduction of the shoulder).64 Resistance exercises for other shoulder movements were optional.
If participants were prescribed exercises at level 2, at least one had to be from the essential
exercise category.
The American College of Sports Medicine guidance for progressive resistance training recommends
two to three sessions of resistance training per week,20 whereas many studies of resistance training in
patients with musculoskeletal disorders use daily exercise programmes.21,72 We attempted to strike a
balance, ensuring that the resistance training was effective, but also regular enough to address other
aims, such as building confidence in moving the arm and re-learning motor skills. We asked GRASP trial
participants to do their exercises 5 days per week, with 2 non-consecutive recovery days.
Physiotherapists were taught to regulate the exercise intensity using the modified Borg scale of
perceived exertion, an 11-point version of the Rating of Perceived Exertion (RPE) scale,73 validated for
quantifying the intensity of resistance exercise.74 Participants started at a moderate load (3 or 4 on
the Borg scale) to enhance motivation and adherence and reduce the likelihood of symptom flare-up.
Figure 2 contains detailed guidance on the scale and how level 2 exercises were initiated, progressed
and regressed. Where appropriate, resistance bands or hand weights were incorporated into the
exercise, with the level of resistance recommended being guided by the RPE scale feedback from
the participant.
Level 3 exercise: patient-specific functional restoration
It was recommended that participants progress to level 3 when their initial problems (e.g. weakness)
began to resolve. The physiotherapist altered the exercise programme to be more task specific (e.g.
returning to sport) by devising a new exercise in consultation with the participant. Level 3 exercises
aimed to modify the essential resistance-training exercises towards the specific movements required to
achieve the participant’s individual functional goals. The exercise could be high or low load, using many
or few repetitions, depending on the participant’s needs. It was recognised that not all GRASP trial
participants would reach or need this stage of the programme. We anticipated that level 3 exercise
instructions would be given face to face and reinforced with written guidance to aid recall.
Optional stretching exercise
Posterior capsule and/or soft tissue stretches of the shoulder (see Appendix 3, Figure 19) were included
as optional exercises at any stage. We recommend selective use, generally for younger adults engaged
in throwing or other overhead athletic or physical activities75 who have posterior capsule tightness.
We anticipated these exercises to be suitable for participants with low irritability and if they did not
provoke symptoms. Although discomfort and stretching sensations were considered acceptable during
stretches, we did not anticipate provocation of anterior shoulder pain or reproduction of the participant’s
specific symptoms. We advised holding stretches for 20–30 seconds, but the physiotherapist and
participant decided the number of repetitions and frequency.
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0 1 2 3 4 5 6 7 8 9 10
Using a number between 0 and 10, indicate on the scale above how hard it is to do the exercise.










































With participant, choose an exercise likely
to be suitable
Estimate a suitable starting load and
attempt three repetitions
Participant rates the perceived exertion
(RPE) from 0 to 10 using the










RPE 3 or 4:
complete f ive more
repetitions (rest of
























Once RPE is at 3 or 4,
start home exercise
with one set of eight
repetitions (advising
to build up to 12
repetitions as
appropriate), once
per day, five times
per week (with 2
non-consecutive
rest days in between)
Repeat for each level 2
exercise in programme





If RPE lower than 3 and has successfully progressed
to 12 repetitions, exercises may be progressed:
• Add sets up to two or three sets of 8–12 repetitions;
    rest 2 minutes between sets
• Increase load/resistance to get back to RPE 3 or 4
• Further increase load/resistance to RPE 4–5, or
    5–7, if participant is conf ident
• Increase in sets and load could be done together
    if the participant and therapist agree
• The maximum volume of sets and repetitions
    (3 × 12) at Borg RPE = 7 is achieved
• If change of exercise is deemed appropriate to
    progress the exercise programme
Regression
If the patient cannot do eight
repetitions of a particular exercise
at the selected load and target RPE,
or can manage this but experiences 
an unacceptable increase in pain,
reduce the load to a level at which
they are able to do at least eight
repetitions
If they are still unable to do one set
of eight repetitions using the lowest
load, then you can:
• Remove load altogether
• Reduce repetitions to fewer 
    than eight
• Reduce range of movement or
    alter the position
• Choose another exercise
(c)
A more dif f icult exercise should be considered
when either:
FIGURE 2 Guidance for setting level 2 resistance exercises in the GRASP trial. (a) Modified Borg scale; (b) setting the
initial exercise; and (c) progression and regression decision guidance.
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Exercise progression
During the physiotherapist training, emphasis was placed on the need to progress the exercise interventions
as much as possible. To determine that this had in fact occurred, treatment logs completed for each
session by the physiotherapists [detailing prescribed exercises, number of sets/repetitions (i.e. volume)
and exercise intensity73] were analysed to allow an estimation of treatment progression for the progressive-
exercise intervention (see Chapter 4). Exercises were categorised and ranked in order of difficulty level





5. loaded exercises (isotonic) in neutral (0 °)
6. loaded exercises (isotonic) at 90 °(supported)
7. as for 6, but unsupported
8. as for 7, but through range.
Progression of the progressive-exercise intervention was defined as an increase in exercise difficulty,
or volume and/or load across attended sessions. Maintained indicates no changes in exercise parameters.
Regressed is defined as a decrease in exercise level, or volume and/or load.
Best-practice advice intervention
The best-practice advice intervention was a single face-to-face session with a physiotherapist, lasting
up to 60 minutes. With only one session, there was a substantially greater reliance on self-management
than in the progressive-exercise intervention. As per the progressive-exercise intervention, participants
were given a participant information booklet and the treating physiotherapist reinforced the education
and advice aspects that were particularly relevant.
Participants were given a simple set of self-guided exercises, including at least one level of resistance
band, to improve shoulder strength and function, which could be progressed and regressed independently
at home, depending on their capability. The exercise instructions were given in the participant information
booklet and in exercise videos available on the internet and DVDs. We aimed to make the information
accessible and appealing to a wide range of individuals by using different media.76
This intervention offered a simpler range of exercise options than the progressive-exercise intervention,
although the underlying principles remained the same. The physiotherapist and participant chose one
or two exercises from the best-practice advice exercise ladder together (see Appendix 3, Figure 21).
The exercises on the ladder were arranged with easier exercises on the lower rungs and more difficult
exercises on the higher rungs. Participants were recommended to start at the level of exercise that they
were capable of undertaking, not necessarily the lowest rung. If two exercises were selected, then these
did not need to be from the same rung. The exercises at the lowest level were simple shoulder exercises
to reduce fear of movement, encourage normal movement, build shoulder mobility and build confidence
in carrying out self-directed exercises. Higher levels introduced a greater extent of resistance exercises
for posterior rotator cuff strengthening.
The Borg RPE scale was not used to measure intensity for participants in the best-practice advice group
to simplify the programme and maximise independent participant progression. We advised participants
that they should find the exercise(s) moderately difficult (i.e. not easy but not extremely hard). They
began with one set of eight repetitions at the selected load and aimed to build up to 12 repetitions,
exercising once daily for 5 days per week, with 2 non-consecutive rest days. If the exercise(s) became
too easy, another set could be added (up to a maximum of three sets). If the expanded set became
too easy, the advice was that the exercise(s) should be exchanged for the next level of difficulty.
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The next exercise, again, started with one set of eight repetitions and built up in the same way.
If the participant encountered difficulties, they were advised to reduce the load and/or number of
sets/repetitions or regress to an easier exercise.
Strategies to encourage exercise adherence
Estimates suggest that up to 70% of patients do not adhere to prescribed physiotherapy treatments.25
As part of the GRASP trial interventions, we, therefore, incorporated strategies to promote adherence to
the exercise interventions. These strategies were less extensive in the best-practice advice intervention
than in the progressive-exercise intervention, as they needed to be feasibly delivered within a single
session (see Appendix 3, Table 27).
Modifiable behavioural targets were identified from a systematic review of barriers to physiotherapy
adherence, including in-treatment exercise adherence, low self-efficacy, depression, anxiety, helplessness,
greater perceived barriers to exercise and pain levels during exercise.24 For a summary of the behaviour
change techniques used in the GRASP exercise interventions, based on the behaviour change techniques
taxonomy,77 see Appendix 3, Table 27. These techniques were selected based on their evidence base,78
successful use in other trials72 and recommendations in the NHS Health Trainer Handbook.79 Participants
were asked to complete an exercise action planner and exercise diary, which were tailored to the
interventions (see Appendix 3, Figures 15, 22 and 23). Although exercise diaries have questionable
reliability for measuring adherence because of issues with real-time compliance and recall bias,80 there
is evidence to suggest that they promote adherence.81 We assessed adherence to exercises in the
follow-up questionnaires, in which participants reported exercise frequency.
Monitoring, quality assurance and safety
We monitored intervention delivery fidelity using site monitoring visits, quality assurance visits
and central monitoring of treatment session logs. Each site was visited annually to ensure that the
physiotherapists adhered to the intervention protocol for each exercise arm. A member of the GRASP trial
research team attended an appointment session for each trial intervention and completed a standardised
checklist covering knowledge of trial procedures, returning trial paperwork, storing trial materials,
intervention delivery timing and adherence to intervention protocols. The delivering physiotherapist
received feedback at the end of each quality assurance visit. If protocol adherence was below the
required standard, further measures (e.g. retraining) were to be instituted after discussion with the
trial team and site. Common problems or failings were also shared across sites through regular trial
newsletters, e-mails and meetings.
Clinicians delivering the GRASP trial intervention were asked to complete treatment logs at the
end of each session. The logs included a checklist that documented the key elements of the session
(e.g. exercises prescribed, sets and repetitions, load, injection type and dosage/volume). These were
returned to the central GRASP trial team, which reviewed the data for each participant and entered
them onto the trial database. For the progressive-exercise intervention, exercise prescription details
were checked on arrival. An assessment of progression of exercises over the sessions was not part of
the ongoing monitoring. As described above, participants were also allowed to maintain or regress
their exercises over the sessions, if clinically appropriate. However, these data were carefully recorded,
analysed on completion of the trial and are reported in Chapter 4.
Custom-designed reports of treatment log data were generated and regularly reviewed during
the conduct of the trial for central monitoring of the intervention delivery, including the timing,
number and duration of sessions, injection details (e.g. volume/dosage), content of treatment sessions,
participant attendance and paperwork return. Intervention delivery was, therefore, monitored
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throughout the trial on a site-by-site and overall basis. Ongoing monitoring during the trial aimed to
reveal deviations or discrepancies from the trial protocol so that they could be investigated and, if
required, measures taken to address them at an early stage throughout the trial.
Completion of the best-practice advice intervention was defined as attendance at one session. For the
progressive-exercise intervention, completion of treatment was defined as attendance at all six treatment
sessions, discharged by the treating physiotherapist or referred on for further investigation/treatment
(e.g. to orthopaedic consultant). Partial completion was defined as attendance of at least one session but
not fulfilling the criteria for full completion described above.
Conclusion
This chapter described the development and details of the GRASP trial interventions for treating
rotator cuff disorders tested as part of the trial. The results on how the interventions were
implemented and the outcomes from onsite monitoring are detailed in Chapter 4.
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Trial sites
Centre characteristics
Twenty English NHS trusts participated in the GRASP trial (see Appendix 4, Table 28). The recruitment
period (20 February 2017 to 2 May 2019) at each trust varied from 9 to 26 months, with resulting
variation in the number of participants recruited at each site.
Participating clinicians
A total of 223 clinicians across the 20 trial sites were involved in providing the study treatment
interventions. Fifty-three physiotherapists and three doctors delivered subacromial corticosteroid
injections to 329 (97%) and 10 (3%) participants, respectively. The best-practice advice and progressive-
exercise interventions were delivered by 83 and 104 physiotherapists to 324 and 339 participants,
respectively (see Appendix 4, Table 29). The physiotherapists and doctors worked in hospital physiotherapy,
orthopaedic outpatient departments or at satellite clinics (e.g. general practices). Nine physiotherapists
at two sites were working for a private company contracted to provide services to NHS patients
[Buckinghamshire Musculoskeletal Integrated Care Service (High Wycombe, UK) and Medway Community
Healthcare (Rochester, UK)]. The number of physiotherapists involved at each site varied from 3 to 43
(see Appendix 4, Table 28). Several physiotherapists provided both the corticosteroid injection and either the
best-practice advice or progressive-exercise intervention. Two physiotherapists swapped treatment groups
during the trial because of staffing issues at sites and, therefore, delivered both exercise interventions.
The level of experience of each physiotherapist (as determined by Agenda for Change pay banding)72
is described in Appendix 4, Table 29. Sixty-four per cent (34/53) of physiotherapists delivering injections
were band 8. Exercise interventions were predominantly delivered by band 6 and 7 physiotherapists
(73% and 80% for best-practice advice and progressive-exercise interventions, respectively).
Participant flow
The overall flow of participants through the study is described in the CONSORT (Consolidated Standards
of Reporting Trials) diagram (Figure 3). Further details for each stage are provided in the following sections.
Recruitment
Screening
Screening and recruitment took place between February 2017 and April 2019. A total of 2287 patients
were screened and assessed to see whether or not they met the GRASP trial eligibility criteria (Table 5).
A total of 1284 (56%) patients were eligible and 708 agreed to participate. Of those participants who did
not meet the eligibility criteria (1003/2287), the most common reasons were owing to another shoulder
disorder (e.g. inflammatory arthritis, frozen shoulder, glenohumeral joint instability) or red flags
consistent with BESS criteria (n = 434, 43%), or had received corticosteroid injection or physiotherapy
for shoulder pain in last 6 months (n = 167, 17%). Of those participants who were eligible but declined to
participate (n = 576), the most common reasons given were not interested in taking part in research
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• Not interested in taking part in research, n = 175
• Does not want to be randomised, n = 39
• Preference for receiving injection, n = 38
• Preference for not receiving injection, n = 158
• Does not want to be randomised to progressive exercise, n = 6
• Does not want to be randomised to best-practice advice, n = 8
• Unable to attend treatment sessions, n = 80
• Prefer not to say, n = 20



















• History of signif icant shoulder trauma, n = 94
• Neurological disease affecting shoulder, n = 23
• Other shoulder disorder, n = 434
• Received injection in last 6 months, n = 167
• Contraindications to injection, n = 31
• Participant does not speak English, n = 32
• Unable to contact to arrange appointment, n = 59
• Symptoms have lasted > 6 months, n = 132
• Other reason, n = 31
Did not meet eligibility criteria
(n = 1003)
FIGURE 3 Participant flow diagram. a, Reasons for not receiving best-practice advice: participant did not attend session
(n = 5), withdrawal (n = 4) and other medical condition (n = 3); b, reasons for not receiving injection only: participant
declined treatment (n = 2) and contraindications (taking anticoagulants, n = 1; previous reaction to injection, n= 1);
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c, reasons for not receiving best-practice advice only: participant did not attend session (n = 5), other medical condition
(n= 2) and received progressive exercise in error (n = 3); d, reasons for not receiving injection and best-practice advice:
participant did not attend session (n= 1), participant declined treatment (n = 2), other medical condition (n= 2) and
previous reaction to injection and received non-GRASP trial treatment (n= 1); e, reason for not receiving progressive
exercise: participant did not attend session (n= 3), received best-practice advice in error (n= 2), received injection in
error (n= 1), received non-GRASP trial treatment (n = 1) and withdrawal (n = 1); f, reasons for not receiving injection
only: participant declined treatment (n= 5) and clinician declined treatment (n = 3); g, reasons for not receiving
progressive exercise only: received best-practice advice in error (n = 2), received non-GRASP trial treatment (n= 3),
other medical condition (n = 1) and participant did not attend session (n = 1); h, reasons for not receiving injection and
progressive exercise: participant did not attend session (n= 2) and other medical condition (n = 1); and i, ‘included in
the analysis’ is all participants with at least one follow-up time point SPADI outcome and the baseline variables used
in the model.










University Hospitals of Derby and Burton NHS
Foundation Trust
152 55 51 46
East Lancashire Hospitals NHS Trust 387 193 92 102
Gloucestershire Hospitals NHS Foundation Trust 435 181 134 120
Birmingham Community Healthcare NHS Trust 81 17 35 29
Sandwell and West Birmingham Hospitals NHS Trust 89 23 31 35
Buckinghamshire Musculoskeletal Integrated Care Service 41 22 5 14
East Cheshire NHS Trust 44 17 13 14
Bedfordshire Hospitals NHS Foundation Trust 72 39 10 23
Wirral University Teaching Hospital NHS Foundation Trust 58 30 15 13
Medway Community Healthcare 34 3 31
Bristol Community Health 6 1 1 4
Somerset Partnership NHS Foundation Trust 255 167 39 49
Doncaster and Bassetlaw Teaching Hospitals NHS
Foundation Trust
81 28 20 33
Sherwood Forest Hospitals NHS Foundation Trust 66 14 23 29
Kent Community Health NHS Foundation Trust 62 10 16 36
Northern Devon Healthcare NHS Trust 127 50 41 36
Airedale NHS Foundation Trust 69 36 8 25
North West Boroughs Healthcare NHS Foundation Trust 163 92 31 40
Warrington and Halton Hospitals NHS Foundation Trust 52 25 9 18
Staffordshire and Stoke-on-Trent Partnership NHS Trust 13 2 11
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(n = 175, 30%) or had a treatment preference for not receiving injection (n = 158, 27%). For full details
see Appendix 4, Table 30. The mean age of those who declined to participate was 55 years (median 56 years,
IQR 46–65 years) and 53% (n = 306) were female.
A total of 708 participants were recruited between March 2017 and May 2019 (see Appendix 4, Figure 24).
This exceeded the target of 704 participant; four participants were randomised once the target was
reached as they were already in the process of joining the study.
Baseline data
Baseline characteristics of participants
The baseline characteristics of participants recruited into the trial are shown in Table 6 (for more detail
see Appendix 4, Tables 31–33). Intervention groups were generally well matched in terms of baseline
demographic data and primary and secondary outcome measurements. Stratification factors used in
the randomisation are shown in Appendix 4, Table 34. The majority of participants were white British
(89.6%), with similar numbers of men and women (50.7% vs. 49.3%). The overall mean age was 55.5
(SD 13.1) years. The majority of participants reported being married (64.8%) or living with a partner
(13.1%). More than two-thirds of participants were classified as either overweight (38.7%) or obese
(30.6%). Approximately half (58.9%) reported being in employment, with one-quarter (25.8%) being
retired. The majority of participants reported being right-handed (87%) and the numbers were similar
in terms of whether the right or left shoulder was affected (49.3% vs. 46.9%). The average duration of
rotator cuff symptoms was 4 (median 4, IQR 3–6) months.
















Age (years), mean (SD), n 55.9 (13.1), 174 56.5 (12.4), 178 54.6 (13.7), 174 54.8 (13.2), 182
18–35 years, n (%)a 11 (6.3) 13 (7.3) 14 (8.0) 17 (9.3)
≥ 36 years, n (%)a 163 (93.7) 165 (92.7) 160 (92.0) 165 (90.7)
Sex, n (%)a
Male 87 (50.0) 89 (50.0) 90 (51.7) 93 (51.1)
Female 87 (50.0) 89 (50.0) 84 (48.3) 89 (48.9)
Ethnicity, n (%)
White 160 (92.0) 167 (93.8) 154 (88.5) 167 (91.8)
Other 14 (8.0) 11 (6.2) 18 (10.4) 15 (8.2)
Missing 0 (0.0) 0 (0.0) 2 (1.1) 0 (0.0)
Marital status, n (%)
Married/civil union 118 (67.8) 107 (60.1) 114 (65.5) 120 (65.9)
Living with partner 24 (13.8) 23 (12.9) 22 (12.6) 24 (13.2)
Other 32 (18.4) 48 (27.0) 36 (20.8) 38 (20.9)
Missing 0 (0.0) 0 (0.0) 2 (1.1) 0 (0.0)
Height (m), mean (SD), n 1.7 (0.0), 174 1.7 (0.0), 178 1.7 (0.2), 172 1.7 (0.2), 182
Weight (kg), mean (SD), n 80.9 (16.6), 174 82.9 (17.4), 176 81.2 (18.4), 170 81.7 (18.0), 180
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Body mass index (kg/m2), mean (SD), n 27.9 (5.0), 174 28.7 (5.4), 176 28.0 (5.4), 170 28.1 (4.8), 180
Underweight (< 18.5 kg/m2), n (%) 3 (1.7) 1 (0.6) 0 (0.0) 0 (0.0)
Normal weight (18.5–24.9 kg/m2), n (%) 51 (29.3) 51 (28.7) 50 (28.7) 53 (29.1)
Overweight (25–29.9 kg/m2), n (%) 68 (39.1) 63 (35.4) 73 (42.0) 70 (38.5)
Obese (≥ 30 kg/m2), n (%) 52 (29.9) 61 (34.3) 47 (27.0) 57 (31.3)
Missing 0 (0.0) 2 (1.1) 4 (2.3) 2 (1.1)
Smoking status, n (%)
Never smoked 85 (48.9) 100 (56.2) 99 (56.9) 101 (55.5)
Former smoker 66 (37.9) 66 (37.1) 61 (35.1) 63 (34.6)
Current smoker 23 (13.2) 12 (6.7) 12 (6.9) 18 (9.9)
Missing 0 (0.0) 0 (0.0) 2 (1.1) 0 (0.0)
Cigarettes smoked per day
(current smoker), median (IQR), n
10 (10, 15), 21 15 (5, 18), 11 13 (8, 18), 12 10 (6, 12), 17
Cigarettes smoked per day
(former smoker), median (IQR), n
13.5 (6–20), 66 15.0 (10–20), 66 10.0 (5–20), 60 10.0 (8–20), 63
Symptoms duration, median (IQR), n 4.0 (2–6), 173 4.0 (3–6), 178 4.0 (3–6), 172 4.0 (3–6), 182
Affected shoulder, n (%)
Left shoulder 89 (51.1) 78 (43.8) 83 (47.7) 82 (45.1)
Right shoulder 78 (44.8) 94 (52.8) 84 (48.3) 93 (51.1)
Both shoulders 7 (4.0) 6 (3.4) 5 (2.9) 7 (3.8)
Missing 0 (0.0) 0 (0.0) 2 (1.1) 0 (0.0)
Hand dominance, n (%)
Left-handed 13 (7.5) 16 (9.0) 21 (12.1) 21 (11.5)
Right-handed 157 (90.2) 153 (86.0) 148 (85.1) 158 (86.8)
Both 4 (2.3) 9 (5.1) 3 (1.7) 3 (1.6)
Missing 0 (0.0) 0 (0.0) 2 (1.1) 0 (0.0)
Current work status, n (%)
Retired 44 (25.3) 50 (28.1) 40 (23.0) 49 (26.9)
Semi-retired 13 (7.5) 10 (5.6) 9 (5.2) 7 (3.8)
Employed 84 (48.2) 91 (51.1) 98 (56.3) 82 (45.1)
Other 33 (19.0) 27 (15.2) 25 (14.4) 43 (23.7)
Missing 0 (0.0) 0 (0.0) 2 (1.1) 1 (0.5)
SPADI, mean (SD), n
Pain subscale 66.0 (17.7), 174 64.2 (18.3), 178 60.7 (17.1), 172 64.6 (17.5), 182
Function subscale 48.1 (23.2), 174 46.3 (22.0), 178 40.3 (21.0), 172 42.6 (21.6), 182
SPADI overall 57.0 (19.2), 174 55.3 (18.9), 178 50.5 (17.5), 172 53.6 (17.8), 182
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The overall mean baseline SPADI score was 54.1 (SD 18.5) (on a scale of 0–100, with higher values
being worse), suggesting a moderate level of disability, with higher levels of shoulder pain (mean SPADI
pain subscale 63.9, SD 17.1) compared with impairment of shoulder function (mean SPADI function
subscale 44.3, SD 22.1). Overall baseline scores for secondary outcome measures were mean 15.1
(SD 5.5) for FABQ-PA, mean 9.7 (SD 2.3) for PSEQ-2, mean 10.5 (SD 6.3) for ISI and mean 7.9 (SD 2.6)
for RDA. Mean baseline values were in the moderate to low range, suggesting that a participant’s
rotator cuff disorder may not be having considerable impact on sleep and daily activities despite higher
levels of pain.
















FABQ-PA, mean (SD), n 15.6 (5.8), 172 15.7 (5.4), 177 14.2 (5.5), 172 14.8 (5.3), 182
PSEQ-2, mean (SD), n 9.6 (2.4), 174 9.5 (2.3), 178 9.8 (2.3), 172 9.7 (2.3), 182
ISI, mean (SD), n 11.0 (6.7), 173 10.4 (6.2), 176 9.5 (5.7), 170 11.1 (6.4), 180
RDA, mean (SD), n 8.0 (2.7), 174 8.2 (2.5), 178 7.6 (2.7), 172 7.7 (2.6), 182
Trial centre, n (%)a
1 12 (6.9) 9 (5.1) 12 (6.9) 13 (7.1)
2 26 (14.9) 26 (14.6) 25 (14.4) 25 (13.7)
3 29 (16.7) 30 (16.9) 31 (17.8) 30 (16.5)
4 8 (4.6) 7 (3.9) 7 (4.0) 7 (3.8)
5 9 (5.2) 8 (4.5) 8 (4.6) 10 (5.5)
6 3 (1.7) 3 (1.7) 4 (2.3) 4 (2.2)
7 3 (1.7) 4 (2.2) 3 (1.7) 4 (2.2)
8 5 (2.9) 6 (3.4) 7 (4.0) 5 (2.7)
9 4 (2.3) 3 (1.7) 4 (2.3) 2 (1.1)
10 7 (4.0) 7 (3.9) 8 (4.6) 9 (4.9)
11 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.5)
12 12 (6.9) 12 (6.7) 13 (7.5) 12 (6.6)
13 8 (4.6) 8 (4.5) 7 (4.0) 10 (5.5)
14 7 (4.0) 9 (5.1) 6 (3.4) 7 (3.8)
15 9 (5.2) 9 (5.1) 8 (4.6) 10 (5.5)
16 9 (5.2) 10 (5.6) 8 (4.6) 9 (4.9)
17 6 (3.4) 7 (3.9) 6 (3.4) 6 (3.3)
18 9 (5.2) 11 (6.2) 9 (5.2) 11 (6.0)
19 2 (1.1) 3 (1.7) 3 (1.7) 3 (1.6)
20 5 (2.9) 5 (2.8) 4 (2.3) 4 (2.2)
a Stratification factor used in randomisation.
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Follow-up
Participants were followed up at 8 weeks and at 6 and 12 months; overall response rates were
91% (641/708), 87% (615/708) and 87% (618/708), respectively. Response rates were generally well
balanced across intervention groups. Appendix 4, Table 35, shows the number of responses according
to type of follow-up (i.e. postal or telephone questionnaire).
Withdrawals
Overall, 26 (3.7%) participants withdrew from the trial: 15 withdrew from the intervention delivery
only and 11 withdrew from both the intervention and follow-up questionnaire completion. Numbers
were very similar across intervention groups. One participant withdrew completely from the trial and
withdrew permission to use their data. Details of the reasons for withdrawal by intervention group are
shown in Table 7. Two participants died and both deaths were unrelated to the trial intervention(s).
Intervention delivery
Compliance with intervention
Of the 708 participants randomised, the majority received treatment as allocated, with 94% (339/360)
of participants randomised to receive subacromial corticosteroid injection prior to either the best-
practice advice or progressive-exercise intervention receiving the injection as allocated (Table 8).





















n % n % n % n % n %
Overalla
Complete withdrawal from use of data 0 0 0 0 1 1 0 0 1 0
Withdrawn from interventiona 3 2 4 2 2 1 6 3 15 2
Believes intervention not working 1 1 1 1 0 0 0 0 2 0
Change of diagnosis since randomisation 0 0 3 2 1 1 4 2 8 1
Had treatment preference 1 1 0 0 0 0 0 0 1 0
No reason given 1 1 0 0 0 0 0 0 1 0
Pain has improved 0 0 0 0 1 1 0 0 1 0
Unable to continue with treatment 0 0 0 0 0 0 2 1 2 0
Withdrawn from intervention and future
assessmentsa
4 2 3 2 3 2 0 0 11 2
Believes intervention not working 0 0 1 1 1 1 0 0 2 0
Change of diagnosis since randomisation 3 2 0 0 1 1 0 0 4 1
No reason given 1 1 2 1 1 1 0 0 4 1
Missing 0 0 0 0 0 0 0 0 1 0
a Death (unrelated to the study intervention) was reported for two participants at the 6-month follow-up. One
participant withdrew from the intervention and another was classified as withdrawn from intervention and future
assessments following notice of their death.
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Injection received, n (%) 168 (94) 171 (94)
Injection not received, n (%) 10 (6) 11 (6)
Did not attend, n (participants) 1 2
Participant declined, n (participants) 4 4
Clinician declined, n (participants) 5 5
Received extra injection, n (participants) 0 2
Completed exercise treatment,c n (%) 162 (93) 162 (91) 138 (79) 139 (76)
Partial exercise completion,d n (%) 29 (17) 33 (18)
Received no treatment, n (%) 12 (7) 16 (9) 7 (4) 10 (5)
Did not attend/unable to contact,
n (participants)
5 6 3 3
Withdrawal/declined, n (participants) 4 2 1 0
Other condition, n (participants) 3 4 0 2
Received wrong trial intervention,
n (participants)
0 3 2 2
Received non-GRASP trial treatment,
n (participants)
0 1 1 3
Median number of sessions (IQR) 1 (1–1) 1 (1–1) 4 (3–6) 4 (3–5)
Attendance, n (%)
Session 1 162 (93) 162 (91) 167 (96) 172 (95)
Session 2 161 (93) 160 (88)
Session 3 144 (83) 136 (75)
Session 4 101 (58) 100 (55)
Session 5 72 (41) 69 (38)
Session 6 44 (25) 38 (21)
Participants receiving additional sessions, n (%) 3 (2) 5 (3) 3 (2) 2 (1)
Additional contact sessions,e n 4 6 3 5
Telephone 2 1 0 1
Face to face 2 5 3 4
a Maximum of one session of best-practice advice.
b Up to six sessions of progressive exercise.
c Best-practice advice: attendance at one or more sessions. Progressive exercise: six sessions attended, discharged by
clinician as treatment completed (as marked on treatment log), discharged by clinician following patient-initiated
follow-up period with no further contact or referred on for further investigation/treatment.
d Defined as attendance at one or more sessions.
e Some participants received more than one additional contact.
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For the exercise interventions, there was no difference in attendance rates between those receiving
the exercise interventions only and those who received exercise in conjunction with a corticosteroid
injection. Overall, 92% (324/352) of participants of those allocated to receive the best-practice advice
intervention attended, and 95% (339/356) of participants allocated to receive progressive exercise
either partially or fully completed the exercise intervention.
The proportion of participants not attending any treatment sessions was roughly equal between
intervention groups. For the progressive-exercise intervention, just over half of participants received
four out of a maximum of six sessions, with almost 80% receiving at least three sessions. Note that,
participants could be discharged prior to attending six sessions if their symptoms had improved sufficiently.
A small number of participants received extra treatment over and above the interventions defined
by the GRASP trial protocol. Two sites reported that two participants received a second subacromial
corticosteroid injection in addition to that received as part of their treatment allocation. With regard to
the exercise interventions, eight participants allocated to receive best-practice advice received a total
of 10 additional sessions. For progressive exercise, five participants received a total of eight additional
sessions over and above the six-session maximum. Three of the 13 participants who received additional
sessions required further reassurance regarding their condition and/or the exercise programme, four
required further session(s) before treatment was concluded satisfactorily, three reported a re-occurrence
or suffered re-injury and three reported no improvement in symptoms. There was no sizeable difference
in the proportion of participants receiving additional sessions (nor the reasons for further contact)
between the four intervention groups.
Timing of delivery of interventions
Appendix 4, Table 36, presents median time from randomisation to first appointments for each intervention
group. Subacromial corticosteroid injections prior to receiving the best-practice advice or progressive-
exercise interventions were largely delivered within 10 days of randomisation in accordance with the
GRASP trial protocol. The first session of the exercise interventions was also delivered within the required
time frames for all trial groups, with the majority of participants being seen between 14 and 28 days after
randomisation. Participants randomised to injection received their first exercise session 6 days later, on
average, than those who were not allocated to receive an injection, possibly because of logistical issues
with booking appointments. The progressive-exercise intervention was generally completed within the
recommended 16-week time frame, with the median time corresponding to between 13 and 15 weeks for
both intervention groups. The initial delay experienced by those who received an injection prior to their
exercise sessions is reflected in the longer time to the last session, although the ‘actual’ exercise treatment
period (i.e. first to last exercise session) was almost identical for both progressive-exercise arms.
Content and adherence to interventions
Injecting clinicians and physiotherapists completed a treatment log for each session, detailing the type
of treatment provided.
Subacromial corticosteroid injection
Triamcinolone acetonide was the most commonly delivered corticosteroid, accounting for 64% (218/339)
of injections delivered overall. The remaining 36% (121/339) of participants received methylprednisolone
injection (Table 9). Lidocaine 1% was the most commonly delivered local anaesthetic (294/339, 87%),
with only 10% (33/339) receiving 0.5% bupivacaine hydrochloride. Twelve participants received no local
anaesthetic (4%), usually because of clinician preference or previous history of adverse reactions. The
majority of injections were administered into the posterior subacromial space (278/339, 82%). There
were no meaningful differences in injection delivery between the two injection groups. The median
dose of corticosteroid prescribed was 40 mg (range of 10–40 mg for methylprednisolone and 20–40 mg
for triamcinolone acetonide) and the median volume of local anaesthetic was 4 (range of 0.2–5) ml for
1% lidocaine and 9 (range 2–10) ml for 0.5% bupivacaine hydrochloride, indicating that the injection
protocol was adhered to by all injecting therapists.
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Best-practice advice intervention
Table 10 provides a summary of the treatment logs per session for the best-practice advice intervention.
The figures indicate a high level of compliance (as recorded by the treating physiotherapist) with the
treatment protocols with regard to provision of exercises, advice, information and treatment compliance
strategies. Resisted (isotonic) shoulder external rotation in neutral and active-assisted (wall) shoulder
flexion were the most commonly prescribed starting exercises. Ninety-eight per cent (318/324) of
participants were prescribed one or two exercises at their treatment session. There were no meaningful
differences between those randomised to receive corticosteroid injection plus band and those who
received best-practice advice only.
Progressive-exercise intervention
Table 11 (see also Appendix 4, Table 37) provides details of the delivery of the progressive-exercise
intervention for each session, as recorded by the treating physiotherapist on the participant treatment
log. Similar to the best-practice advice intervention, the figures illustrate a high level of compliance
in delivering the various components of the intervention. The most commonly prescribed exercises
were from the core exercise section, aimed at strengthening the posterior rotator cuff muscles.
All participants in the progressive-exercise intervention received the required number of exercises
(i.e. three or less). Level 2 strengthening exercises were the core element of the progressive-exercise
intervention and, when these were prescribed, participants were initially expected to perform one set
of up to eight repetitions at a load of 3–4 on the modified 10-point Borg scale. Of the 339 participants
who attended, 98% (332/339) received these core exercises. In accordance with the trial protocol,
data from the treatment logs suggest that on initial presentation, 72% (238/332) of participants











Corticosteroid, n (%), median dose/volume (IQR)
Methylprednisolone (mg) 60 (35), 40 (32–40) 61 (36), 40 (30–30) 121 (36), 40 (30–40)
Triamcinolone acetonide (mg) 111 (65), 40 (20–20) 107 (64), 40 (20–40) 218 (64), 40 (20–40)
Local anaesthetic, n (%), median dose/volume (IQR)
1% lidocaine (ml) 148 (87), 4 (2–5) 146 (87), 4 (2–5) 294 (87), 4 (2–5)
0.5% bupivacaine hydrochloride (ml) 18 (11), 9 (9–9) 15 (9), 9 (9–10) 33 (10), 9 (9–9)
None 5 (3) 7 (4) 12 (4)
Shoulder, n (%)
Right shoulder 91 (53) 90 (54) 181 (53)
Left shoulder 80 (47) 78 (46) 158 (47)
Injection site, n (%)
Anterior subacromial 13 (7) 14 (8) 27 (8)
Posterior subacromial 142 (83) 136 (81) 278 (82)
Lateral subacromial 15 (9) 15 (9) 30 (9)
Glenohumeral joint 1 (1) 3 (2) 4 (1)
a Per cent of participants who received injection.
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were prescribed one set of exercises, 74% (247/332) were prescribed up to eight repetitions and 83%
(277/332) were requested to perform at a load of 3–4 on the Borg scale. Note that 55% (184/332)
of participants were prescribed all of these components correctly in combination and in accordance
with the protocol. Where the protocol was not adhered to, clinicians nearly always overprescribed by
including additional sets and/or repetitions, or by setting higher intensities with target Borg scale
scores of > 4. Only 3% (10/332) of participants were underprescribed at the initial session, with all of
these relating to lower-target Borg scale scores.
Exercise progression
Appendix 4, Table 38, describes the proportion of participants who were progressed, maintained or
regressed, as defined previously in Chapter 3. Two-thirds (227/339) of participants who received the
progressive-exercise intervention had their exercise progressed in accordance with the instructions
provided in training. A small minority of participants had their exercise programme regressed (39/339,
12%) overall, whereas the remaining participants maintained (73/339; 22%) exercising at the same
level as the initial session over the course of their treatment.
TABLE 10 Content of best-practice advice intervention
Treatment component
Best-practice advice












Exercises prescribed 162 (100) 162 (100) 324 (100)
Advice/information booklet provided 161 (99) 162 (100) 323 (100)
Exercise diary issued 162 (100) 159 (98) 321 (99)
Action planner completed 160 (99) 160 (99) 320 (99)
Exercise video online/DVD provided 160 (99) 158 (98) 318 (98)
Exerciseb
1 (a) Shoulder abduction supported
by table in sitting
31 (10) 20 (6) 51 (8)
(b) Shoulder flexion supported by
table in sitting
22 (7) 18 (6) 40 (6)
2 (a) Isometric shoulder external
rotation
29 (9) 30 (9) 59 (9)
(b) Isometric shoulder abduction 36 (11) 35 (11) 71 (11)
3 (a) Resisted shoulder external
rotation: 0 degrees
89 (28) 82 (26) 171 (27)
(b) Shoulder flexion up a wall 60 (19) 66 (21) 126 (20)
4 (a) Resisted shoulder external
rotation: 90 degrees
16 (5) 32 (10) 48 (8)
(b) Shoulder raise using a weight 26 (8) 30 (9) 56 (9)
5 (a) Resisted shoulder abduction/
external rotationc
11 (3) 7 (2) 18 (3)
Total 320 (100) 320 (100) 640 (100)
a Per cent of those who attended best-practice advice.
b Number of times exercise prescribed. Number of participants attending = 324, but participants usually received
more than one exercise.
c Using resistance band.
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1 Progressive exercise only 167 (100) 167 (100) 166 (99) 164 (98) 163 (98) 165 (99)
Injection plus progressive exercise 172 (100) 172 (100) 171 (99) 171 (99) 172 (100) 172 (100)
2 Progressive exercise only 161 (100) 160 (99) 30 (19) 153 (95) 91 (57) 150 (93)
Injection plus progressive exercise 160 (100) 158 (99) 28 (18) 147 (92) 99 (62) 144 (90)
3 Progressive exercise only 144 (100) 138 (96) 23 (16) 133 (92) 88 (61) 124 (86)
Injection plus progressive exercise 136 (100) 132 (97) 25 (18) 126 (93) 88 (65) 117 (86)
4 Progressive exercise only 101 (100) 96 (95) 22 (22) 94 (93) 69 (68) 88 (87)
Injection plus progressive exercise 100 (100) 94 (94) 19 (19) 93 (93) 67 (67) 88 (88)
5 Progressive exercise only 72 (100) 66 (92) 16 (22) 66 (92) 52 (72) 62 (86)
Injection plus progressive exercise 69 (100) 66 (96) 11 (16) 64 (93) 49 (71) 62 (90)
6 Progressive exercise only 44 (100) 42 (95) 14 (32) 38 (86) 31 (70) 37 (84)
Injection plus progressive exercise 38 (100) 36 (95) 4 (11) 35 (92) 25 (66) 34 (89)




























Participant-reported adherence to exercise
As part of the participant follow-up questionnaires, participants were asked whether or not they were
currently performing the exercises the physiotherapist asked them to complete at home as part of the
GRASP trial. A total of 77.8% of participants reported ‘yes’ at 8 weeks, but this dropped to 49.3% and
32.1% at 6 and 12 months, respectively. Participants were also asked how often they were performing
these exercises. Appendix 4, Table 39, shows the difference in proportions across intervention groups.
At 8 weeks, participants who received progressive exercise were more likely to report performing their
exercises 5 days per week than those receiving best-practice advice (60.4% vs. 43.2%) and there was
little difference at 6 and 12 months. At 8 weeks and 6 months, participants who received injection were
more likely to report performing their exercises 5 days per week than those who received no injection
(8 weeks, 57.5% vs. 46.0%; 6 months, 21.4% vs. 12.1%). There was little difference at 12 months.
Quality assurance
As well as monitoring intervention delivery using the treatment logs, annual site visits using a
standardised checklist to audit adherence to the GRASP trial protocol were conducted to evaluate the
delivery of the interventions. A total of 48 visits involving 45 physiotherapists took place during the
trial at 19 of the 20 trial sites. One site was not visited because of the small numbers recruited (n = 4).
Observation of the treatment sessions indicated that all physiotherapists were following the protocol
satisfactorily. Only two physiotherapists swapped treatment groups during the trial, because of staffing
issues, and, therefore, delivered both exercise interventions. Feedback regarding suggested areas of
improvement was provided after the treatment session. In general, the most common areas discussed
were related to improving the assessment of potential barriers to participants’ performance of the
home exercise programme, linking the performance of the exercises with relevant functional goals and
attempting to involve the participant more in the exercise prescription process.
Outcomes and estimations
The primary analysis was ITT and was based on all participants with at least one follow-up time point
SPADI outcome and the baseline variables used in the model. From the 708 participants randomised,
primary outcome data were available for 90.1% (n = 638) of participants at 8 weeks, 86.9% (n = 615) of
participants at 6 months and 87.1% (n = 617) of participants at 12 months. A total of 1869 participant
data points contributed to the primary outcome-adjusted analysis model. The number of participants
contributing data to each of the secondary outcomes are presented separately.
Primary outcome: shoulder pain and function – SPADI
The primary outcome was shoulder pain and function measured using the SPADI scale over 12 months.
There was a considerable overall improvement in SPADI score in each of the four intervention groups
from baseline over time. Overall, this represents a 32.2 (SD 23.9)-point improvement on the SPADI
scale [overall SPADI score 54.1 (SD 18.4) at baseline and 21.9 (SD 23.4) at 12 months] (Table 12).
There is no substantial evidence of a floor or ceiling effect in SPADI score, which is considered to be
present if > 15% of the respondents achieved the lowest or highest possible score, respectively.83
Interaction
As per the SAP,37 the presence of an interaction on the primary outcome was formally investigated.
A repeated-measures linear mixed-effects regression model was fitted to test the presence of an
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interaction between injection and progressive exercise. The model was adjusted for the fixed effects
of age (continuous value), sex, baseline SPADI and time point, with random intercepts by centre,
physiotherapist and observations within participant. The physiotherapist treating the largest number
of sessions was selected for each participant and included in the model. The interaction coefficient
between progressive exercise and injection over 12 months was 2.17 (95% CI –2.96 to 7.31; p = 0.407),
showing no evidence of a statistically significant interaction effect. Additionally, the interaction was
assessed at each time point using a regression model adjusted for similar variables. At 8 weeks, the
interaction was 3.41 (95% CI –3.24 to 10.06; p = 0.314), at 6 months the interaction was –1.88 (95% CI
–9.98 to 6.22; p = 0.649) and at 12 months the interaction was 2.25 (95% CI –5.76 to 10.26; p = 0.581),
showing no evidence of a statistically significant effect. As per the SAP, the analysis at the margins is,
therefore, the primary analysis for interpretation (i.e. considering the main effects of injection vs. no
injection and progressive exercise vs. best-practice advice). Inside-the-table analysis results are reported
in Appendix 4, Tables 40 and 41, for completeness.
The results presented here are for the two main effect comparisons:
1. an individually tailored progressive-exercise programme compared with a best-practice advice
session with a physiotherapist supported by high-quality materials
2. subacromial corticosteroid injection compared with no injection.
SPADI: progressive exercise compared with best-practice advice
Table 13 presents the unadjusted and adjusted results for SPADI at 8 weeks and at 6 and 12 months.
Figure 4 shows an improvement in shoulder pain and function in both intervention groups over time.
However, there was no evidence of a statistically significant difference between the progressive-
exercise intervention and best-practice advice intervention in shoulder pain and function when
analysed over 12 months (adjusted mean SPADI difference between groups –0.66, 99% CI –4.52 to
3.20). There was also no statistically significant difference between progressive exercise and best-
practice advice when analysed at 8 weeks and at 6 at 12 months (adjusted MD at 12 months –3.10,
99% CI –7.85 to 1.64).
SPADI: injection compared with no injection
Table 14 presents the unadjusted and adjusted results for SPADI at 8 weeks and at 6 and 12 months.
Figure 5 shows an improvement in shoulder pain and function in both groups over time. Injection
resulted in an improvement in shoulder pain and function when analysed at 8 weeks compared
with no injection (adjusted mean SPADI difference between groups –5.64, 99% CI –9.93 to –1.35).















Baseline 57.0 (19.0), 174 55.3 (19.0), 178 50.5 (17.4), 172 53.6 (17.8), 182 54.1 (18.5), 706
8 weeks 43.8 (22.6), 149 33.5 (21.6), 163 39.7 (21.6), 157 37.9 (24.0), 169 38.6 (22.8), 638
6 months 28.3 (24.4), 143 28.1 (23.4), 158 24.1 (22.2), 151 26.6 (24.0), 163 26.8 (23.6), 615
12 months 24.0 (24.8), 143 23.9 (23.5), 160 17.9 (21.1), 153 21.7 (24.0), 161 21.9 (23.4), 617
Note
Values are mean (SD), n.
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TABLE 13 Progressive exercise vs. best-practice advice at-the-margins analysis of SPADI
SPADI n












Baseline 352 56.1 (19) 354 52.1 (17.7)
8 weeks 312 38.4 (22.7) 297 36.96 (1.32) 326 38.7 (22.9) 316 39.50 (1.26) 2.54
(–2.16 to 7.23)
0.164
6 months 301 28.2 (23.8) 288 27.39 (1.33) 314 25.4 (23.1) 307 25.87 (1.27) –1.52
(–6.26 to 3.22)
0.410













a SPADI analysis adjusted for age, sex and baseline SPADI, with random effects within participant, physiotherapist and centre.




















2.54 (–2.16 to 7.23)
–1.52 (–6.26 to 3.22)
–3.10 (–7.85 to 1.64)
SPADI over 12 months –0.66 (–4.52 to 3.20)
Baseline 8 weeks 6 months 12 months
Time point
FIGURE 4 Marginal adjusted mean SPADI values from the repeated measures mixed-effects model and associated
99% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise.
TABLE 14 Injection vs. no injection at-the-margins analysis of SPADI
SPADI












Baseline 346 53.8 (18.6) 360 54.4 (18.4)
8 weeks 306 41.7 (22.2) 300 41.16 (1.24) 332 35.7 (22.9) 313 35.52 (1.22) –5.64
(–9.93 to –1.35)
0.001
6 months 294 26.2 (23.4) 289 26.33 (1.26) 321 27.3 (23.7) 306 26.85 (1.23) 0.52
(–3.82 to 4.86)
0.758













a SPADI analysis adjusted for age, sex and baseline SPADI, with random effects within participant, physiotherapist and centre.
b 95% CI presented.
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This difference was not deemed clinically significant where the MCID on the SPADI scale is 8 points on
a scale of 0–100. There was no statistically significant difference between injection and no injection
when analysed over 12 months (adjusted MD –1.11, 99% CI –4.47 to 2.26) or when analysed at 6 and
12 months (adjusted MD at 12 months 1.93, 99% CI –2.41 to 6.27).
Sensitivity analysis
Complier-average causal effect analysis
The primary outcome was analysed in the ITT population. An additional CACE analysis was used
to investigate the role of compliance with intervention on the trial effects for the primary outcome.
Compliance with intervention was defined in the SAP37 as follows. For the progressive-exercise intervention,
participants were considered compliant with treatment if they had been signed off for completing
treatment or if they received all six physiotherapy sessions. For the injection intervention, participants
were considered compliant if they received at least one injection. Compliance with treatment by
intervention group is summarised in Table 8. As no evidence of a statistical interaction effect between
interventions was identified, the CACE analysis was conducted at the margins for the two main
effect comparisons.
Progressive exercise compared with best-practice advice
The proportion of compliers in the progressive-exercise intervention group was 78%. Compliance with
the progressive-exercise intervention did not have a significant effect on the primary outcome. The
CACE estimate analysis for progressive exercise over 12 months was (mean adjusted difference) –0.27
(95% CI –2.69 to 2.16; p = 0.830) (see Table 13). The model included 1869 participant data points and
was adjusted for sex, age, baseline SPADI and centre. The variable for primary physiotherapist was
omitted from this analysis because of collinearity.
Injection compared with no injection
The proportion of compliers in the injection treatment group was 94%. Compliance with injection did
not have a significant effect on the primary outcome. The CACE estimate analysis for injection over
12 months was mean adjusted difference –1.50 (95% CI –3.61 to 0.61; p = 0.164) (see Table 14).
The model included 1869 participant data points and was adjusted for sex, age, baseline SPADI and
centre. The variable for primary physiotherapist was, again, omitted because of collinearity.
Secondary outcomes




















–5.64 (–9.93 to –1.35)
0.52 (–3.82 to 4.86)
1.93 (–2.41 to 6.27)
SPADI over 12 months –1.11 (–4.47 to 2.26)
Baseline 8 weeks 6 months 12 months
Time point
FIGURE 5 Marginal adjusted mean SPADI values from the repeated measures mixed-effects model and associated
99% CIs for the two treatment groups from baseline to 12 months: injection vs. no injection.
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Progressive exercise compared with best-practice advice
Table 15 presents the adjusted analysis results for the comparison of progressive exercise with
best-practice advice for each of the secondary outcomes at 8 weeks and at 6 and 12 months
(for unadjusted results see Appendix 4, Table 42).
TABLE 15 Analysis of secondary outcomes for progressive exercise vs. best-practice advice at 8 weeks, 6 months and
12 months
Secondary outcome
Best-practice advice Progressive exercise Between-group
adjusted difference
(95% CI) p-valuean Adjusted mean (SE) n Adjusted mean (SE)
SPADI: pain
8 weeks 300 49.9 (1.4) 316 39.5 (1.3) 2.12 (–1.94 to 6.17) 0.306
6 months 289 32.0 (1.4) 307 25.9 (1.3) –3.06 (–7.16 to 1.04) 0.144
12 months 290 25.8 (1.4) 307 20.6 (1.3) –4.01 (–8.11 to 0.09) 0.055
Over 12 months 339 36.0 (1.3) 343 34.5 (1.2) –1.61 (–4.94 to 1.72) 0.343
SPADI: function
8 weeks 298 29.40 (1.24) 316 31.77 (1.19) 2.37 (–1.01 to 5.76) 0.169
6 months 288 20.95 (1.26) 307 20.65 (1.21) –0.30 (–3.72 to 3.12) 0.863
12 months 288 18.74 (1.26) 307 16.12 (1.20) –2.61 (–6.03 to 0.81) 0.134
Over 12 months 339 23.1 (1.0) 343 22.9 (1.0) –0.15 (–2.92 to 2.61) 0.913
FABQ-PA
8 weeks 269 11.62 (0.37) 301 11.94 (0.35) 0.32 (–0.68 to 1.33) 0.531
6 months 266 9.93 (0.37) 281 9.51 (0.36) –0.42 (–1.44 to 0.60) 0.417
12 months 266 9.29 (0.37) 284 8.32 (0.36) –0.97 (–1.99 to 0.05) 0.061
Over 12 months 324 10.3 (0.30) 332 9.94 (0.28) –0.35 (–1.16 to 0.46) 0.396
PSEQ-2
8 weeks 271 10.25 (0.13) 300 10.19 (0.12) –0.06 (–0.39 to 0.27) 0.737
6 months 267 10.41 (0.13) 282 10.42 (0.13) 0.01 (–0.33 to 0.34) 0.960
12 months 267 10.59 (0.13) 284 10.70 (0.13) 0.12 (–0.22 to 0.45) 0.492
Over 12 months 325 10.41 (0.10) 332 10.43 (0.10) 0.02 (–0.23 to 0.27) 0.863
ISI
8 weeks 267 7.46 (0.32) 294 8.09 (0.31) 0.63 (–0.25 to 1.50) 0.159
6 months 264 6.20 (0.32) 281 6.20 (0.31) –0.01 (–0.89 to 0.88) 0.990
12 months 267 5.92 (0.32) 282 5.40 (0.31) –0.52 (–1.40 to 0.36) 0.249
Over 12 months 323 6.53 (0.27) 329 6.57 (0.26) 0.04 (–0.69 to 0.77) 0.916
RDA
8 weeks 270 6.08 (0.14) 297 6.33 (0.13) 0.25 (–0.12 to 0.62) 0.189
6 months 267 5.42 (0.14) 284 5.10 (0.14) –0.31 (–0.69 to 0.06) 0.101
12 months 268 4.81 (0.14) 285 4.67 (0.14) –0.14 (–0.51 to 0.24) 0.466
Over 12 months 325 5.44 (0.11) 332 5.38 (0.11) –0.06 (–0.36 to 0.23) 0.662
continued
DOI: 10.3310/hta25480 Health Technology Assessment 2021 Vol. 25 No. 48
Copyright © 2021 Hopewell et al. This work was produced by Hopewell et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
45
SPADI: shoulder pain subscale
There was an improvement in shoulder pain in both intervention groups over time (Figure 6). However,
there was no statistically significant difference between the progressive-exercise intervention and best-
practice advice in shoulder pain when analysed over 12 months (adjusted mean SPADI pain subscale
difference between groups –1.61, 95% CI –4.94 to 1.72) or when analysed at 8 weeks or at 6 and
12 months (adjusted MD at 12 months –4.01, 95% CI –8.11 to 0.09).
SPADI: shoulder function subscale
There was an improvement in shoulder function in both intervention groups over time (Figure 7).
However, there was no statistically significant difference between the progressive-exercise
intervention and best-practice advice in shoulder function when analysed over 12 months (adjusted
mean SPADI function subscale difference between groups –0.15, 95% CI –2.92 to 2.61) or when
analysed at 8 weeks or at 6 and 12 months (adjusted MD at 12 months –2.61, 95% CI –6.03 to 0.81).
Fear Avoidance Belief Questionnaire – Physical Activity
There was an improvement in fear avoidance behaviour in both intervention groups over time.
However, there was no statistically significant difference between the progressive-exercise intervention
and the best-practice advice intervention in fear avoidance behaviour when analysed over 12 months
(adjusted mean FABQ-PA score difference between groups –0.35, 95% CI –1.16 to 0.46) or when
analysed at 8 weeks, 6 months or 12 months (adjusted MD at 12 months –0.97, 95% CI –1.99 to 0.05).
TABLE 15 Analysis of secondary outcomes for progressive exercise vs. best-practice advice at 8 weeks, 6 months and
12 months (continued )
Secondary outcome
Best-practice advice Progressive exercise Between-group
adjusted difference
(95% CI) p-valuean Adjusted mean (SE) n Adjusted mean (SE)
GIT
8 weeks 269 7.65 (0.13) 298 7.75 (0.13) 0.11 (–0.25 to 0.47) 0.555
6 months 267 8.16 (0.13) 285 8.69 (0.13) 0.53 (0.17 to 0.90) 0.004
12 months 270 8.57 (0.13) 286 9.08 (0.13) 0.51 (0.14 to 0.87) 0.006
Over 12 months 326 8.12 (0.10) 332 8.50 (0.10) 0.38 (0.10 to 0.66) 0.007
























2.12 (–1.94 to 6.17)
–3.06 (–7.16 to 1.04)
–4.01 (–8.11 to 0.09)
SPADI pain over 12 months: –1.61 (–4.94 to 1.72)
Baseline 8 weeks 6 months 12 months
Time point
FIGURE 6 Marginal adjusted mean SPADI pain values from the repeated measures mixed-effects model and associated
95% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise.
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Pain Self-Efficacy Questionnaire
There was no statistically significant difference between the progressive-exercise intervention and
best-practice advice intervention in patient-reported pain self-efficacy when analysed over 12 months
(adjusted mean PSEQ-2 score difference between groups 0.02, 95% CI –0.23 to 0.27) or when analysed
at 8 weeks, 6 months or 12 months (adjusted MD at 12 months 0.12, 95% CI –0.22 to 0.45). A ceiling
effect was noted for this outcome, with most participants reporting higher confidence levels despite
experiencing pain.
Insomnia Severity Index
There was an improvement in patient-reported perception of insomnia in both intervention groups
over time. However, there was no statistically significant difference between the progressive-exercise
intervention and best-practice advice in patient-reported perception of insomnia when analysed over
12 months (adjusted mean ISI difference between groups 0.04, 95% CI –0.69 to 0.77) or when
analysed at 8 weeks, 6 months or 12 months (adjusted MD at 12 months –0.52, 95% CI –1.40 to 0.36).
Return to desired activities
There was an improvement in patient-reported RDA in both intervention groups over time. However,
there was no statistically significant difference between the progressive-exercise intervention and best-
practice advice intervention in patient-reported RDA when analysed over 12 months (adjusted mean
RDA difference between groups –0.06, 95% CI –0.36 to 0.23) or when analysed at 8 weeks, 6 months
or 12 months (adjusted MD at 12 months –0.14, 95% CI –0.51 to 0.24).
Global Impression of Treatment
Progressive exercise resulted in an improvement in patient-reported GIT success over 12 months
(adjusted mean GIT difference between groups 0.38, 95% CI 0.10 to 0.66) and at 6 and 12 months
(adjusted MD at 12 months 0.51, 95% CI 0.14 to 0.87), compared with best-practice advice. However,
this result was not seen at 8 weeks and the difference was not clinically significant (MCID on the GIT
scale is 2 points on an 11-point scale).
Injection compared with no injection
Table 16 presents the adjusted results for the comparison of injection with no injection for each of the
secondary outcomes at 8 weeks, 6 months and 12 months (for unadjusted results, see Appendix 4, Table 42).
SPADI: shoulder pain subscale
There was an improvement in shoulder pain in both groups over time (Figure 8). Injection resulted in an
improvement in shoulder pain when analysed at 8 weeks, compared with no injection (adjusted mean

























2.37 (–1.01 to 5.76)
–0.30 (–3.72 to 3.12)
–2.61 (–6.03 to 0.81)
SPADI function over 12 months –0.15 (–2.92 to 2.61)
Baseline 8 weeks 6 months 12 months
Time point
FIGURE 7 Marginal adjusted mean SPADI function values from the repeated measures mixed-effects model and associated
95% CIs for the two treatment groups from baseline to 12 months: best-practice advice vs. progressive exercise.
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TABLE 16 Analysis of secondary outcomes for injection vs. no injection at 8 weeks, 6 months and 12 months
Secondary outcome
No injection Injection Between-group
adjusted difference
(95% CI) p-valuean Adjusted mean (SE) n Adjusted mean (SE)
SPADI: pain
8 weeks 300 49.9 (1.4) 315 42.9 (1.4) –7.38 (–11.10 to –3.67) 0.000
6 months 289 32.0 (1.4) 306 32.9 (1.4) 0.89 (–2.88 to 4.66) 0.643
12 months 290 25.8 (1.4) 306 27.8 (1.4) 2.05 (–1.72 to 5.81) 0.286
Over 12 months 339 36.0 (1.3) 343 34.5 (1.1) –1.55 (–4.46 to 1.37) 0.299
SPADI: function
8 weeks 301 32.59 (1.18) 313 28.75 (1.16) –3.84 (–6.95 to –0.73) 0.015
6 months 289 20.69 (1.19) 306 20.89 (1.17) 0.20 (–2.95 to 3.35) 0.900
12 months 290 16.38 (1.19) 305 18.34 (1.17) 1.97 (–1.18 to 5.11) 0.221
Over 12 months 339 23.31 (0.93) 343 22.72 (0.92) –0.59 (–3.02 to 1.83) 0.631
FABQ-PA
8 weeks 274 12.02 (0.36) 296 11.59 (0.35) –0.43 (–1.39 to 0.53) 0.381
6 months 262 9.70 (0.37) 285 9.72 (0.35) 0.03 (–0.95 to 1.01) 0.954
12 months 265 8.55 (0.37) 285 9.01 (0.35) 0.47 (–0.51 to 1.44) 0.349
Over 12 months 316 8.22 (0.10) 340 8.41 (0.10) 0.02 (–0.74 to 0.77) 0.967
PSEQ-2
8 weeks 275 10.13 (0.13) 296 10.30 (0.12) 0.17 (–0.16 to 0.50) 0.307
6 months 264 10.44 (0.13) 285 10.39 (0.13) –0.05 (–0.38 to 0.28) 0.773
12 months 266 10.80 (0.13) 285 10.50 (0.13) –0.30 (–0.63 to 0.03) 0.078
Over 12 months 317 10.45 (0.10) 340 10.40 (0.10) –0.06 (–0.31 to 0.19) 0.659
ISI
8 weeks 270 8.57 (0.31) 291 7.07 (0.30) –1.50 (–2.32 to –0.68) 0.000
6 months 262 6.21 (0.31) 283 6.18 (0.30) –0.03 (–0.86 to 0.80) 0.947
12 months 265 5.48 (0.31) 284 5.80 (0.30) 0.32 (–0.51 to 1.15) 0.449
Over 12 months 314 6.77 (0.25) 338 6.35 (0.25) –0.41 (–1.08 to 0.26) 0.227
RDA
8 weeks 273 6.49 (0.14) 294 5.96 (0.13) –0.53 (–0.89 to –0.17) 0.004
6 months 266 5.27 (0.14) 285 5.24 (0.14) –0.03 (–0.39 to 0.34) 0.893
12 months 268 4.63 (0.14) 285 4.84 (0.14) 0.21 (–0.15 to 0.57) 0.258
Over 12 months 317 5.47 (0.11) 340 5.35 (0.11) –0.12 (–0.40 to 0.16) 0.409
GIT
8 weeks 273 7.34 (0.13) 294 8.03 (0.13) 0.69 (0.35 to 1.03) 0.000
6 months 267 8.42 (0.13) 285 8.45 (0.13) 0.04 (–0.31 to 0.39) 0.832
12 months 269 8.91 (0.13) 287 8.76 (0.13) –0.14 (–0.49 to 0.20) 0.416
Over 12 months 317 8.22 (0.10) 347 8.41 (0.10) 0.20 (–0.06 to 0.46) 0.138
a Outcome analysis adjusted for age, sex and baseline outcome value, with random effects within participant,
physiotherapist and centre.
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not clinically significant (MCID on the SPADI scale is 8 points on a scale of 0–100). There was no
statistically significant difference between injection and no injection when analysed over 12 months
(adjusted MD over 12 months –1.55, 95% CI –4.46 to 1.37) or when analysed at 6 and 12 months
(adjusted MD at 12 months 2.05, 95% CI –1.72 to 5.81).
SPADI: shoulder function subscale
There was an improvement in shoulder function in both groups over time (Figure 9). Injection resulted
in an improvement in shoulder function when analysed at 8 weeks compared with no injection
(adjusted mean SPADI function subscale difference between groups –3.84, 95% CI –6.95 to –0.73).
This difference was not clinically significant. There was no statistically significant difference between
injection and no injection when analysed over 12 months (adjusted MD over 12 months –0.59, 95% CI
–3.02 to 1.83) or when analysed at 6 and 12 months (adjusted MD at 12 months 1.97, 95% CI –1.18
to 5.11).
Fear Avoidance Belief Questionnaire – Physical Activity
There was an improvement in fear avoidance behaviour in both groups over time. However, there was
no statistically significant difference between injection and no injection in fear avoidance behaviour
when analysed over 12 months (adjusted mean FABQ-PA score difference between groups over
12 months 0.02, 95% CI –0.74 to 0.77) or when analysed at 8 weeks, 6 months or 12 months
(adjusted MD at 12 months 0.47, 95% CI –0.51 to 1.44).
Pain Self-Efficacy Questionnaire
There was no statistically significant difference between injection and no injection in patient-reported
pain self-efficacy when analysed over 12 months (adjusted mean PSEQ-2 score difference between
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FIGURE 8 Marginal adjusted mean SPADI pain values from the repeated measures mixed-effects model and associated
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FIGURE 9 Marginal adjusted mean SPADI function values from the repeated measures mixed-effects model and
associated 95% CIs for the two treatment groups from baseline to 12 months: injection vs. no injection.
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12 months (adjusted MD at 12 months –0.30, 95% CI –0.63 to 0.03). A ceiling effect was noted for this
outcome, with most participants reporting higher confidence levels despite experiencing pain.
Insomnia Severity Index
There was an improvement in patient-reported perception of insomnia in both groups over time.
Injection resulted in an improvement in patient-reported perception of insomnia when analysed at
8 weeks compared with no injection (adjusted mean ISI difference between groups –1.50, 95% CI
–2.32 to –0.68). There was no statistically significant difference between injection and no injection
when analysed over 12 months (adjusted MD over 12 months –0.41, 95% CI –1.08 to 0.26) or when
analysed at 6 and 12 months (adjusted MD at 12 months 0.32, 95% CI –0.51 to 1.15).
Return to desired activities
There was an improvement in patient-reported RDA in both groups over time. Injection resulted in an
improvement in patient-reported RDA when analysed at 8 weeks compared with no injection (adjusted
mean RDA difference between groups –0.53, 95% CI –0.89 to –0.17). There was no statistically
significant difference between injection and no injection when analysed over 12 months (adjusted MD
over 12 months –0.12, 95% CI –0.40 to 0.16) or when analysed at 6 and 12 months (adjusted MD at
12 months 0.21, 95% CI –0.15 to 0.57).
Global Impression of Treatment
Injection resulted in an improvement in patient-reported GIT success when analysed at 8 weeks compared
with no injection (adjusted mean GIT difference between groups 0.69, 95% CI 0.35 to 1.03). There was
no statistically significant difference between injection and no injection when analysed over 12 months
(adjusted MD over 12 months 0.20, 95% CI –0.06 to 0.46) or when analysed at 6 and 12 months (adjusted
MD at 12 months –0.14, 95% CI –0.49 to 0.20).
Other outcomes
Participant-reported shoulder condition
As part of the follow-up questionnaires, a total of 23 (3%) participants reported ‘yes’ to the question
‘have you been told you will need to have surgery because of your shoulder problem’. Two, six and
15 participants reported ‘yes’ at 8 weeks, 6 months and 12 months, respectively, and the numbers
were similar across intervention groups. Three participants reported that they had been admitted to
hospital as an NHS inpatient because of their shoulder. The type of surgery recorded was surgery to
repair rotator cuff tear (n = 1; injection plus progressive-exercise intervention), frozen shoulder surgery
diagnosed after randomisation (n = 1; best-practice advice intervention), subacromial decompression
and cuff repair (n = 1; injection plus best-practice advice intervention).
Participant-reported injection outside the trial
As part of the follow-up questionnaires, 16 (4%) participants in the injection group and four (1%)
participants in the no injection group reported ‘yes’ to the question ‘have you had a steroid injection
as a result of pain in your shoulder?’ at 8 weeks. Twelve (3%) participants in the injection group and
18 (5%) participants in the no injection group reported ‘yes’ to the question at 6 months, and 20 (6%)
participants in the injection group and six (2%) participants in the no injection group reported ‘yes’ at
12 months. This excluded the injection(s) participants may have received as part of the GRASP trial.
Harms
There were no SAEs recorded as part of the GRASP trial.
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Missing data
There were small numbers of missing data. A total of 641 (90.5%) participants returned the 8-week
follow-up questionnaire, 615 (86.9%) returned their 6 month-questionnaire and 618 (87.3%) returned
their 12-month questionnaire. Where items were missing within scales, these were dealt with based
on published recommendations. SPADI score was imputed as per scoring instructions (see Chapter 2);
eight (1.1%) SPADI scores were imputed at baseline, six (0.8%) SPADI scores were imputed at 8 weeks,
four (0.6%) SPADI scores were imputed at 6 months and two (0.3%) SPADI scores were imputed at
12 months. Missing continuous data for primary and secondary outcomes were accounted for as part
of the likelihood-based estimation of the repeated measures linear mixed-effects model, assuming that
data were missing at random.
Prespecified subgroup analysis
The following prespecified subgroup analyses were carried out in line with the primary outcome analysis
approach: age (≤ 64 years/≥ 65 years), sex (male/female), smoking status (never smoked/former smoker
or current smoker), higher SPADI score at baseline [SPADI ≥ 50 at baseline (scale 0–100)] and higher
pain self-efficacy score at baseline [PSEQ-2 ≥ 8 at baseline (scale 0–12)]. The results presented here for
prespecified subgroup analyses are for the two main effect comparisons.
Progressive exercise compared with best-practice advice
There were no statistically significant subgroup differences between the progressive-exercise intervention
and best-practice advice intervention in shoulder pain and function when analysed over 12 months
(Figure 10) or when analysed at 8 weeks, 6 months or 12 months (see Appendix 4, Figure 25).
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FIGURE 10 Subgroup-adjusted SPADI analysis for progressive exercise over 12 months.
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Injection compared with no injection
There were no statistically significant subgroup differences for age, sex, smoking status and pain self-
efficacy between injection and no injection interventions in shoulder pain and function when analysed
over 12 months (Figure 11) or when analysed at 8 weeks, 6 months or 12 months (see Appendix 4,
Figure 28). At 8 weeks, the effect of injection was stronger in participants with a higher baseline SPADI
score (adjusted MD –9.67, 99% CI –15.37 to –3.97) than in those who received injection but had a
lower baseline SPADI score (adjusted MD –0.36, 99% CI –6.87 to 6.16). This difference was clinically
significant (see Appendix 4, Figure 28). There was no statistically significant subgroup difference when
analysed over 12 months or when analysed at 6 and 12 months.
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FIGURE 11 Subgroup-adjusted SPADI analysis for injection over 12 months.
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Chapter 5 Health economics
Introduction
This chapter presents the cost-effectiveness analysis of the GRASP trial. This analysis took an NHS
and PSS perspective and tested (using a 2 × 2 factorial design) four physiotherapy-led interventions:
(1) progressive exercise, (2) best-practice advice, (3) progressive exercise preceded by a corticosteroid
injection and (4) best-practice advice preceded by a corticosteroid injection. Health-care resource
utilisation data and utility data were collected alongside clinical data over the 12-month trial period;
these were used to conduct a cost–utility analysis, calculating the cost per quality-adjusted life-year
(QALY) gained, as the main aim of treatment is to improve patients’ quality of life.
Current guidelines for conducting an economic evaluation within clinical trials have been followed,
including guidance for resource use data capture,84 which highlighted the need for a health economics
analysis plan to incorporate time horizon, frequency of data collection and methods of analysis, as well
as other important components, such as resource use measure, perspective and unit costs.85 We also
followed further guidance on how to conduct economic evaluation alongside randomised trials,86 and
considerations of the methodological issues around these trials.87 In relation to conducting an economic
evaluation within a factorial design trial, the challenges and methods discussed by Dakin and Gray88
have been taken into account in the GRASP trial analysis.
Methods
Aim
The aim of the GRASP trial’s economic evaluation was to address the following question:
What is the cost-effectiveness of individually tailored progressive exercise compared with best-practice
advice, with or without corticosteroid injection, in people with a new episode of a rotator cuff disorder?
The within-trial economic analysis was performed using individual patient-level data from the GRASP
trial. The analysis uses data from the GRASP trial only and did not combine this trial with any external
evidence because, to the best of our knowledge, no study has evaluated exactly the same progressive-
exercise intervention evaluated in this study. The analytical approach took the form of a cost–utility
analysis. Based on trial evidence, net monetary benefit (NMB) statistics were calculated as QALYs
multiplied by willingness-to-pay threshold minus cost to enable comparison between treatment groups.
The economic analysis compared the costs and consequences of each intervention group over the
12-month period following randomisation, with no extrapolation beyond the study period of
12 months, as prespecified in the health economics analysis plan, because there was no statistical
difference in clinical outcome between treatment groups at 12 months.85
Measurement of resource use and costs
Resource use data for the economic evaluation were collected during the trial period from questionnaires
sent to participants (at 8 weeks, 6 months and 12 months after randomisation to the GRASP trial) and
from treatment logs completed by the treating physiotherapists at sites. The questionnaire captured
both NHS- and PSS-perspective resource use and costs borne by the participant and their family
attributable to a rotator cuff disorder. This included the frequency of use of inpatient care, outpatient
care and community-based health care (both private and NHS) that was not part of the GRASP trial. It
also recorded direct medical costs that were not part of the trial (e.g. medications and steroid injections)
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and direct non-medical costs (e.g. help with housework/childcare and travel), the latter being excluded
from the base-case economic evaluation. Free-text responses (applicable to all the ‘other’ options)
were reclassified to the appropriate cost category, were removed if deemed unrelated/irrelevant to
the trial by clinical experts (e.g. shoulder specialists) or were analysed collectively as ‘other’ in the
descriptive analysis.
Some of the assumptions made when cleaning, analysing or costing the data included (1) if a patient
answered ‘no’ to a prompt question about resource utilisation, then we assumed that the frequency
of service use for this category of resources was equal to zero, (2) injections performed outside the
GRASP trial were assumed to have been given by a GP within the duration of a typical GP visit and
(3) for the self-reported questions on prescribed and over-the-counter medication, when participants
failed to specify the duration or reported ‘as needed’, ‘when in pain’ or ‘occasionally’ and similar, we
assumed an intake duration of 3 weeks based on clinical expert opinion.
Costing of the interventions
Subacromial corticosteroid injection
Participants randomised to receive corticosteroid injection were given either methylprednisolone or
triamcinolone acetonide (median dose of 40 mg) with a local anaesthetic. Injections were mainly
given by extended-scope physiotherapists (bands 6–8a); in three cases injections were given by doctors
(two orthopaedic consultants and one specialist registrar in orthopaedics). The consultation time varied
from 20 minutes to 45 minutes based on the information provided by the physiotherapists. We based the
cost of injections on the median injection administration time of 30 minutes, as a median is more robust
against outliers and the weighted average cost per hour for each physiotherapist/clinician delivering
injections.89 Most participants also received local anaesthetic: either 1% lidocaine (up to 5 ml) or 0.5%
bupivacaine hydrochloride (up to 10 ml) (see Appendix 5, Table 43 for unit costs of corticosteroid injection
and anaesthetic). The total cost of administering the injection to each participant was calculated by adding
the weighted mean administration cost per participant to the mean cost of corticosteroid injections and
mean cost of anaesthetic per participant.
Best-practice advice
Participants randomised to best-practice advice received one 45- to 60-minute session with a physiotherapist
(band 5–8a), when they were provided with a set of eight 2-week exercise diaries (i.e. a normal A4 printed
sheet totalling 16 pages), a three-page document printed on non-carbon copy paper that served as an action
planner, an information booklet, one piece of resistance band (with an average of 1 yard per participant) and
either a DVD or details of how to access online exercise videos (Table 17). The cost of physiotherapists’
time was calculated by multiplying the median therapist cost per hour by the median estimate (in minutes)
of the exercise session.
Progressive exercise
Participants randomised to progressive exercise received a median of four sessions with a physiotherapist
(band 5–8a). The first session lasted between 45 and 60 minutes and the rest generally lasted between
20 and 30 minutes. Participants were given a set of eight 2-week exercise diaries (i.e. a normal A4 printed
sheet totalling 16 pages), a three-page document printed on non-carbon copy paper that served as an
action planner, an information booklet and at least one piece of resistance band if they were prescribed
an exercise that required this (an average of 1 yard per participant) (see Table 17). Again, the cost of
physiotherapists’ time was calculated by multiplying the median therapist cost per hour by the median
estimate (in minutes) of the exercise session.
In both the best-practice advice and progressive-exercise interventions, we estimated costs based on
median estimates, as they are more robust against outliers. Storage boxes given to study centres were
excluded from the costings, as they were deemed to be protocol-driven resources.
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Training
We included the cost of training the physiotherapists in how to deliver the best-practice advice and
progressive-exercise interventions, as they are not part of standard NHS practice. No training was
provided for the injections, as these were delivered as per standard NHS practice and in accordance
with the trial protocol.
The cost of training was calculated separately for best-practice advice and progressive exercise by
multiplying the mean training time per physiotherapist by the physiotherapist cost per hour (Table 18).

















Exercise diary ✓ ✓ ✓ ✓ Item/set 0.64
Action planner ✓ ✓ ✓ ✓ Item 0.24
TheraBand® 1 yard
(TheraBand, Akron, OH, USA)
✓ ✓ ✓ ✓ Item 0.94
DVD or online access to
exercise videos
✓ ✓ ✗ ✗ Item 1.20
Information booklet for
best-practice advice
✓ ✓ ✓ ✓ Item 2.60
Information booklet for
progressive exercise
✗ ✗ ✓ ✓ Item 4.00
TABLE 18 Assumptions for costing physiotherapist time
Physiotherapist time Unit Source
Training for best-practice advice and progressive exercise
Number of physiotherapists 187a Therapist diaries
Mean training time (hours) per best-practice advice physiotherapist 3.5 Therapist diaries
Mean training time (hours) per progressive-exercise physiotherapist 4.5
Physiotherapist cost (£) per hour 35–67 PSSRU p. 143 (band 5–8a)89
Mean cost (£) of training each best-practice advice physiotherapist 168.49
Mean cost (£) of training each progressive-exercise physiotherapist 177.94
Mean number of patients treated per best-practice advice physiotherapist 3.9 Therapist diaries
Mean number of patients treated per progressive-exercise physiotherapist 3.6
Length of session
First session (minutes) 52.5 Median estimate
Second session (minutes) 25
Third session (minutes) 25
Fourth session (minutes) 25
Fifth session (minutes) 25
Sixth session (minutes) 25
PSSRU, Personal Social Service Research Unit.
a Although there 307 clinicians were recorded for the training, some undertook the training twice, which brings the
number of therapists down to 298. However, only 187 physiotherapists both were trained and delivered the exercises.
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Training time for therapists to provide the best-practice advice was 3.5 hours and progressive exercise
training was 4.5 hours. In the training courses provided as part of the GRASP trial, physiotherapists
received an additional hour of training specific to the trial protocol (e.g. completing treatment logs),
which was considered to be a protocol-driven resource use and was, therefore, excluded from the
analysis. Some sites received refresher training sessions, with each lasting approximately 2.5 hours.
The face-to-face training was delivered by four physiotherapists who were part of the GRASP trial
team, but only one physiotherapist attended each training session. We costed the physiotherapist time
for delivering the training by multiplying the cost of a grade 7 physiotherapist by the duration of the
training session. In total, 298 physiotherapists (bands 5–8a) attended the training programme as part
of the trial, of whom 223 delivered the intervention. The cost of the trainers’ time was divided by the
total number of physiotherapists attending training.
As there is uncertainty about how training would be delivered in routine clinical practice, we have
calculated the cost of training physiotherapists to the interventions based on three scenarios
(base case, best case and worst case), depending on different hypotheses.
Base-case analysis
The base-case analysis aimed to reflect the NHS cost of face-to-face training as it was delivered in the
GRASP trial. It included the time cost for the physiotherapists attending the face-to-face training and
the time cost for the physiotherapist delivering the training to the sites (Table 19). The cost of refresher
training and the trainers’ travel costs to each site, venue hire and NHS parking charges were excluded
from the analysis. In the base-case analysis, we calculated the total cost of training each physiotherapist










Clinician training 43.20 43.20 49.43 49.43
Consumables 5.62 5.62 5.82 5.82
Injections 0 40.1 0 40.1
Physiotherapist time
Session 1 44.63 44.63 44.63 44.63
Session 2 21.25 21.25
Session 3 21.25 21.25
Session 4 21.25 21.25
Session 5 21.25 21.25
Session 6 21.25 21.25
Total cost by number of sessions attended
No sessions 0 0 0 0
One session 93.45 133.55 99.88 139.98
Two sessions 121.13 161.23
Three sessions 142.38 182.48
Four sessions 163.63 203.73
Five sessions 184.88 224.98
Six sessions 206.13 246.23
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and divided it by the mean number of patients treated per physiotherapist (among physiotherapists
receiving this training) to estimate the cost of training as it was delivered in the trial. The total cost of
training each physiotherapist was divided by the mean number of participants treated by each physiotherapist
in the trial.We estimated the mean number of participants per physiotherapist separately for best-practice
advice and progressive exercise, as physiotherapists giving the best-practice advice intervention could
treat more people per week than those delivering progressive exercise. The mean numbers of participants
treated per physiotherapist in the best-practice advice and the progressive-exercise groups were 3.9 and
3.6, respectively.
Worst-case scenario
This was the same as the base-case analysis, but also included the cost of refresher training, travel,
venue hire and NHS parking charges as part of the training delivery cost. Refresher session cost was
calculated by multiplying the 2.5-hour training time by the hourly cost of a grade 7 physiotherapist.
Travel cost was calculated as the mileage from Oxford to the site and back by car multiplied by a flat
cost per mile (£0.45 for the first 10,000 business miles).90 Venue hire was calculated based on an
average cost of hiring an NHS room of a maximum capacity of 30 people.91 We also assumed an
average of £2 per hour NHS parking charge for the duration of the training. Accommodation charges
for overnight stay were not included.
Best-case scenario
The best-case scenario assumes that if the trial interventions were to be implemented in routine clinical
practice, the training would be delivered on a free-to-access online platform. The cost of developing the
online training materials were based on the team’s experience of developing training materials for the
NIHR HTA-funded BeST (Back Skills Training) trial for the treatment of low back pain in primary care.45
This includes 6 weeks of a full-time grade 8 physiotherapist’s time to develop the training materials for
the progressive-exercise intervention and 1 month to develop the best-practice advice intervention.
It also includes the cost of a grade 7 physiotherapist researcher to maintain it for a 10-year period
(spending 30 hours/year). There are approximately 10,000 users per year using the online learning
platform [URL: www.futurelearn.com/courses/back-skills-training-programme (accessed 24 May 2021)].
We, therefore, assumed that this researcher would support all 10,000 learners. We included the cost
of the physiotherapists treating participants based on having a one-off training session of 3.5 hours for
best-practice advice and of 4.5 hours for progressive exercise. We assumed that the training would last
10 years without a refresher session and that each physiotherapist would treat patients for 10 years
after being trained. We assumed that each physiotherapist would treat approximately 100 patients per
year, based on an assumption of 2.74 new patients per week over 1 year (9.6 patients per week and
3.5 patients per session on average).
The best- and worst-case scenarios have been presented as part of the sensitivity analysis.
We averaged and applied the cost of training for each intervention across all participants randomised,
regardless of how many sessions they attended. Other intervention costs were estimated at the
individual patient level, based on the recorded number of sessions that they attended. The estimated
costs for different numbers of sessions attended of progressive exercise, best-practice advice, progressive
exercise preceded by a corticosteroid injection and best-practice advice preceded by a corticosteroid
injection are shown in Table 19. Following our base-case assumptions, the cost of best-practice advice is
£93.45 and best-practice advice plus injection is £133.55. For a progressive-exercise patient attending
all six sessions, the cost is £206.13, compared with £246.23 for a patient attending all recommended
sessions in the progressive-exercise and injection treatment arm.
Measurement of broader resource use
The unit costs of direct non-medical resource items, such as help with child care, travel to appointments,
help with housework and any other additional expenses attributable to having a rotator cuff disorder
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incurred by the participant, were obtained directly from the postal follow-up questionnaires and are
tabulated in Appendix 5, Table 44. However, these costs, private health-care costs and any other
non-NHS/PSS costs (e.g. over-the-counter medications) were excluded from the base-case economic
evaluation, as they are outside the perspective of this analysis, but are included in the sensitivity analysis
presented in Appendix 5.
Valuation of resource use
Unit costs of direct medical care that is not part of the trial, such as inpatient care, outpatient care and
NHS community care, were sourced from the latest available NHS Reference Costs92 (see Appendix 5,
Table 44). The unit costs of medications related to rotator cuff disorders have been sourced using the
latest available British National Formulary (BNF)93 (see Appendix 5, Table 43). Costs of medications for
individual participants were estimated based on their reported doses and frequencies, when these were
available, or based on an assumed daily dose using BNF recommendations. When a dose range was
reported as ‘as required’ or when the quantities were not recorded, expert opinion was sought to make
reasonable assumptions. The cost of NHS health-care resource use per participant was computed by
multiplying the frequency of health resource utilisation reported by the participant by the unit cost
of each resource item. In the case of non-NHS costs, participants self-reported the cost of additional
expenses. All costs were expressed in 2018/19 Great British pounds. No discounting was applied, as the
time horizon of the analysis did not exceed 12 months.
Calculation of utilities and quality-adjusted life-years
Participants’ questionnaires contained the EQ-5D-5L questionnaire for self-completion at baseline
and at 8 weeks, 6 months and 12 months post randomisation. The EQ-5D-5L instrument94 facilitates
the generation of a utility score from a person’s health-related quality of life while reducing the
ceiling effect and being more sensitive than its three-level predecessor.95 A utility score refers to
the preference of the general population for any particular set of health outcomes. As per the NICE
position statement, the responses to the EQ-5D-5L were converted into multiattribute utility scores
using the approved ‘crosswalk’ to the three-level instrument and applying the mapping function
developed by van Hout et al.,96 and the converted responses were valued using the established time
trade-off utility algorithm for the UK.97 QALYs were calculated as the area under the utility curve
of utility scores from baseline, 8-week, 6-month and 12-month data using the trapezoidal rule.98
Deceased patients were assigned a utility of zero from the date of death. We assumed that utility
remained constant between the last utility measurement and the date of death.
Missing data
Because within-trial health economic evaluations draw on many sources of information on patient
characteristics, treatments, outcomes and resource use over the whole trial, incomplete data are a
particular issue that require careful attention. Consequently, the base-case analysis imputed missing
data using fully conditional multiple imputation under chained equations, using the Stata command
‘mi impute chained’. Within multiple imputation under chained equations, regression models were used
to impute unobserved costs and utilities at each time point using the baseline covariates [i.e. age, sex
and EuroQol-5 Dimensions (EQ-5D)] as predictor variables. The imputation model included a dummy
variable for allocation to injection, a dummy variable for allocation to progressive exercise and an
interaction term equal to the product of these two variables, following recommended practice for
factorial trials.88 Different components of costs and EQ-5D utility scores at each time point contributed
as both predictors and imputed variables.
Multiple imputation was used to generate 25 data sets (or ‘draws’) using predictive mean matching,
which provides plausible values when costs and utilities are non-normally distributed. In line with
recommended practice,99 the imputation model was validated by comparing the distributions of
the imputed data with the observed data. The imputation was run following the rule of thumb that the
number of imputations (M) should be similar to the percentage of incomplete cases (in this case M = 25).99
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Analyses of resource use, costs and outcome data
Cost-effectiveness analysis
The analysis was conducted based on the ITT principle and incremental cost-effectiveness ratios (ICERs)
were calculated as the difference in mean costs divided by the difference in mean QALYs between a
pair of interventions. The NICE100 cost-effectiveness threshold of £20,000 per additional QALY was used
to identify which of the following treatments represent best value for money (i.e. has the highest NMB):
(1) best-practice advice, (2) best-practice advice plus corticosteroid injection, (3) progressive exercise or
(4) progressive exercise plus corticosteroid injection.
In addition to calculating and reporting ICERs and NMBs, the results are presented graphically in
cost-effectiveness planes, and cost-effectiveness acceptability curves (CEACs) are used to show the
probability that each of the four treatment groups has the highest NMB. Measures of uncertainty
(SEs and CIs) are also reported around the mean costs and QALYs (95% CIs are presented around
ICERs if they are defined). SEs and CEACs were generated using non-parametric bootstrapping
with 1000 replicates, as described in the next section. This accommodates sampling (or stochastic)
uncertainty and varying levels of willingness to pay for an additional QALY. We made no adjustment
for clustering of participants by physiotherapist when analysing costs, QALYs or cost-effectiveness,
as the randomisation was carried out on an individual basis, stratified by centre, rather than using
cluster randomisation, and the subacromial corticosteroid injections and physiotherapy sessions were
delivered in accordance with a standard protocol.
As the GRASP trial is a factorial trial, it was important to consider the interactions [i.e. to examine
whether or not the differences in costs, QALYs or NMB between best-practice advice and progressive
exercise were affected by the use of corticosteroid injection (or vice versa)]. In the GRASP trial clinical
analysis, the primary outcome was analysed at the margins, assuming no interactions and that interaction
terms were included in the model only if interactions were significant at the 0.05 level. From the economics
point of view, this approach was not appropriate, as health economics findings are interpreted in terms of
the absolute magnitude of ICERs, rather than focusing on hypothesis testing, and several mechanisms have
been suggested that may introduce large but non-significant interactions for economic end point, but not
clinical end point.88 It is more important to avoid the bias that may result from ignoring interactions
rather than maximising statistical power. We, therefore, compared specific treatment combinations
(e.g. best-practice advice, injection only, progressive exercise only and injection plus progressive exercise)
incrementally and identified the combination that represents best value for money, rather than making
separate decisions on injection and exercise, as the former provides more relevant information for
decision-makers if there is any interaction.
For the GRASP trial, the base-case economic analysis was prespecified as regression analysis with an
interaction term, although regression analysis without interaction terms has been used as a sensitivity
analysis to assess whether or not the assumptions about interactions change the conclusions of the
analysis. Benefits of using regression analysis in the context of factorial design trial are that it allows
for variation in sample size between groups, adjusts for the effect of the other intervention, facilitates
adjustment for baseline utility and can predict the mean outcomes for each cell in the factorial design.
Regression analysis with interaction term (base-case analysis)
Linear regression analyses that predicted both costs and QALYs were calculated for each bootstrap
sample on each imputed data set. Randomisation to corticosteroid and randomisation to exercise were
included as dummy variables and the base-case analysis also included an interaction between these two
variables. The ordinary least squares regression that predicted QALYs also controlled for baseline utility to
avoid the bias that would otherwise arise from any imbalance in baseline utility between groups.101 A total
of 1000 bootstrap samples were drawn for each imputed data set. Mean costs, QALYs and the NMB in
each of the four treatment groups were estimated based on the regression coefficients for each bootstrap
of each imputed data set.
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We combined uncertainty around missing data with sampling uncertainty using the MI Boot pooled
sample approach of Schomaker and Heumann,102 which has been shown to yield valid inference and
to be equivalent to nesting bootstraps within imputations and combining results using Rubin’s rule.
Pooling bootstraps is simpler to implement than Rubin’s rule and facilitates presentation of CEACs.
In addition, a simulation study has shown it to give good coverage with ≥ 20 imputations. To implement
this in our data set, we averaged across the 25 imputed data sets for the original (non-bootstrapped)
sample to get point estimates and estimated 95% CIs as the 2.5th and 97.5th percentiles across all
25,000 bootstraps, adapting the code used previously.103 CEACs were estimated across all 25,000
bootstraps. The regression models used to predict cost and QALYs are presented in Appendix 5,
Model 1: regression analysis model with interaction term (base-case analysis).
Regression analysis without interaction term (sensitivity analysis)
Regression techniques with an interaction term provide an alternative to at-the-margins analysis,
which also assumes no interaction.88 The description of the analysis and the model are presented in
Appendix 5, Model 2: regression analysis without interaction term (sensitivity analysis).
Results of economic analysis
Completion rate
Among the 708 participants randomised in the trial, 174 were randomised to best-practice advice, 178
were randomised to best-practice advice plus injection, 174 were randomised to progressive exercise
and 182 were randomised to progressive exercise plus injection. The completion rates of all health
resource items by treatment intervention for each time point are displayed in Table 20. In addition,
Table 21 shows the response rate of EQ-5D-5L by follow-up points and treatment group.
Health-care resource use and costs
Information about the use of other relevant NHS services was obtained by participant self-reported
data at 8 weeks, 6 months and 12 months. Estimates of health-care use have been presented in Appendix 5
as follows: from baseline to 8 weeks (see Appendix 5, Table 45), from 8 weeks to 6 months (see Appendix 5,
Table 46) and from 6 to 12 months (see Appendix 5, Table 47). These resource quantities were multiplied by
the relevant unit cost (see Appendix 5, Table 44) to provide estimated mean costs per patient from baseline
to 8 weeks (see Appendix 5, Table 48), from 8 weeks to 6 months (see Appendix 5, Table 49) and from 6 to
12 months (see Appendix 5, Table 50).
Prescribed medication usage was recorded at 8 weeks, 6 months and 12 months. Participants were
asked to list the drugs that they were currently taking and to report the dose and frequency of use.
The yielded estimate of the cost of prescribed medications for each individual over the three time
intervals can be seen in Appendix 5, Table 51. The mean cost per participant of prescribed medication
over the 12-month period was quite low for all treatment groups (£10.89 for best-practice advice
compared with £5.36 for best-practice advice plus injection, £2.90 for progressive exercise and £17.57
for progressive exercise plus injection). A summary of all included costs from the NHS and PSS
perspective (i.e. intervention cost, NHS service utilisation cost, prescribed medication cost and cost of
non-GRASP trial steroid injection) over the trial are given in Table 22. It is worth noting that NHS
service cost is lower in the progressive-exercise group than in the other intervention groups, which
indicates that participants in the progressive-exercise intervention group made less use of primary and
secondary health-care services.
Table 23 presents the mean cost and SD of non-NHS costs and any additional expenses, medication and
private care that was borne by GRASP trial participants. In terms of employment status, at 8 weeks,
49.44% of participants were in paid employment, of whom 4.66% took time off work. At 6 and 12 months,
the percentages were quite similar, with 46.06% and 46.75% of the participants being in paid employment
and only 3.81% and 3.67%, respectively, taking time off work. The mean cost of work loss by treatment
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TABLE 20 Completion rate (%) of health resource use by treatment interventions and follow-up time points
Type of care
Best-practice advice (N= 174)
Injection plus best-practice advice
(N= 178) Progressive exercise (N= 174)


























Baseline to 8 weeks
Primary care (NHS
community-based services)
16 (9.20) 113 (64.94) 45 (25.86) 8 (4.49) 142 (79.78) 28 (15.73) 22 (12.64) 124 (71.26) 28 (16.09) 11 (6.04) 151 (82.97) 20 (10.99)
Secondary care (NHS
outpatient services)
6 (3.45) 123 (70.69) 45 (25.86) 6 (3.37) 144 (80.90) 28 (15.73) 10 (5.75) 136 (78.16) 28 (16.09) 3 (1.65) 160 (87.91) 19 (10.44)
Private care 2 (1.15) 127 (72.99) 45 (25.86) 1 (0.56) 150 (84.27) 27 (15.17) 3 (1.72) 143 (82.18) 28 (16.09) 0 162 (89.01) 20 (10.99)
Injection utilisation 1 (0.57) 129 (74.14) 44 (25.29) 7 (3.93) 144 (80.90) 27 (15.17) 3 (1.72) 144 (82.76) 27 (15.52) 10 (5.49) 153 (84.07) 19 (10.44)
Non-medical expenses 5 (2.87) 124 (71.26) 45 (25.86) 5 (2.81) 145 (81.46) 28 (15.73) 15 (8.62) 131 (75.29) 28 (16.09) 18 (9.89) 144 (79.12) 20 (10.99)
8 weeks to 6 months
Primary care (NHS
community-based services)
16 (9.20) 111 (63.79) 47 (27.01) 15 (8.43) 132 (74.16) 31 (17.42) 18 (10.34) 122 (70.11) 34 (19.54) 16 (8.79) 134 (73.63) 32 (17.58)
Secondary care (NHS
outpatient services)
7 (4.02) 120 (68.97) 47 (27.01) 9 (5.06) 137 (76.97) 32 (17.98) 8 (4.60) 132 (75.86) 34 (19.54) 2 (1.10) 148 (81.32) 32 (17.58)
Private care 8 (4.60) 120 (68.97) 46 (26.44) 6 (3.37) 141 (79.21) 31 (17.42) 8 (4.60) 132 (75.86) 34 (19.54) 4 (2.20) 146 (80.22) 32 (17.58)
Injection utilisation 9 (5.17) 121 (69.54) 44 (25.29) 6 (3.37) 141 (79.21) 31 (17.42) 9 (5.17) 131 (75.29) 34 (19.54) 6 (3.30) 143 (78.57) 33 (18.13)




17 (9.77) 116 (66.67) 41 (23.56) 22 (12.36) 128 (71.91) 28 (15.73) 14 (8.05) 126 (72.41) 34 (19.54) 24 (13.19) 128 (70.33) 30 (16.48)
Secondary care (NHS
outpatient services)
10 (5.75) 123 (70.69) 41 (23.56) 15 (8.43) 135 (75.84) 28 (15.73) 9 (5.17) 132 (75.86) 33 (18.97) 15 (8.24) 137 (75.27) 30 (16.48)
Private care 8 (4.60) 125 (71.84) 41 (23.56) 3 (1.69) 147 ( 82.58) 28 (15.73) 8 (4.60) 133 (76.44) 33 (18.97) 9 (4.95) 143 (78.57) 30 (16.48)
Injection utilisation 12 (6.90) 121 (69.54) 41 (23.56) 8 (4.49) 142 (79.78) 28 (15.73) 9 (5.17) 132 (75.86) 33 (18.97) 12 (6.59) 138 (75.82) 32 (17.58)













































































































































































































































































































n Missing, n (%) n Missing, n (%) n Missing, n (%) n Missing, n (%)
8 weeks 132 42 (24.14) 151 27 (15.17) 147 27 (15.52) 164 18 (9.89)
6 months 134 40 (22.99) 151 27 (15.17) 143 31 (17.82) 154 28 (15.38)
12 months 138 36 (20.69) 158 20 (11.24) 144 30 (17.24) 154 28 (15.38)





















Intervention 167 43.20 (0) 164 43.20 (0) 166 49.43 (29.50) 171 49.43 (30.94)
NHS services 174 60.44 (311.76) 178 61.29 (312.85) 174 39.33 (103.79) 182 61.19 (317.38)









103 193.31 (414.85) 119 203.23 (146.97) 116 236.95 (151.67) 124 308.68 (407.61)
a Number column refers to the participants who answered the question ‘did you use X resource use?’ at each time
point [i.e. 103 out of 174 participants in the best-practice advice group responded to the question if they had an
injection outside the GRASP trial, of whom one participant (0.57%) had an injection (see Table 21)].






















Time off work 174 107.58 (576.68) 178 105.17 (658.46) 174 36.98 (309.12) 182 102.86 (704.33)
Additional
expenses




115 13.34 (30.97) 132 15.71 (29.64) 127 20.11 (49.82) 139 17.74 (38.90)
Private care 174 22.07 (131.22) 178 16.98 (161.47) 174 15.95 (79.78) 182 18.62 (100.24)
Total cost
(societal)
101 229.78 (926.49) 123 185.68 (818.29) 119 110.30 (412.65) 133 441.39 (3448.15)
a The number column refers to the participants who answered the question ‘did you use X resource use?’ at each time point.
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allocation for the 12-month period is also shown in Table 23. Table 23 further indicates that the non-NHS
cost of ‘additional expenses’ and ‘total cost (societal)’ was higher in the injection and progressive-exercise
intervention groups than in the other intervention groups. Utilisation of corticosteroid injections outside
the GRASP trial is presented in Appendix 5, Table 52. The use of corticosteroid injections outside the trial
varied slightly across treatment groups and follow-up periods, but, overall, was very low, with the largest
number of participants receiving injection (n= 12) recorded between 6 and 12 months from the best-
practice advice group. In addition, < 1% of participants reported paying for an injection privately. Similarly,
physiotherapy sessions taken outside the GRASP trial have been recorded and presented in Appendix 5,
Tables 44–47. The number of physiotherapy sessions taken outside the trial was, overall, very small across
all treatment groups and follow-up periods, and varied slightly.
Utility and quality-adjusted life-years
Utility scores were estimated using validated EQ-5D-5L questionnaires completed by participants at
baseline, 8 weeks, 6 months and 12 months. The summary statistics of the unadjusted and adjusted
EQ-5D utility scores for all observed cases across all time points by treatment interventions are
presented in Table 24 and Appendix 5, Table 53. EQ-5D-5L scores at 12 months were higher than the
baseline scores in all treatment groups. Baseline EQ-5D was markedly higher in the group randomised
to progressive exercise only. Consequently, unadjusted EQ-5D utilities and QALYs should be interpreted
with caution.












na Mean (SD) na Mean (SD) na Mean (SD) na Mean (SD)
Available cases without imputation and no adjustment for baseline utility
Baseline 174 0.65 (0.20) 178 0.64 (0.18) 172 0.69 (0.15) 181 0.64 (0.18)
8 weeks 132 0.68 (0.20) 151 0.73 (0.17) 147 0.70 (0.15) 164 0.69 (0.20)
6 months 134 0.74 (0.20) 151 0.75 (0.16) 143 0.78 (0.16) 154 0.72 (0.23)
12 months 138 0.77 (0.20) 158 0.77 (0.16) 144 0.81 (0.16) 154 0.75 (0.22)
QALYs 101 0.73 (0.17) 132 0.75 (0.12) 124 0.76 (0.28) 137 0.73 (0.18)
Imputation and no adjustment for baseline utility
Baseline 174 0.65 (0.20) 178 0.64 (0.18) 174 0.69 (0.15) 182 0.64 (0.18)
8 weeks 174 0.69 (0.20) 178 0.72 (0.17) 174 0.69 (0.15) 182 0.68 (0.21)
6 months 174 0.73 (0.20) 178 0.75 (0.17) 174 0.76 (0.17) 182 0.72 (0.23)
12 months 174 0.76 (0.21) 178 0.77 (0.16) 174 0.81 (0.16) 182 0.76 (0.21)
QALYs 174 0.72 (0.18) 178 0.75 (0.13) 174 0.77 (0.28) 182 0.74 (0.17)
Imputation and adjustment for baseline utility
QALYs 174 0.74 (0.15) 178 0.74 (0.15) 174 0.77 (0.12) 182 0.72 (0.17)
a The number column refers to the participants who answered the question ‘did you use X resource use?’ at each
time point.
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Table 25 presents the costs and QALYs associated with the four interventions under investigation.
This analysis evaluated the impact of exercise treatment and injection and interactions between these
two interventions inside the table, while imputing missing values and adjusting for age, sex and
baseline utility.
When all randomised patients were included in the analysis and missing values were imputed using
multiple imputation, patients receiving best-practice advice accrued an average of 0.737 (95% CI 0.710
to 0.763) QALYs and an NHS cost of £195 over the 12-month period (see Table 25). In the base-case
analysis, adding injection to best-practice advice gained 0.021 QALYs (p = 0.184) and increased the
cost by £10 per participant (p = 0.747) compared with best-practice advice alone. Progressive exercise
alone was £52 (p = 0.247) more expensive per participant than best-practice advice, while gaining
0.019 QALYs (p = 0.220). However, there was a non-significant interaction for cost (p = 0.397), which
meant that when injection was added to progressive exercise it generated an additional cost of £60
per participant (i.e. £50 more than the difference between best-practice advice and injection only).
There was also a non-significant qualitative interaction for QALYs (p = 0.106), whereby adding injection
to best-practice advice increased QALYs, but adding injection to progressive exercise reduced QALYs;
the groups receiving injection alone or progressive exercise alone accrued more QALYs than the group
receiving best-practice advice, whereas the group that received both of these treatments had lower
QALYs than either of the groups receiving only one treatment. Best-practice advice plus injection
cost £475.59 more per QALY gained than best-practice advice alone. Progressive exercise alone and
progressive exercise plus injection were both strongly dominated by best-practice advice plus injection,
being both more costly and accruing fewer QALYs.
The 2013 NICE cost-effectiveness threshold of £20,000 per additional QALY100 was used to identify
which treatments represent best value for money (i.e. has highest NMB). The interactions for cost and
QALYs combine to give a qualitative, but non-significant interaction for NMB (p = 0.100). Best-practice
advice plus injection had a 54.93% probability of being the most cost-effective treatment at a ceiling
TABLE 25 Regression analysis with an interaction term, including imputation of missing values and adjustment for
baseline utility, sex and age (base-case analysis)
Regression analysis
Total costs (£),
mean (SE) QALYs, mean (SE) NMB (£),a mean (SE)
BPA 195 (54) 0.737 (0.013) 14,538 (290)
IBPA 205 (20) 0.757 (0.011) 14,939 (227)
ProgEx 247 (23) 0.756 (0.012) 14,865 (255)
IProgEx 307 (30) 0.742 (0.012) 14,524 (263)
Injection simple effect (IBPA – BPA) 10 (44) (p = 0.747) 0.021 (0.015) (p = 0.184) 402 (322) (p = 0.212)
ProgEx simple effect (ProgEx – BPA) 52 (44) (p = 0.247) 0.019 (0.016) (p = 0.220) 327 (323) (p = 0.309)
Interaction (BPA – IBPA – ProgEx +
IProgEx): ProgEx by injection
50 (57) (p = 0.397) –0.035 (0.022) (p = 0.106) –743 (455) (p = 0.100)
BPA, best-practice advice; IBPA, injection plus best-practice advice; IProgEx, injection plus progressive exercise;
ProgEx, progressive exercise.
a NMB calculated at a ceiling ratio of £20,000 per QALY.
Notes
Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there
was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment
and the interaction between treatments are assumed to be the same for all participant subgroups, although the
absolute costs and absolute QALYs may be higher or lower, depending on participants’ sex, age and baseline utility.
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ratio of £20,000 per QALY (Figure 12). Progressive exercise alone had the second highest NMB and
had a 35.64% probability of being cost-effective at a ceiling ratio of £20,000 per QALY.
Sensitivity analyses
The analysis ignoring the interaction between exercise treatment and injection also found it to be
cost-effective to adopt injection, but not progressive exercise, although there remained substantial
uncertainty around this conclusion (see Appendix 5, Table 54). In this analysis, progressive exercise
(with/without injection) had a statistically significant effect on cost (p = 0.012), with an increase of
£78 per participant compared with no progressive exercise (with/without injection), but gained < 0.001
QALYs (p = 0.984). Progressive exercise, therefore, cost £438,089 per QALYs gained compared with
no progressive exercise. Injection (with/without progressive exercise) non-significantly increased
cost (£35 per participant; p = 0.239) while offering a negligible QALY gain (0.003; p = 0.818), but was,
nonetheless, expected to be cost-effective compared with no injection (with/without progressive
exercise), costing £15,110 per QALY gained.
Appendix 5, Table 55, presents an extension to the NHS and PSS perspective taken by the base-case
analysis to further consider the societal perspective, which included expenses borne by participants
in the study, over-the-counter medication cost, income loss and cost of private care. In this analysis,
adding injection to best-practice advice gained 0.02 QALYs (p = 0.183) and decreased the cost by £34
per participant (p = 0.813). Progressive exercise alone was £60 (p = 0.247) less expensive per participant
than best-practice advice, while offering a gain of 0.019 QALYs (p = 0.229). When injection was added to
progressive exercise, it increased costs by £374 per participant, as there was a very large non-significant
qualitative interaction for QALYs (£408; p = 0.106). The interactions for cost and QALYs combined to give
a qualitative and borderline statistically significant interaction for NMB (p = 0.049). Best-practice advice
plus injection was expected to be the most cost-effective treatment (with a 47.55% probability of being
cost-effective), followed by progressive exercise only (with a 44.87% probability of being cost-effective).
As described above, we extended the base-case analysis by considering the maximum cost of delivering
the training for best-practice advice and progressive exercise (e.g. travel cost, venue hire, parking)
while calculating the treatment cost of the intervention. In this analysis, the total cost of training was
£139.44 per participant for best-practice advice and £166.69 per participant for progressive exercise.
The results of the worst-case cost-effectiveness analysis are shown in Appendix 5, Table 56. QALY gains
from the interventions are virtually identical to the base-case analysis (differing only from Monte Carlo
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FIGURE 12 The CEAC for the comparison between treatment groups (base-case analysis). The frontier indicated which
treatment is economically preferred at different threshold values for cost-effectiveness.
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The total training cost per participant was £416.54 higher than in the base case, although the incremental
cost of progressive exercise compared with best-practice advice alone increased by only £41 compared
with the base case. At a £20,000 per QALY ceiling ratio, best-practice advice plus injection remained the
most cost-effective treatment, with a 53.59% probability of being cost-effective. Progressive exercise and
progressive exercise plus injection were dominated (i.e. more costly and less effective) by best-practice
advice plus injection.
Finally, we conducted a sensitivity analysis that assumed that study interventions would be implemented in
routine clinical practice with the training delivered on an online platform. The best-case analysis results are
presented in Appendix 5, Table 57. The total cost of training was £2.35 per participant for best-practice
advice and £3.02 for progressive exercise, which is, respectively, £40.85 and £46.41 less expensive per
participant than the base case. At a £20,000 per QALY ceiling ratio, best-practice advice plus injection
remained the most cost-effective treatment, with a 53.6% probability of being cost-effective. Progressive
exercise and progressive exercise plus injection were dominated (i.e. more costly and less effective) by
best-practice advice plus injection.
Discussion
The GRASP trial economic analysis evaluated the cost–utility of best-practice advice alone, best-
practice advice preceded by a corticosteroid injection, progressive exercise alone and progressive
exercise preceded by a corticosteroid injection, and compared alternative methodological approaches
for conducting economic evaluation alongside factorial trials.
At a £20,000 per QALY ceiling ratio, a corticosteroid injection followed by best-practice advice was
expected to be the most cost-effective treatment for people with a new episode of a rotator cuff
disorder, regardless of the analytical approach adopted, although there was substantial uncertainty
around this conclusion. There were no significant differences in costs or QALYs and there was a 36%
chance that progressive exercise alone is the most cost-effective strategy. In addition, the strength of
evidence in favour of best-practice advice plus injection did not vary considerably between the base-case
analysis, ignoring interactions, and the two sensitivity analyses varying the assumptions about training cost.
Across these analyses, NMBs for best-practice advice plus injection ranged from £14,783 to £14,986.
Although missing data are usually an issue in economic analysis and may introduce bias into the health
economics results, the rate of complete response to the health-care resource use questions and EQ-5D
questionnaire was reasonably high in the GRASP trial. Regardless, robust multiple imputation models
have been applied and included all treatment indicators.
One of the advantages of conducting a factorial design trial is that it enables us to compare four
treatment options within a single trial and explore whether or not there are interactions between
treatments. We observed interactions for both costs and QALYs, which were very large compared with
the main effect of treatment and meant that adding injections to best-practice advice increased mean
QALYs, whereas adding injections to progressive exercise decreased mean QALYs. The opposite trend
was observed for costs when a societal perspective was taken, which translated to a statistically
significant interaction for NMB. We are not aware of a clinical mechanism that may explain these
interactions and these interactions (only one of which was statistically significant) may have arisen by
chance. Furthermore, even relatively small interactions will change the direction of clinical effect in
studies such as this where the simple effect of treatment is very small. As randomised controlled trials,
in general, are not powered based on economic end points but rather clinical outcomes, there is an
ongoing argument that the economic evaluations are very likely underpowered. This argument is more
prominent in a factorial design setting and increases the degree of uncertainty around the economic
estimates in particular. We followed recent methodological work in prespecifying that the economic
evaluation would include an interaction term regardless of statistical significance.88 In the base-case
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analysis, interactions between treatments were not statistically significant, suggesting that the standard
statistical approach would have been to conduct an at-the-margins approach. Only when the broader
societal perspective was taken together with the base-case NHS perspective did the interactions for
cost and QALYs combine to give a qualitative and statistically significant interaction for NMB. However,
our sensitivity analysis demonstrated that the conclusion that best-practice advice plus injection was
the most cost-effective treatment remained unchanged in the sensitivity analysis omitting the interaction
term. Dakin and Gray88 have discussed the challenges associated with the economic evaluations
conducted alongside factorial trials, but further research is needed in this area.
The current economic evaluation used the newly developed EQ-5D-5L to capture the health-related
quality of life for patients with a new episode of a rotator cuff disorder. It is regarded as more
sensitive in capturing health changes than its predecessor (i.e. the EuroQol-5 Dimensions, three-level
version). Nonetheless, as a generic measure of health, it is not disease specific and, hence, not expected
to capture all the treatment benefits. The economic analysis showed a negligible and non-statistically
significant QALY difference between the treatment groups, which is also consistent with the primary
clinical outcome (i.e. SPADI) in this trial.
Finally, our economic evaluation included data from the GRASP trial only. Although there are no
previous data on the specific progressive exercise regimen used in this study, there have been a
number of previous studies of injections.30 In principle, future analyses could use methods such as
Bayesian bootstrapping88,104,105 to combine evidence from the GRASP trial with previous evidence on
the efficacy of injection compared with no injection.
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This chapter provides an overview of the aims of the GRASP trial and summarises the main findings,before considering its internal and external validity. The interpretation of the findings are then
considered in the context of data from other similar trials in this area.
Interpretation
Aim and overview of trial findings
Shoulder pain in the UK is very common, with the most common attribution being the rotator cuff,
which accounts for around 70% of new episodes of shoulder pain presenting in primary care.2 The
majority of shoulder pain is managed in primary care or at primary care interface services by physiotherapists
and GPs. Current treatments aim to improve pain and function with standard care that includes rest, advice,
analgesia, physiotherapist-prescribed exercise and corticosteroid injection; however, there are no NICE
clinical guidelines for this area.4 Prior to the GRASP trial, limited evidence existed regarding the most
clinically effective and cost-effective form of physiotherapist-prescribed exercise and delivery mechanism
associated with the best outcomes for people with a rotator cuff disorder.There was also uncertainty around
the long-term benefits and harms associated with corticosteroid injection. In the GRASP trial, we aimed to
assess the clinical effectiveness and cost-effectiveness of whether or not (1) an individually tailored
progressive, home exercise programme prescribed and supervised by a physiotherapist provided greater
improvement in shoulder pain and function over 12 months (measured using the SPADI score) compared
with a best-practice advice session with a physiotherapist and provision of high-quality self-management
materials, and (2) subacromial corticosteroid injection provided greater improvement in shoulder pain and
function over 12 months compared with no injection.
For the primary outcome, there was no evidence of a difference in the SPADI scores over 12 months
between participants randomised to receive the progressive-exercise intervention and those who received
best-practice advice. Likewise, there was no evidence when analysed at the 8-week and 6-and 12-month
time points. In both intervention groups, shoulder pain and function did improve over time, although SPADI
scores at 12 months showed that the condition did not resolve completely, as most participants still
reported some symptoms. There was also no difference between groups for secondary outcome
measures, with the exception of progressive exercise, which resulted in an improvement in patient-
reported GIT over 12 months and at the 6- and 12-month time points. There were no significant
subgroup differences in shoulder pain and function across the different time points when assessed for
age, sex, baseline smoking status, SPADI and pain self-efficacy.
Over 12 months, there was no evidence of a difference in SPADI scores between participants randomised to
receive corticosteroid injection and those receiving no injection, nor when analysed at the 6- and 12-month
time points.There was a small difference in SPADI scores at 8 weeks, in favour of injection, but this was just
below the threshold for a clinically important difference in the SPADI.There were no differences between
groups for secondary outcome measures, with the exception of corticosteroid injection at 8 weeks, which
resulted in a small improvement in shoulder pain, shoulder function, sleep disturbance, RDA and GIT.
Prespecified subgroup analysis showed that the effect of corticosteroid injection was stronger at 8 weeks in
people with a higher baseline SPADI score (i.e. SPADI ≥ 50) than in those who received injection but had a
lower baseline SPADI score. No differences were observed for other prespecified subgroup analyses.
At 8 weeks and 6 months, participants who received injections were more likely to report performing
their exercises 5 days per week, in accordance with the advice from the treating physiotherapist, than
participants who did not receive injections. This suggests that, although the effect of corticosteroid
injection is short lived, it may facilitate engagement with prescribed home exercises. There were no
SAEs recorded as part of the trial as a result of either corticosteroid injection or physiotherapy.
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A cost–utility analysis investigated the impact of progressive exercise, injection and the interaction
between progressive-exercise treatment and injection, accounting for missing values and adjusting for
baseline imbalance. There were no statistically significant differences between the treatment groups in
terms of costs or QALYs over the 12-month period. More specifically, the addition of injection to best-
practice advice produced a negligible and non-statistically significant QALY gain, with a small extra
cost. Progressive exercise was more expensive per participant than best-practice advice, but, again,
with a negligible and non-statistically significant QALY gain. Progressive exercise alone and progressive
exercise plus injection were both strongly dominated by best-practice advice plus injection, being more
costly and accruing fewer QALYs. Among the treatments under investigation, the one expected to
provide the best value for money was the best-practice advice session with a physiotherapist and
injection, although there is substantial uncertainty around this conclusion. Although the benefits of
corticosteroid injection were limited both in size and to the early phase of recovery, this combination
of interventions dominated in terms of their cost-effectiveness.
Generalisability
Internal validity and methodology
The GRASP trial was a pragmatic multicentre superiority 2 × 2 factorial randomised controlled trial.
Given the factorial design, we first formally tested for an interaction effect. In the absence of any
significant interaction, we were able to assess the effects of our two main comparisons: (1) progressive-
exercise programme compared with best-practice advice session and (2) subacromial corticosteroid
injection compared with no injection. In accordance with the sample size estimation (see Chapter 4),
data from 704 participants were required to detect a standardised effect size of 0.33 (equivalent to
8 points on the SPADI total score) with 90% power and 1% two-sided statistical significance, allowing
for 20% loss to follow-up at 12 months and potential for a small clustering effect by physiotherapist.36
The DMEC reviewed the sample size assumptions after 338 participants had been recruited and did not
recommend any changes to the final sample size. We recruited a total of 708 participants and had a lower
than estimated loss to follow-up rate of 13% at 12 months, and so the trial was adequately powered to
detect a statistically and clinically important difference between interventions. Measurements for the
primary and secondary outcomes were collected by postal questionnaires at 8 weeks, 6 months and
12 months. When postal questionnaires were returned to the GRASP trial office, data were checked and
if missing data were identified, either for part or a whole outcome measure, then the participant was
contacted and information collected by telephone. As a result, we had limited missing outcome data
from the completed questionnaires.
Randomisation was generated using the centralised computer randomisation service provided by
OCTRU. Randomisation was stratified by site, age and sex using variable block size, ensuring that
participants were balanced across interventions groups and minimising the chances of research staff
anticipating treatment allocation prior to randomisation. It was not possible to blind participants and
treating physiotherapists because of the nature of the interventions being tested. Both the primary
and secondary outcomes were patient reported and collected using postal questionnaires. There was
potential for bias as participants were aware of treatment allocation, but this reflects the difficultly
of achieving and maintaining blinding in pragmatic rehabilitation trials of this nature.72 In the small
number of cases where outcome data were collected by telephone (e.g. participants who did not
respond to postal reminders), the researcher was blinded to the treatment allocated and participants
were asked not to disclose which intervention they had received.
Physiotherapists were trained to deliver either the best-practice advice intervention or the progressive-
exercise intervention to minimise possible contamination between treatment groups. Only two
physiotherapists swapped treatment groups during the trial, because of staffing issues at sites, and
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so ended up delivering both interventions. According to the results of the GIT questionnaire, the
interventions were generally well received by the participants. Interventions were also delivered with high
levels of fidelity by the physiotherapists, as determined by quality assurance visits conducted at site and
review of treatment logs. Attendance rates were 94% for injection, 95% for progressive exercise (either
partially or full completed) and 92% for best-practice advice. These attendance rates are above those
normally expected for NHS outpatient physiotherapy, with non-attendance rates estimated to be 10.4%
according to recent NHS Hospital Episode Statistics data.41 There was no difference in attendance rates
between those receiving the physiotherapist-delivered exercise interventions and those who received
physiotherapist-delivered exercise interventions in conjunction with a corticosteroid injection.
Despite some initial concerns from physiotherapists raised during site training regarding the adequacy of a
single contact with a physiotherapist to start a self-guided exercise programme, very few participants in the
best-practice advice intervention required an additional contact session during the trial. Most participants in
the progressive-exercise intervention group attended a median of four sessions (out of a maximum of six
sessions) before being discharged. Progression of exercises, defined as an increase in exercise difficulty or
volume and/or load, was regarded as key to achieving the overload and subsequent physiological response
in the neuromuscular system to improve muscle function. Treatment logs provided evidence that 67%
of participants in the progressive-exercise group had exercise progression between their first and last
session, 22% maintained the initial exercise dose during treatment and only 12% had to regress their
exercise dose over the sessions. The maintenance or regression of the level of exercise over the sessions
was consistent with the tailoring and modification of the exercise programme allowed in the intervention
protocol in the trial. The intervention was designed to enable therapists to adapt the programme according
to the participant’s response to exercising the shoulder.
A small proportion of participants (3.8%) withdrew from the GRASP trial. This was either withdrawal
from the intervention only or withdrawal from both the intervention and future follow-up assessment.
The most common reason was a change in diagnosis since randomisation, and not dissatisfaction with
treatment. Numbers were balanced across intervention groups. Participants were advised that they
may seek other forms of treatment/medication outside the GRASP trial. This information was collected
as part of the participant follow-up questionnaires. There were no significant differences in medication
type or other health-care resources usage across the intervention groups, suggesting that the effects
seen in terms of any improvement in shoulder pain and function were due to the trial interventions.
External validity and generalisability of study findings
The GRASP trial recruited participants from 20 primary care-based musculoskeletal services and their
related physiotherapy services in the NHS. We had originally planned for eight sites; however, slower
than anticipated recruitment meant that we increased our overall number of sites. The advantage of
this was a greater range of centres in terms of geography and size, making it more representative
of the NHS as a whole.
The training provided to the staff in these centres was relatively brief, with most NHS physiotherapy
staff having expertise in delivering the best-practice advice intervention, with limited additional
training. The best-practice advice intervention places emphasis on strategies to optimise self-management,
with participants receiving a single face-to-face session rather than four to six sessions, as would be
more typical of standard NHS physiotherapy treatment for this condition. As a result, we believe that
the implementation of the best-practice advice intervention in the NHS would be straightforward
and would involve relatively small training costs. No additional training was required for the subacromial
corticosteroid injection, as this was delivered in accordance with current NHS practice and predominantly
by extended-scope physiotherapists with the appropriate post-registration qualification in injection therapy.
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We believe that the participants recruited into the GRASP trial are representative of patients referred
to NHS primary care-based musculoskeletal and physiotherapy services with a new episode of shoulder
pain due to a rotator cuff disorder, in terms of their age and sex. Screening log data showed that the
age and sex of patients who declined to take part in the trial were similar to those who did take part.
However, one of the main reasons that participants declined to take part in the trial was because they
were not interested in taking part in research (30%) or that they had a treatment preference for not
wanting to receive corticosteroid injection (27%), as opposed to 7% having a treatment preference for
wanting to receive injection. The extent to which this is representative of clinical practice outside a
trial setting is unclear.
The mean age of participants recruited into the GRASP trial was 55.5 years, with a similar proportion
of men and women. This is consistent with data from a large epidemiological study of rotator cuff
pathology106 using The Health Improvement Network database (a large UK primary care database) in
which the highest incidence of rotator cuff pathology was found in those aged between 55 and 59 years,
with no significant difference between men and women. This study also showed that people in the lowest
socioeconomic group (with the Townsend deprivation score used as a measure of material deprivation)
had the highest disease incidence.106 This is reflected in the findings of the GRASP trial, in which, despite
around half of participants reporting being in employment, their reported household income was low.
Our population was predominantly white British (89.7%) and this figure is higher than the population
in England as a whole (78.7%).107 The prevalence of rotator cuff disorder in ethnic minority groups
is not well known or understood and so it is difficult to infer what influence this may have on the
generalisability of our results. More than two-thirds of participants included in the GRASP trial were
considered to be overweight or obese based on their body mass index. Again, the effect of obesity
on the prevalence of rotator cuff disorders is not well known, including the extent to which it can
contribute to symptoms108 and ability to exercise effectively. There is some evidence that obesity can
lead to poorer outcomes after surgery to repair a rotator cuff tear.109
The mean duration of symptoms for participants included in the GRASP trial was 4 months. Our eligibility
criteria meant that we specifically wanted to target those participants with a new episode of shoulder pain
attributable to a rotator cuff and who had not received corticosteroid injection or physiotherapy for
shoulder pain in the last 6 months. The overall mean SPADI baseline score was 54.1 (on a scale of 0–100),
with higher reported levels of shoulder pain (mean 63.9) than impairment of shoulder function (mean 44.3).
Irrespective of the allocated intervention, participant shoulder pain and function improved over time,
although overall SPADI scores at 12 months (mean 21.9) show that symptoms did not resolve completely.
These findings are consistent with a large epidemiological study of the prevalence of people consulting for
shoulder pain in UK primary care, whereby 13.6% of people with shoulder pain continued to consult
beyond 2 years from initial presentation.1 The SELF trial, which compared the effectiveness of usual
physiotherapy treatment with a programme of self-management, also found that rotator cuff symptoms
had not resolved completely when measured using the SPADI scale at 12 months.67
Overall evidence: comparison with other literature
Exercise intervention
Findings from a Cochrane review published in 2016, before the start of the GRASP trial, highlighted
the lack of evidence about the long-term clinical effectiveness and cost-effectiveness of physiotherapy
for the treatment of rotator cuff disorders, despite its widespread provision.14 Evidence from several
small trials with short-term follow-up also raised uncertainty about which types of exercise and
delivery mechanisms were associated with best outcomes.15,16
We searched MEDLINE, EMBASE and Cumulative Index to Nursing and Allied Health Literature
(CINHAL) to identify new evidence relevant to the GRASP trial (date of last search: June 2020).
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From an initial 2354 records, we identified seven trials67,110–115 published between 2013 and 2020,
comparing the effects of supervised exercise with unsupervised exercise, or no intervention, in people
with a rotator cuff disorder (excluding those who required surgery). Most of the trials concluded that there
was little or no difference between supervised and unsupervised exercise.The populations were comparable
to the GRASP trial, with the exception of the trial by Krischak et al.,110 which evaluated people with
atraumatic full-thickness rotator cuff tears. All trials were small, with the exception of the trial by Contreras
et al.113 (n = 271) and the SUPPORT trial115 [which had 64 participants in each group (2 × 2 factorial trial)
and 256 participants in total]. Only two67,115 of the seven trials reported on the effect of exercise on
shoulder pain and function at 12 months, two reported medium-term follow-up data (24 or 26 weeks111,113)
and the remaining three trials reported outcomes at ≤ 6 weeks (see Appendix 6, Table 58). This reinforces
the importance of the GRASP trial findings in terms of their definitive nature and length of follow-up.
Corticosteroid injection
At the time of planning the GRASP trial, there was systematic review evidence that, in comparison
with placebo, corticosteroid injections had short-term benefit for treating tendinopathy, although there
was some uncertainty regarding its use for rotator cuff disorders. There were also concerns about the
longer-term safety of corticosteroid injection and its effect on the tendon.30
We searched MEDLINE, EMBASE, the Allied and Complementary Medicine Database (AMED),
CINHAL, the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov and the
World Health Organization International Clinical Trials Registry to identify new evidence relevant to
the GRASP trial (date of last search: June 2020).91 From an initial 794 records, we identified one small
trial116 that compared the effects of corticosteroid injection with no injection in people with a rotator cuff
tear and found no difference in shoulder pain and function when analysed at 3 or 6 months, measured
using the Constant–Murley score (MD at 6 months –1.9, 95% CI –10.89 to 7.09; patients, n = 40).
We identified an additional 10 trials7,90,117–124 that compared the effects of corticosteroid injection
with placebo injection (see Appendix 6, Table 59), of which four7,118,121,122 were judged as suitable for
inclusion in a meta-analysis. The remaining studies could not be included because of either incomplete
or incompatible outcome data. Three trials,118,121,122 with a total of 215 patients, compared subacromial
corticosteroid injection with placebo injection for combined shoulder pain and function in the short
term (i.e. ≤ 8 weeks), with results favouring corticosteroid over placebo [standardised mean difference
(SMD) –0.51, 95% CI –1.02 to 0.00; I2 = 69%; n = 3; patients, n = 215; rated as having moderate-quality
evidence]. Two of the trials118,122 also reported outcome data for medium-term follow-up (i.e. 3–6 months),
in which no difference was apparent (SMD 0.08, 95% CI –0.24 to 0.39; I2 = 0%; n = 2; patients, n = 151;
rated as having moderate-quality evidence). With regard to shoulder pain only, three trials reported
short-term outcomes118,121,122 and two reported medium-term outcomes.118,122 The results mirrored those
seen for combined shoulder pain and function, which favoured corticosteroid injection over placebo in the
short term (SMD –0.35, 95% CI –0.65 to –0.05; I2 = 17%; n= 3; patients, n= 215; rated as having moderate
quality evidence), but not the medium term (SMD 0.05, 95% CI –0.27 to 0.37; I2 = 0%; n = 2; patients,
n = 151; rated as having moderate-quality evidence). Two trials7,122 reported on shoulder functional
improvement in the short and medium term and, again, there was a short-term benefit favouring
corticosteroid injection (SMD –0.33, 95% CI –0.67 to 0.00; I2 = 0%; n = 2; patients, n = 143; rated as
having moderate-quality evidence), but there was no difference seen in medium-term functional outcomes
(SMD –0.24, 95% CI –0.59 to 0.10; I2 = 0%; n = 2; patients, n = 131; rated as having moderate-quality
evidence). No trials provided outcome data beyond 6-month follow-up and none reported any SAEs as a
result of injection.
These findings reinforce the importance of the results of the GRASP trial in terms of the short-term benefit
of subacromial corticosteroid injection, a benefit which is not maintained at 6- and 12-month follow-up.
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This chapter provides interpretation of the GRASP trial findings for clinical practice and policy,and provides recommendations for future research.
In adults with a new episode of shoulder pain (i.e. within the last 6 months) attributable to a rotator
cuff disorder, there was no difference in the primary outcome (SPADI) or other prespecified secondary
outcomes between participants randomised to receive (1) progressive exercise compared with best-
practice advice, or (2) subacromial corticosteroid injection compared with no injection, when analysed
over 12 months. Irrespective of allocated intervention, participants’ shoulder pain and function improved
over time, although SPADI scores at 12 months show that the condition did not resolve completely, as
participants still reported some symptoms. Participants randomised to receive subacromial corticosteroid
injection reported an improvement in shoulder pain and function at 8 weeks, but injection provided
modest short-term benefit only. The greatest benefit of injection was seen in the subgroup of participants
who reported higher SPADI scores at baseline; however, as this is based on subgroup analysis, this should
be viewed with caution. No SAEs were reported as a result of the intervention(s). The cost–utility
analysis, performed as part of the GRASP trial, suggests that, at a £20,000 per QALY ceiling ratio, a
corticosteroid injection followed by best-practice advice is likely to be the most cost-effective treatment
combination for people with a new episode of a rotator cuff disorder. There are no significant differences
in costs or QALYs.
Implications for health care
Early and effective management of rotator cuff disorders in primary care and primary care interface
musculoskeletal services is vital, given their associated disability and commonality. Consequences of
poor initial management may lead to an increased likelihood of recurrent or persistent problems in
older age and the subsequent need for surgery. This is particularly important given recent evidence
from the NIHR HTA-funded CSAW trial125 and updated Cochrane review93 that showed a lack of
benefit from subacromial decompression surgery, which is often used after non-operative interventions
have failed.
The GRASP trial shows that a single face-to-face session with a physiotherapist is likely to be more
cost-effective and is not significantly different in terms of clinical outcomes than a comprehensive
physiotherapy intervention of up to six face-to-face sessions. This is particularly important given the
incidence of rotator cuff disorders and the need to develop cost-effective and pragmatic methods
of dealing with this high-volume condition. Subacromial corticosteroid injection provides a modest
short-term benefit and is associated with an increased level of engagement in exercise. The greatest
benefit was observed in those with higher levels of pain and functional impairment at baseline.
Physiotherapists delivering the best-practice advice intervention attended a short face-to-face training
session where focus was on strategies to promote self-management and independent progression of
exercise, adherence to exercise and addressing barriers to exercise. The exercises prescribed were
those within the range that physiotherapists deliver in usual practice. We are exploring the use of an
online training module where physiotherapists can access the best-practice advice intervention training
virtually. This has proved very successful in implementation of physiotherapy interventions from other
musculoskeletal trials.45 In addition, the materials provided to participants in terms of the best-practice
advice booklet, exercise DVD and website are in English and, therefore, there is a need to explore
translation of these materials into other languages. There may also be some people for whom a single
session is not appropriate, for example those with low levels of literacy or inability to engage with
self-management care, in which case additional physiotherapy sessions may be required.
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Implications for research
There is a case to extend follow-up beyond 12 months, as some participants still reported pain and
impaired shoulder function at 12 months. There is a need to better understand the natural history
of rotator cuff disorders, including whether symptoms resolve over an extended period of time or
persist in the longer term. Part of this investigation could involve studies examining the natural
course of rotator cuff disorders and could include a randomised trial that compares the effects of no
physiotherapy with best-practice advice.
Although subacromial corticosteroid injection provided short-term benefit, there are still concerns
regarding long-term harm due to its possible effects on tendon structure.126 Very few participants
reported having undergone surgery related to their rotator cuff disorder during the 12-month follow-up
period. Twelve months may be too early to measure this effectively, as participants may still be undergoing
other forms of non-operative treatment. Therefore, longer-term follow-up would be beneficial.
Finally, screening data from trial sites as part of the recruitment process showed that some people
had a clear preference not to receive corticosteroid injection and, therefore, declined to take part
in the trial. The reason for this strong treatment preference is not clear and would warrant further
investigation to establish the reasons why.
CONCLUSION
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Appendix 1 Chapter 1 appendix
FIGURE 13 The BESS diagnostic algorithm.4 Reproduced with permission (Professor Jonathan L Rees, Nuffield
Orthopaedic Centre, 2021, personal communication).
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changes Details of changes made
1 Version 2.0 20 March 2017 Sally Hopewell Clarification of eligibility criteria to include
those predominantly seeking treatment for
one shoulder
Clarification of timelines for injection and
physiotherapy referral
Minor clarifications on physiotherapy
intervention content, including revision
of Figure 2
Correction to month of recruitment
Addition of PROMPTS (personalised text
message versus standard text message
prompts for increasing response to postal
questionnaires) substudy
4 Version 3.0 13 September 2017 Sally Hopewell Minor clarification regarding methods of data
collection and management
Minor change of wording regarding injection
delivery
12 Version 4.0 14 May 2018 Sally Hopewell Addition of monetary incentive at 12-month
follow-up
16 Version 5.0 2 January 2019 Sally Hopewell Addition of text reminder at 12 months
Change to wording regarding duration of
recruitment
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FIGURE 14 Injection referral form and treatment log. OCTRU logo reproduced with permission (Vicki Barber, Oxford
Clinical Trials Research Unit, 2021, personal communication).
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Appendix 3 Chapter 3 appendix
TABLE 27 Behavioural strategies to address barriers to exercise, highlighting common and discrete components to each
exercise intervention
Behaviour change
technique Progressive exercise Best-practice advice
Education and persuasion Information on benefits of exercise
provided face to face and in participant
information booklet
Information on benefits of exercise
provided face to face and in participant
information booklet
Training Exercises demonstrated, instructions
provided in written form, exercises
practised within the session and at home
independently, and exercises reviewed at
each appointment and feedback provided
Exercises demonstrated, instructions
provided in written and video form (web
and/or DVD), and exercises practised
within the session and at home
independently
continued
TABLE 26 Categories of exercise considered by the delegates of the GRASP trial intervention development meeting
Exercise category
Included in intervention
Best-practice advice Progressive exercise
Pectoralis major and anterior capsule stretch
Posterior shoulder/capsule stretch ✓
Other shoulder stretches
Scapular stability exercises and ‘setting’ (isolated positional changes





External shoulder rotation (low challenge exercises) ✓ ✓
External shoulder rotation (in shoulder elevation < 90°) ✓ ✓
External shoulder rotation (in shoulder elevation ≈ 90°) ✓ ✓
External shoulder rotation (in shoulder elevation > 90°) ✓ ✓
Internal shoulder rotation (low challenge exercises)
Internal shoulder rotation (in shoulder elevation < 90°)
Internal shoulder rotation (in shoulder elevation ≈ 90°)
Pendulum exercise
Assisted shoulder flexion ✓ ✓
Active shoulder flexion (unresisted) ✓ ✓
Shoulder extension
Shoulder adduction
Shoulder abduction ✓ ✓
Resisted functional movement ✓
Thoracic extension
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TABLE 27 Behavioural strategies to address barriers to exercise, highlighting common and discrete components to each
exercise intervention (continued )
Behaviour change
technique Progressive exercise Best-practice advice
Graded tasks Focus on starting with a manageable
amount of exercise (up to three exercises).
Use of modified Borg scale to set resistance
exercise [initially at lower levels and then
increase difficulty, volume and load
(see Figure 3)]
Focus on starting with a manageable
amount of exercise (one or two exercises).
Participants to increase volume and load
according to set progression advice
Equipment provision to
enable exercise
Resistance band issued if appropriate.
Advice on what can be used for hand
weights
All participants issued resistance band to
enable exercise performance. Advice on
what can be used for hand weights
Problem-solving Over the sessions, therapists facilitate
participant problem-solving and encourage
the participant to lead the decision-making
about progression/regression of programme.
Barriers to exercise (e.g. belief or
practicalities) are reviewed and ways to
overcome these are discussed. An exercise
plan is agreed collaboratively
Therapists encourage participant problem-
solving within the session. A starting point
on exercise ladder is agreed collaboratively
Action planning An action planner document is to be
completed (i.e. where and when exercises
will be carried out), including contingency
plans, prompts/cues for when to do
the exercises, a plan of what to do if
pain increases and information on when
and where the exercise diary will be
completed. See also Behavioural contract
and Confidence ruler
An action planner document is to
completed (i.e. where and when exercises
will be carried out), including contingency
plans, prompts/cues for when to do the
exercises, a plan of what to do if pain
increases and information on when and
where the exercise diary will be completed
Goal-setting Agree a long- and a short-term goal
(which are specific, measurable, achievable,
relevant and timed) and reinforce link
between goal and exercise plan
Agree a long-term goal (which is specific,
measurable, achievable, relevant and
timed) and reinforce link between goal
and exercise plan
Review goals Goals reviewed and adjusted at each
session
Not applicable
Confidence ruler Use the confidence ruler (from 0 to 10)
to assess participant’s confidence in
undertaking agreed exercise plan. If the
participant selects ≤ 7, discuss reasons
and adapt programme (see Graded tasks)





Within and between sessions, review
action planners and diaries at each





Progress in physical performance and
symptoms highlighted after reassessment
at each session
Not applicable
Self-monitoring of exercise Exercise diary to complete each day Same as Progressive exercise
Behavioural contract Therapist and participant sign action
planner document. Participant commits
to undertaking exercises and bringing
documents to be reviewed at next
appointment. Therapist to review
exercise diary
Not applicable
Reduce negative emotions Simple advice on managing low mood
in the information booklet. Provide
reassurance about condition and capacity
to exercise
Same as Progressive exercise
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
FIGURE 15 Progressive exercise intervention: action planner. OCTRU logo reproduced with permission (Vicki Barber,
Oxford Clinical Trials Research Unit, 2021, personal communication).
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FIGURE 16 Progressive exercise intervention: exercise diary. OCTRU logo reproduced with permission (Vicki Barber,
Oxford Clinical Trials Research Unit, 2021, personal communication).
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FIGURE 17 Progressive exercise intervention: level 1 simple shoulder movement exercises. Exercises can be modified in
a number of ways: (1) the range of motion through which an exercise is performed may be increased or decreased; and
(2) the position may be modified, for example some exercises may be carried out in lying, sitting or standing positions to
accommodate the patient’s comfort and preferences.
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FIGURE 18 Progressive exercise intervention: level 2 essential resistance exercises. Exercises can be modified in a
number of ways: (1): the range of motion through which an exercise is performed may be increased or decreased;
and (2) the position may be modified, for example some exercises may be carried out in lying, sitting or standing
positions to accommodate the patient’s comfort and preferences.
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FIGURE 19 Progressive exercise intervention: level 2 optional resistance exercises. Exercises can be modified in a
number of ways: (1): the range of motion through which an exercise is performed may be increased or decreased;
and (2) the position may be modified, for example some exercises may be carried out in lying, sitting or standing
positions to accommodate the patient’s comfort and preferences.
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FIGURE 21 Best-practice advice intervention: exercise progression ladder.
FIGURE 20 Progressive exercise intervention: level 2 optional resistance exercises. To be used selectively and only for
younger adults engaged in throwing or other overhead athletic or physical activities75 who have posterior capsule tightness.
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FIGURE 22 Best-practice advice intervention: exercise diary. OCTRU logo reproduced with permission (Vicki Barber,
Oxford Clinical Trials Research Unit, 2021, personal communication).
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FIGURE 23 Best-practice advice intervention: action planner. OCTRU logo reproduced with permission (Vicki Barber,
Oxford Clinical Trials Research Unit, 2021, personal communication).
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Appendix 4 Chapter 4 appendix






University Hospitals of Derby and Burton NHS Foundation Trust 20 February 2017 26 18
East Lancashire Hospitals NHS Trust 2 March 2017 26 17
Gloucestershire Hospitals NHS Foundation Trust 12 April 2017 24 43
Birmingham Community Healthcare NHS Trust 13 April 2017 24 13
Sandwell and West Birmingham Hospitals NHS Trust 19 May 2017 23 13
Buckinghamshire Musculoskeletal Integrated Care Service 26 May 2017 23 3
Bedfordshire Hospitals NHS Foundation Trust 8 June 2017 22 7
East Cheshire NHS Trust 10 July 2017 21 8
Wirral University Teaching Hospital NHS Foundation Trust 18 August 2017 20 6
Medway Community Healthcare 10 August 2017 20 6
Bristol Community Health 29 September 2017 19 4
Doncaster and Bassetlaw Teaching Hospitals NHS
Foundation Trust
27 November 2017 17 9
Somerset Partnership NHS Foundation Trust 23 November 2017 17 13
Sherwood Forest Hospitals NHS Foundation Trust 20 December 2017 16 4
Kent Community Health NHS Foundation Trust 19 January 2018 15 10
Northern Devon Healthcare NHS Trust 8 February 2018 14 17
Airedale NHS Foundation Trust 20 February 2018 14 7
North West Boroughs Healthcare NHS Foundation Trust 29 March 2018 13 10
Staffordshire and Stoke-on-Trent Partnership NHS Trust 26 April 2018 12 6
Warrington and Halton Hospitals NHS Foundation Trust 16 July 2018 9 9
Total 26 223
a Recruitment ended 2 May 2019.
b The number of clinicians who delivered trial interventions.
TABLE 29 Characteristics of participating physiotherapists
Participating physiotherapist
Agenda for Change grade, n (%)
Band 5 Band 6 Band 7 Band 8a Othera Totalb
Injectors 0 (0) 6 (11) 13 (23) 34 (61) 3 (5) 56 (100)
Best-practice advice 17 (20) 38 (46) 22 (27) 6 (7) 0 (0) 83 (100)
Progressive exercise 16 (15) 55 (53) 28 (27) 5 (5) 0 (0) 104 (100)
a Two orthopaedic consultants and one specialist registrar in orthopaedics.
b Some physiotherapists provided both injection and exercise interventions. Two physiotherapists delivered both
exercise interventions.
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History of significant shoulder trauma (e.g. dislocation, fracture, full-thickness tear requiring surgery) 94 (9)
Neurological disease affecting shoulder 23 (2)
Other shoulder disorder (e.g. inflammatory arthritis, frozen shoulder, glenohumeral joint instability)
or red flags consistent with BESS criteria
434 (43)
Received corticosteroid injection or physiotherapy for shoulder pain in last 6 months 167 (17)
Contraindications to corticosteroid injection 31 (3)
Symptoms > 6 months 132 (13)
Did not speak English 32 (3)
Other reason 28 (3)
Other (neither declined nor ineligible) 3 (0.3)
Unable to contact 59 (6)
Declined, n 576
Not interested in taking part in research 175 (30)
Does not want to be randomised 39 (7)
Already has treatment preference for receiving injection 38 (7)
Already has treatment preference for not receiving injection 158 (27)
Does not want to be randomised to receive progressive-exercise intervention 6 (1)
Does not want to be randomised to receive best-practice advice intervention 8 (1)
Unable to attend treatment sessions 71 (12)
Leaving the area 9 (2)
Prefer not to say 20 (3)
Other/no information 52 (9)
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Predicted patients/month 6 12 12 12 18 28 32 32 32 32 32 32 32 32 36 36 36 36 36 36 30 30 29 30 30 29
Predicted total 6 18 30 42 60 88 120 152 184 216 248 280 312 344 380 416 452 488 524 560 556 586 615 645 675 704
Actual total 0 1 7 21 44 69 86 110 135 158 178 211 236 274 312 346 395 436 467 507 556 590 613 649 672 688 707 708









































































































































































































































































































































































































































































n % n % n % n %
Ethnicity
White British 158 90.8 162 91.0 152 87.4 163 89.6
White other 2 1.1 5 2.8 2 1.1 4 2.2
Mixed 1 0.6 0 0.0 2 1.1 3 1.6
Indian 4 2.3 3 1.7 3 1.7 4 2.2
Pakistani 4 2.3 2 1.1 7 4.0 2 1.1
Bangladeshi 1 0.6 0 0.0 0 0.0 1 0.5
Black or black British 3 1.7 3 1.7 4 2.3 4 2.2
Chinese 0 0.0 0 0.0 0 0.0 0 0.0
Other 0 0.0 3 1.7 1 0.6 1 0.5
Prefer not to say 1 0.6 0 0.0 1 0.6 0 0.0
Missing 0 0.0 0 0.0 2 1.1 0 0.0
Marital status
Married/civil union 118 67.8 107 60.1 114 65.5 120 65.9
Living with partner 24 13.8 23 12.9 22 12.6 24 13.2
Unmarried (never married) 10 5.7 11 6.2 14 8.0 17 9.3
Separated/divorced 13 7.5 29 16.3 13 7.5 13 7.1
Widow/widower 7 4.0 6 3.4 8 4.6 6 3.3
Prefer not to say 2 1.1 2 1.1 1 0.6 2 1.1
Missing 0 0.0 0 0.0 2 1.1 0 0.0
Current work status
Retired 44 25.3 50 28.1 40 23.0 49 26.9
Semi-retired 13 7.5 10 5.6 9 5.2 7 3.8
Employed 84 48.3 91 51.1 98 56.3 82 45.1
Self-employed 19 10.9 14 7.9 12 6.9 17 9.3
Unemployed 2 1.1 5 2.8 5 2.9 9 4.9
Permanently sick or disabled 4 2.3 1 0.6 1 0.6 4 2.2
Looking after home or family 6 3.4 6 3.4 4 2.3 8 4.4
Other 2 1.1 1 0.6 3 1.7 5 2.7
Missing 0 0.0 0 0.0 2 1.1 1 0.5
Level of education
None or primary education 2 1.1 4 2.2 4 2.3 6 3.3
Secondary 92 52.9 92 51.7 74 42.5 89 48.9
Higher professional or
university education
80 46.0 82 46.1 94 54.0 87 47.8
Missing 0 0.0 0 0.0 2 1.1 0 0.0
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n % n % n % n %
Household income
< £10,000 36 20.7 27 15.2 22 12.6 27 14.8
Between £10,000 and
£19,999
39 22.4 60 33.7 46 26.4 52 28.6
Between £20,000 and
£29,000
41 23.6 26 14.6 36 20.7 30 16.5
Between £30,000 and
£39,999
21 12.1 23 12.9 20 11.5 23 12.6
Between £40,000 and
£49,999
12 6.9 12 6.7 8 4.6 14 7.7
≥ £50,000 12 6.9 10 5.6 19 10.9 10 5.5
Prefer not to answer 13 7.5 20 11.2 20 11.5 25 13.7
Missing 0 0.0 0 0.0 3 1.7 1 0.5
State benefits
Yes 37 21.3 36 20.2 30 17.2 41 22.5
No 136 78.2 139 78.1 140 80.5 139 76.4
Prefer not to say 1 0.6 3 1.7 2 1.1 1 0.5
Missing 0 0.0 0 0.0 2 1.1 1 0.5
Benefits received
Attendance Allowance 1 0.6 2 1.1 0 0.0 0 0.0
Carer’s Allowance 6 3.4 2 1.1 2 1.1 2 1.1
Child Benefit 16 9.2 14 7.9 14 8.0 14 7.7
Child Tax Credit 8 4.6 9 5.1 8 4.6 3 1.6
Council Tax Benefit 7 4.0 5 2.8 4 2.3 2 1.1
Disability Living Allowance 5 2.9 6 3.4 3 1.7 7 3.8
Employment and Support
Allowance
2 1.1 4 2.2 2 1.1 8 4.4
Income Support 3 1.7 1 0.6 2 1.1 3 1.6
Housing Benefit 5 2.9 3 1.7 3 1.7 4 2.2
Jobseeker’s Allowance 2 1.1 1 0.6 0 0.0 1 0.5
Working Tax Credit 4 2.3 7 3.9 5 2.9 5 2.7
Other 10 5.7 9 5.1 8 4.6 9 4.9
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n % n % n % n % n %
Ethnicity
White British 320 90.9 315 88.5 310 89.1 325 90.3 635 89.7
White other 7 2.0 6 1.7 4 1.1 9 2.5 13 1.8
Mixed 1 0.3 5 1.4 3 0.9 3 0.8 6 0.8
Indian 7 2.0 7 2.0 7 2.0 7 1.9 14 2.0
Pakistani 6 1.7 9 2.5 11 3.2 4 1.1 15 2.1
Bangladeshi 1 0.3 1 0.3 1 0.3 1 0.3 2 0.3
Black or black British 6 1.7 8 2.2 7 2.0 7 1.9 14 2.0
Chinese 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Other 3 0.9 2 0.6 1 0.3 4 1.1 5 0.7
Missing 0 0.0 2 0.6 2 0.6 0 0.0 2 0.3
Marital status
Married/civil union 225 63.9 234 65.7 232 66.7 227 63.1 459 64.8
Living with partner 47 13.4 46 12.9 46 13.2 47 13.1 93 13.1
Unmarried (never
married)
21 6.0 31 8.7 24 6.9 28 7.8 52 7.3
Separated/divorced 42 11.9 26 7.3 26 7.5 42 11.7 68 9.6
Widow/widower 13 3.7 14 3.9 15 4.3 12 3.3 27 3.8
Prefer not to say 4 1.1 3 0.8 3 0.9 4 1.1 7 1.0
Missing 0 0.0 2 0.6 2 0.6 0 0.0 2 0.3
Body mass index (kg/m2)
Underweight (< 18.5) 4 1.1 0 0.0 3 0.9 1 0.3 4 0.6
Normal weight
(18.5–24.9)
102 29.0 103 28.9 101 29.0 104 28.9 205 29.0
Overweight (25–29.9) 131 37.2 143 40.2 141 40.5 133 36.9 274 38.7
Obese (≥ 30) 113 32.1 104 29.2 99 28.4 118 32.8 217 30.6
Missing 2 0.6 6 1.7 4 1.1 4 1.1 8 1.1
Smoking status
Never smoked 185 52.6 200 56.2 184 52.9 201 55.8 635 89.7
Former smoker 132 37.5 124 34.8 127 36.5 129 35.8 13 1.8
Current smoker 35 9.9 30 8.4 35 10.1 30 8.3 6 0.8
Missing 0 0.0 2 0.6 2 0.6 0 0.0 2 0.3
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n % n % n % n % n %
Affected shoulder
Left shoulder 167 47.4 165 46.3 172 49.4 160 44.4 332 46.9
Right shoulder 172 48.9 177 49.7 162 46.6 187 51.9 349 49.3
Both shoulders 13 3.7 12 3.4 12 3.4 13 3.6 25 3.5
Missing 0 0.0 2 0.6 2 0.6 0 0.0 2 0.3
Hand dominance
Left handed 29 8.2 42 11.8 34 9.8 37 10.3 71 10.0
Right handed 310 88.1 306 86.0 305 87.6 311 86.4 616 87.0
Both 13 3.7 6 1.7 7 2.0 12 3.3 19 2.7
Missing 0 0.0 2 0.6 2 0.6 0 0.0 2 0.3
Current work status
Retired 94 26.7 89 25.0 84 24.1 99 27.5 183 25.8
Semi-retired 23 6.5 16 4.5 22 6.3 17 4.7 39 5.5
Employed 175 49.7 180 50.6 182 52.3 173 48.1 355 50.1
Self-employed 33 9.4 29 8.1 31 8.9 31 8.6 62 8.8
Unemployed 7 2.0 14 3.9 7 2.0 14 3.9 21 3.0
Permanently sick
or disabled
5 1.4 5 1.4 5 1.4 5 1.4 10 1.4
Looking after home
or family
12 3.4 12 3.4 10 2.9 14 3.9 24 3.4
Other 3 0.9 8 2.2 5 1.4 6 1.7 11 1.6




6 1.7 10 2.8 6 1.7 10 2.8 16 2.3
Secondary 184 52.3 163 45.8 166 47.7 181 50.3 347 49.0
Higher professional or
university education
162 46.0 181 50.8 174 50.0 169 46.9 343 48.4
Missing 0 0.0 2 0.6 2 0.6 0 0.0 2 0.3
Household income
≤ £10,000 63 17.9 49 13.8 58 16.7 54 15.0 112 15.8
Between £10,000 and
£19,999
99 28.1 98 27.5 85 24.4 112 31.1 197 27.8
Between £20,000 and
£29,000
67 19.0 66 18.5 77 22.1 56 15.6 133 18.8
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n % n % n % n % n %
Between £30,000 and
£39,999
44 12.5 43 12.1 41 11.8 46 12.8 87 12.3
Between £40,000 and
£49,999
24 6.8 22 6.2 20 5.7 26 7.2 46 6.5
≥ £50,000 22 6.3 29 8.1 31 8.9 20 5.6 51 7.2
Prefer not to answer 33 9.4 45 12.6 33 9.5 45 12.5 78 11.0
Missing 0 0.0 4 1.1 3 0.9 1 0.3 4 0.6
State benefits
Yes 73 20.7 71 19.9 67 19.3 77 21.4 114 20.3
No 275 78.1 279 78.4 276 79.3 278 77.2 554 78.2
Prefer not to say 4 1.1 3 0.8 3 0.9 4 1.1 7 10
Missing 0 0.0 3 0.8 2 0.6 1 0.3 3 0.4
Benefits received
Attendance Allowance 3 0.9 0 0.0 1 0.3 2 0.6 3 0.4
Carer’s Allowance 8 2.3 4 1.1 8 2.3 4 1.1 12 1.7
Child Benefit 30 8.5 28 7.9 30 8.6 28 7.8 58 8.2
Child Tax Credit 17 4.8 11 3.1 16 4.6 12 3.3 28 4.0
Council Tax Benefit 12 3.4 6 1.7 11 3.2 7 1.9 18 2.5
Disability Living
Allowance
11 3.1 10 2.8 8 2.3 13 3.6 21 3.0
Employment and Support
Allowance
6 1.7 10 2.8 4 1.1 12 3.3 16 2.3
Income Support 4 1.1 5 1.4 5 1.4 4 1.1 9 1.3
Housing Benefit 8 2.3 7 2.0 8 2.3 7 1.9 15 2.1
Jobseeker’s Allowance 3 0.9 1 0.3 2 0.6 2 0.6 4 0.6
Working Tax Credit 11 3.1 10 2.8 9 2.6 12 3.3 21 3.0
Other 19 5.4 17 4.8 18 5.2 18 5.0 36 5.1
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(N= 356) No (N= 348) Yes (N= 360)
Height (m), mean (SD), n 1.7 (0.0), 352 1.7 (0.0), 354 1.7 (0.0), 346 1.7 (0.2), 360 1.7 (0.0), 706
Weight (kg), mean (SD), n 81.9 (17.0), 350 81.5 (18.2), 350 81.1 (17.6), 344 82.3 (17.6), 356 81.7 (17.6), 700
Body mass index (kg/m2),
mean (SD), n
28.3 (5.2), 350 28.0 (5.2), 350 27.9 (5.2), 344 28.4 (5.2), 356 28.2 (5.2), 700








15.0 (7–20), 132 10.0 (5–20), 123 12.0 (5–20), 126 10.0 (8–20), 129 12.0 (6–20), 255
Symptoms duration,
median (IQR), n
4.0 (2–6), 351 4.0 (3–6), 354 4.0 (3–6), 345 4.0 (3–6), 360 4.0 (3–6), 705
SPADI, mean (SD), n
Pain subscale 65.1 (18.0), 352 62.7 (17.4), 354 63.3 (17.6), 346 64.4 (17.9), 360 63.9 (17.7), 706
Function subscale 47.2 (22.6), 352 41.5 (21.3), 354 44.2 (22.4), 346 44.5 (21.9), 360 44.3 (22.1), 706
SPADI overall 56.1 (19.0), 352 52.1 (17.7), 354 53.8 (18.6), 346 54.4 (18.4), 360 54.1 (18.5), 706
FABQ-PA, mean (SD), n 15.6 (5.6), 349 14.5 (5.4), 354 14.9 (5.7), 344 15.2 (5.3), 359 15.1 (5.5), 703
PSEQ-2, mean (SD), n 9.6 (2.4), 352 9.8 (2.3), 354 9.7 (2.3), 346 9.6 (2.3), 360 9.7 (2.3), 706
ISI, mean (SD), n 10.7 (6.4), 349 10.3 (6.1), 350 10.2 (6.3), 343 10.7 (6.3), 356 10.5 (6.3), 699
RDA, mean (SD), n
Overall 8.1 (2.6), 352 7.7 (2.6), 354 7.8 (2.7), 346 7.9 (2.5), 360 7.9 (2.6), 706
Recreational 3.0 (1.0), 352 2.8 (1.0), 354 2.9 (1.0), 346 2.9 (1.0), 360 2.9 (1.0), 706
Social life 2.5 (1.1), 352 2.3 (1.1), 354 2.3 (1.1), 346 2.5 (1.1), 360 2.4 (1.1), 706
Work 2.6 (1.0), 352 2.5 (1.0), 354 2.6 (1.0), 346 2.6 (1.0), 360 2.6 (1.0), 706
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TABLE 34 Stratification factors (at the margins)
Factor
Progressive exercise Injection
OverallBest-practice advice Progressive exercise No Yes
n % n % n % n % n %
Sex
Male 176 50.0 183 51.4 177 50.9 182 50.6 359 50.7
Female 176 50.0 173 48.6 171 49.1 178 49.4 349 49.3
Age group (years)
18–35 24 6.8 31 8.7 25 7.2 30 8.3 55 7.8
≥ 36 328 93.2 325 91.3 323 92.8 330 91.7 653 92.2
Trial centre
1 21 6.0 25 7.0 24 6.9 22 6.1 46 6.5
2 52 14.8 50 14.0 51 14.7 51 14.2 102 14.4
3 59 16.8 61 17.1 60 17.2 60 16.7 120 16.9
4 15 4.3 14 3.9 15 4.3 14 3.9 29 4.1
5 17 4.8 18 5.1 17 4.9 18 5.0 35 4.9
6 6 1.7 8 2.2 7 2.0 7 1.9 14 2.0
7 7 2.0 7 2.0 6 1.7 8 2.2 14 2.0
8 11 3.1 12 3.4 12 3.4 11 3.1 23 3.2
9 7 2.0 6 1.7 8 2.3 5 1.4 13 1.8
10 14 4.0 17 4.8 15 4.3 16 4.4 31 4.4
11 2 0.6 2 0.6 2 0.6 2 0.6 4 0.6
12 24 6.8 25 7.0 25 7.2 24 6.7 49 6.9
13 16 4.5 17 4.8 15 4.3 18 5.0 33 4.7
14 16 4.5 13 3.7 13 3.7 16 4.4 29 4.1
15 18 5.1 18 5.1 17 4.9 19 5.3 36 5.1
16 19 5.4 17 4.8 17 4.9 19 5.3 36 5.1
17 13 3.7 12 3.4 12 3.4 13 3.6 25 3.5
18 20 5.7 20 5.6 18 5.2 22 6.1 40 5.6
19 5 1.4 6 1.7 5 1.4 6 1.7 11 1.6
20 10 2.8 8 2.2 9 2.6 9 2.5 18 2.5
TABLE 35 Response rates
Response rate 8 weeks (N= 708), n (%) 6 months (N= 708), n (%) 12 months (N= 708), n (%)
Questionnaires posted 706 (99) 698 (99) 694 (98)
Overall response 642 (91) 615 (87) 618 (87)
Postal response 563 (80) 524 (74) 516 (73)
Telephone response 79 (11) 82 (12) 88 (12)
Electronic response – 9 (1) 14 (2)
Non-responder (missing data) 67 (9) 93 (13) 90 (13)
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Randomisation to injection attendance (days) 6 (0–9) 7 (0–10)
Randomisation to first exercise session
attended (days)
21 (15–28) 15 (12–21) 22 (17–28) 16 (10–21)
Randomisation to last exercise session (days) 103 (68–135) 92 (64–121)
First to last exercise session attended (days) 78 (41–105) 77 (49–106)
TABLE 37 Exercises prescribed: progressive–exercise intervention
Level Exercise
Exercises prescribed, na





13 5 2 3 3 0 26 (1)
Shoulder abduction
supported by table
34 11 6 6 4 1 62 (2)
Shoulder flexion
supported by table in
standing
18 4 3 2 1 0 28 (1)
Shoulder abduction
supported by table in
standing
15 6 5 2 1 1 30 (1)
Shoulder flexion
(self-assisted): supine
18 14 5 3 1 0 41 (1)
Shoulder flexion
(self-assisted): up a wall
43 21 12 7 4 2 89 (3)
2: core Isometric shoulder
external rotation
70 38 28 13 3 4 156 (5)
Isometric shoulder
abduction
41 25 18 9 6 3 102 (3)
bResisted shoulder
external rotation; 0o
138 112 71 33 24 16 394 (12)
bResisted shoulder
abduction
74 92 72 51 36 17 342 (10)
Shoulder flexion up a wall 38 33 26 12 7 7 123 (4)
Shoulder raise using a
weight








19 34 28 28 25 18 152 (5)
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TABLE 37 Exercises prescribed: progressive–exercise intervention (continued )
Level Exercise
Exercises prescribed, na









32 37 43 28 15 12 167 (5)
2: optional Isometric shoulder
internal rotation
9 12 8 6 3 0 38 (1)
bResisted shoulder
internal rotation: 0o












0 3 11 6 7 4 31 (1)
Shoulder retraction:
prone
9 7 9 11 8 5 49 (1)
Shoulder flexion (elbow
bent): prone
0 7 2 5 1 3 18 (1)
Shoulder flexion
(elbow straight): prone
1 3 6 4 1 0 15 (0)
Shoulder flexion
(crawl position)
9 14 16 13 11 7 70 (2)
Press-ups (on knees) 14 17 17 17 15 7 87 (3)
Press-ups (normal) 3 7 7 6 7 1 31 (1)
Optional
stretches
Sleeper stretch 9 11 13 10 5 2 50 (1)
Horizontal adduction
stretch
5 4 6 4 3 1 23 (1)
3 Therapist-designed
exercise(s)
7 25 43 40 33 20 168 (5)
Unknown exercise 1 7 0 2 5 3 18 (1)
Total, n (%) 819 (25) 797 (24) 692 (21) 489 (15) 342 (10) 200 (6) 3339 (100)
a Number of times exercise prescribed. Participants generally received more than one exercise and participant may
have received same exercise more than once.
b With resistance band.
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exercise, n (%) Total, n (%)
Progresseda 118 (71) 109 (63) 227 (67)
Maintainedb 34 (20) 39 (23) 73 (22)
Regressedc 15 (9) 24 (14) 39 (12)
Total 167 (100) 172 (100) 339 (100)
a Progression defined as an increase in exercise difficulty level, or either volume and/or load across attended
exercise sessions.
b Maintained defined as no change in any of exercise difficulty level, or either volume and/or load across attended
exercise sessions. If volume increased and load decreased (or vice versa), the exercise was considered to have been
maintained (assuming exercise difficulty level remained the same).
c Regression defined as a decrease in exercise difficulty level, or either volume and/or load across attended
exercise sessions.
TABLE 39 Participant-reported exercise adherence
Adherence
Best-practice advice Progressive exercise No injection Injection Overall
n % n % n % n % n %
8 weeks
Every day 34 9.7 40 11.2 34 9.8 40 11.1 74 10.5
6 days per week 15 4.3 15 4.2 15 4.3 15 4.2 30 4.2
5 days per week 152 43.2 215 60.4 160 46.0 207 57.5 367 51.8
4 days per week 26 7.4 19 5.3 27 7.8 18 5.0 45 6.4
3 days per week 15 4.3 6 1.7 15 4.3 6 1.7 21 3.0
2 days per week 9 2.6 2 0.6 6 1.7 5 1.4 11 1.6
1 day per week 3 0.9 0 0.0 1 0.3 2 0.6 3 0.4
None 28 8.0 11 3.1 18 5.2 21 5.8 39 5.5
Missing 70 19.9 48 13.5 72 20.7 46 12.8 118 16.7
6 months
Every day 19 5.4 14 3.9 14 4.0 19 5.3 33 4.7
6 days per week 5 1.4 4 1.1 7 2.0 2 0.6 9 1.3
5 days per week 53 15.1 66 18.5 42 12.1 77 21.4 119 16.8
4 days per week 24 6.8 26 7.3 22 6.3 28 7.8 50 7.1
3 days per week 33 9.4 33 9.3 34 9.8 32 8.9 66 9.3
2 days per week 27 7.7 19 5.3 20 5.7 26 7.2 46 6.5
1 day per week 13 3.7 11 3.1 13 3.7 11 3.1 24 3.4
None 101 28.7 117 32.9 116 33.3 102 28.3 218 30.8
Missing 76 21.6 65 18.3 79 22.7 62 17.2 141 19.9
continued
DOI: 10.3310/hta25480 Health Technology Assessment 2021 Vol. 25 No. 48
Copyright © 2021 Hopewell et al. This work was produced by Hopewell et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
117
TABLE 39 Participant-reported exercise adherence (continued )
Adherence
Best-practice advice Progressive exercise No injection Injection Overall
n % n % n % n % n %
12 months
Every day 15 4.3 16 4.5 9 2.6 22 6.1 31 4.4
6 days per week 3 0.9 1 0.3 3 0.9 1 0.3 4 0.6
5 days per week 22 6.3 15 4.2 13 3.7 24 6.7 37 5.2
4 days per week 16 4.5 12 3.4 14 4.0 14 3.9 28 4.0
3 days per week 24 6.8 26 7.3 21 6.0 29 8.1 50 7.1
2 days per week 19 5.4 22 6.2 17 4.9 24 6.7 41 5.8
1 day per week 18 5.1 16 4.5 21 6.0 13 3.6 34 4.8
None 165 46.9 183 51.4 176 50.6 172 47.8 348 49.2
Missing 69 19.6 64 18.0 74 21.3 59 16.4 133 18.8
TABLE 40 Progressive exercise vs. best-practice advice and injection vs. best-practice advice: inside-the-table analysis of
SPADI overall
SPADI over 12 months
Progressive exercise (N= 174) vs.
best-practice advice (N= 174)
Injection plus best-practice advice
(N= 178) vs. best-practice advice
(N= 174)
Unadjusted mean (SD), na 27.36 (23.49), 166 32.21 (25.39), 164 28.55 (23.11), 175 32.21 (25.39), 164
Adjusted mean (SE), nb 28.79 (1.39), 154 30.55 (1.43), 146 28.32 (1.41), 151 30.55 (1.43), 146
Unadjusted difference (99% CI)a –4.64 (–10.20 to 0.91) –3.50 (–8.99 to 1.99)
Adjusted difference (99% CI),
p-valueb
–1.76 (–6.91 to 3.39), 0.380 –2.23 (–7.03 to 2.57), 0.230
a Unadjusted SPADI analysis using a mixed-effects model with random effects for observations within participant, with
time-by-treatment interaction. A total of 1870 participant data points contribute to the unadjusted model.
b SPADI-adjusted analysis using a mixed-effects model with fixed effects for age, sex and baseline SPADI, and random
effects for observations within participant, physiotherapist and centre, with time-by-treatment interaction. A total of
1869 participant data points contribute to the adjusted model.
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TABLE 41 Progressive exercise vs. best-practice advice and injection vs. best-practice advice: inside-the-table analysis of SPADI at each time point
SPADI at each
time point













8 weeks 41.22 (1.78), 156 41.09 (1.72), 149 –0.13 (–6.52 to 6.27) 0.959 32.89 (1.75), 163 37.97 (1.68), 149 –8.33 (–14.46 to –2.19) 0.000
6 months 26.99 (1.81), 151 25.71 (1.74), 143 –1.28 (–7.76 to 5.20) 0.611 27.75 (1.76), 158 26.02 (1.70), 143 0.76 (–5.45 to 6.97) 0.752
12 months 23.12 (1.81), 153 19.19 (1.74), 143 –3.93 (–10.40 to 2.55) 0.118 24.17 (1.76), 160 21.90 (1.71), 143 1.05 (–5.15 to 7.26) 0.663
a SPADI-adjusted analysis using a mixed-effects model with fixed effects for age, sex and baseline SPADI, and random effects for observations within participant, physiotherapist and


































































































































































































































































































TABLE 42 Secondary outcomes analysis: unadjusted mean and SD
Secondary outcome











Baseline 352 65.1 (18) 354 62.7 (17.4) 346 63.3 (17.6) 360 64.4 (17.9)
8 weeks 314 46.0 (24.5) 326 46.7 (24.5) 306 50.2 (23.4) 334 42.7 (24.9)
6 months 301 34.4 (26.4) 314 30.9 (25.7) 294 31.7 (25.6) 321 33.5 (26.5)
12 months 304 28.7 (27.1) 314 24.6 (25.5) 296 25.5 (25.9) 322 27.7 (26.8)
Over 12 months 339 36.6 (27.0) 343 34.2 (26.9) 339 35.9 (27.1) 343 34.7 (26.8)
SPADI function
Baseline 352 47.2 (22.6) 354 41.5 (21.3) 346 44.2 (22.4) 360 44.5 (21.9)
8 weeks 313 31.3 (23.6) 326 30.8 (23.5) 307 33.3 (23.5) 332 29.0 (23.3)
6 months 301 22.0 (22.6) 314 19.9 (22.1) 294 20.7 (22.6) 321 21.2 (22.2)
12 months 303 19.4 (22.6) 314 15.1 (21) 296 16.3 (21.8) 321 18.0 (22.1)
Over 12 months 339 24.3 (23.5) 343 22.0 (23.2) 339 23.6 (23.7) 343 22.8 (23.0)
FABQ-PA
Baseline 349 15.6 (5.6) 354 14.5 (5.4) 344 14.9 (5.7) 359 15.2 (5.3)
8 weeks 279 11.9 (6.4) 307 11.9 (6.0) 276 12.0 (6.3) 310 11.8 (6.1)
6 months 276 9.9 (6.5) 287 9.4 (6.4) 265 9.4 (6.6) 298 9.8 (6.3)
12 months 280 9.5 (6.6) 291 8.1 (6.8) 271 8.5 (6.9) 300 9.1 (6.5)
Over 12 months 324 10.4 (6.6) 332 9.8 (6.6) 316 10.0 (6.8) 340 10.2 (6.4)
PSEQ-2
Baseline 352 9.6 (2.4) 354 9.8 (2.3) 346 9.7 (2.3) 360 9.6 (2.3)
8 weeks 280 10.2 (2.4) 306 10.3 (2.2) 276 10.2 (2.3) 310 10.3 (2.3)
6 months 276 10.5 (2.1) 288 10.4 (2.2) 266 10.5 (2.1) 298 10.4 (2.2)
12 months 280 10.7 (2.0) 291 10.8 (2.2) 271 10.9 (1.8) 300 10.6 (2.3)
Over 12 months 325 10.5 (2.2) 332 10.5 (2.2) 317 10.5 (2.1) 340 10.4 (2.3)
ISI
Baseline 349 10.7 (6.4) 350 10.3 (6.1) 343 10.2 (6.3) 356 10.7 (6.3)
8 weeks 277 7.5 (6.2) 303 8.0 (6.1) 274 8.7 (6.3) 306 7.0 (6.0)
6 months 275 6.1 (5.8) 290 6.2 (6.1) 267 6.1 (5.9) 298 6.2 (6.0)
12 months 281 5.8 (6.1) 292 5.2 (5.7) 272 5.4 (5.9) 301 5.6 (6.0)
Over 12 months 323 6.5 (6.1) 329 6.5 (6.1) 314 6.7 (6.2) 338 6.3 (6.0)
RDA
Baseline 352 8.1 (2.6) 354 7.7 (2.6) 346 7.8 (2.7) 360 7.9 (2.5)
8 weeks 278 6.2 (2.5) 303 6.2 (2.5) 274 6.5 (2.6) 307 5.9 (2.4)
6 months 276 5.4 (2.4) 290 5.0 (2.3) 268 5.1 (2.4) 298 5.2 (2.3)
12 months 281 4.8 (2.3) 292 4.6 (2.3) 273 4.6 (2.4) 300 4.8 (2.3)
Over 12 months 325 5.5 (2.5) 332 5.3 (2.5) 317 5.4 (2.6) 340 5.3 (2.4)
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TABLE 42 Secondary outcomes analysis: unadjusted mean and SD (continued )
Secondary outcome












8 weeks 277 7.6 (2.1) 304 7.8 (1.8) 274 7.3 (2.0) 307 8.1 (1.8)
6 months 276 8.2 (2.2) 291 8.7 (2.1) 269 8.5 (2.2) 298 8.5 (2.2)
12 months 283 8.6 (2.3) 293 9.1 (2.2) 274 8.9 (2.1) 302 8.8 (2.4)
Over 12 months 326 8.2 (2.2) 332 8.5 (2.1) 317 8.2 (2.2) 347 8.5 (2.1)
















SPADI at 8 weeks 297 vs. 316
 
   2.54 (–2.95 to 8.02)
   2.17 (–6.04 to 10.38)
 
   1.68 (–4.63 to 7.99)
   3.55 (–2.87 to 9.98)
 
   2.04 (–4.08 to 8.17)
   3.23 (–3.48 to 9.95)
 
–0.37 (–7.19 to 6.45)
   5.25 (–0.77 to 11.26)
 
   2.03 (–2.94 to 7.01)
   5.65 (–5.87 to 17.17)
   2.54 (–2.16 to 7.23)
–17.2 0










Former or current smoker
Baseline SPADI
Baseline SPADI lower disability (< 50)
Baseline SPADI higher disability (≥ 50)
Baseline PSEQ-2
Higher PSEQ-2 at baseline (≥ 8)
Lower PSEQ-2 at baseline (< 8)
FIGURE 25 Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 8 weeks.
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SPADI at 6 months 288 vs. 307
 
–0.67 (–6.26 to 4.91)
–3.73 (–11.89 to 4.43)
 
–0.15 (–6.48 to 6.18)
–3.17 (–9.73 to 3.38)
 
–1.81 (–7.93 to 4.32)
–1.25 (–8.13 to 5.63)
 
–3.54 (–10.40 to 3.32)
–0.11 (–6.21 to 5.99)
 
–2.15 (–7.17 to 2.87)
   1.91 (–9.83 to 13.64)
–1.52 (–6.26 to 3.22)
–13.6 0










Former or current smoker
Baseline SPADI
Baseline SPADI lower disability (< 50)
Baseline SPADI higher disability (≥ 50)
Baseline PSEQ-2
Higher PSEQ-2 at baseline (≥ 8)
Lower PSEQ-2 at baseline (< 8)
FIGURE 26 Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 6 months.
















SPADI at 12 months 288 vs. 307
 
–3.17 (–8.75 to 2.41)
–3.38 (–11.57 to 4.82)
 
–4.70 (–11.04 to 1.65)
–1.49 (–8.03 to 5.06)
 
–3.66 (–9.76 to 2.44)
–2.47 (–9.39 to 4.44)
 
–5.31 (–12.13 to 1.51)
–1.56 (–7.69 to 4.57)
 
–3.82 (–8.84 to 1.19)
   1.25 (–10.59 to 13.09)
–3.10 (–7.85 to 1.64)
–13.1 0










Former or current smoker
Baseline SPADI
Baseline SPADI lower disability (< 50)
Baseline SPADI higher disability (≥ 50)
Baseline PSEQ-2
Higher PSEQ-2 at baseline (≥ 8)
Lower PSEQ-2 at baseline (< 8)
FIGURE 27 Subgroup-adjusted SPADI analysis for progressive exercise vs. best-practice advice at 12 months.
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SPADI at 8 weeks 300 vs. 313
 
–7.14 (–12.23 to –2.05)
–1.81 (–9.77 to 6.16)
 
–4.41 (–10.43 to 1.61)
–7.03 (–13.14 to –0.92)
 
–5.50 (–11.28 to 0.29)
–5.73 (–12.16 to 0.70)
 
–0.36 (–6.87 to 6.16)
–9.67 (–15.37 to –3.97)
 
–5.42 (–10.05 to –0.79)
–7.32 (–18.64 to 4.01)
–5.64 (–9.93 to –1.35)
–18.6 0










Former or current smoker
Baseline SPADI
Baseline SPADI lower disability (< 50)
Baseline SPADI higher disability (≥ 50)
Baseline PSEQ-2
Higher PSEQ-2 at baseline (≥ 8)
Lower PSEQ-2 at baseline (< 8)
FIGURE 28 Subgroup-adjusted SPADI analysis for injection vs. no injection at 8 weeks.
















SPADI at 6 months 289 vs. 306
 
   1.62 (–3.57 to 6.81)
–1.50 (–9.42 to 6.41)
 
   3.29 (–2.75 to 9.32)
–2.40 (–8.65 to 3.85)
 
–0.20 (–5.99 to 5.59)
   1.47 (–5.13 to 8.07)
 
   3.73 (–2.84 to 10.30)
–1.99 (–7.78 to 3.80)
 
   0.93 (–3.75 to 5.61)
–2.25 (–13.79 to 9.28)
   0.52 (–3.82 to 4.86)
–13.8 0










Former or current smoker
Baseline SPADI
Baseline SPADI lower disability (< 50)
Baseline SPADI higher disability (≥ 50)
Baseline PSEQ-2
Higher PSEQ-2 at baseline (≥ 8)
Lower PSEQ-2 at baseline (< 8)
FIGURE 29 Subgroup-adjusted SPADI analysis for injection vs. no injection at 6 months.
DOI: 10.3310/hta25480 Health Technology Assessment 2021 Vol. 25 No. 48
Copyright © 2021 Hopewell et al. This work was produced by Hopewell et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
123









Former or current smoker
Baseline SPADI
Baseline SPADI lower disability (< 50)
Baseline SPADI higher disability (≥ 50)
Baseline PSEQ-2
Higher PSEQ-2 at baseline (≥ 8)
















SPADI at 12 months 296 vs. 321
 
   1.49 (–3.69 to 6.66)
   3.33 (–4.62 to 11.28)
 
   2.95 (–3.09 to 8.99)
   0.86 (–5.37 to 7.09)
 
–0.28 (–6.03 to 5.48)
   4.87 (–1.77 to 11.51)
 
   4.23 (–2.29 to 10.75)
   0.14 (–5.68 to 5.95)
 
   1.14 (–3.53 to 5.81)
   6.80 (–4.84 to 18.44)
   1.93 (–2.41 to 6.27)
–18.4 0
Favours injection Favours no injection
18.4
FIGURE 30 Subgroup-adjusted SPADI analysis for injection vs. no injection at 12 months.
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Appendix 5 Chapter 5 appendix
TABLE 43 Summary of prescribed medication unit cost (in 2019 £)
Medication Unit type Unit cost (£) Source
Analgesics
Amitriptyline (10 mg) Pack of 28 1.01 NHS Electronic Drug Tariff127
Co-codamol (30 mg/500 mg) Pack of 100 4.60 NHS Electronic Drug Tariff127
Solpadol (30 mg) Pack of 100 5.28 NHS Electronic Drug Tariff127
Codeine (60 mg) Pack of 28 1.89 NHS Electronic Drug Tariff127
Co-dydramol (10 mg) Pack of 30 0.93 NHS Electronic Drug Tariff127
Tramadol (50 mg) Pack of 30 0.85 NHS Electronic Drug Tariff127
Paracetamol (500 mg) Pack of 100 2.28 NHS Electronic Drug Tariff127
Morphine sulphate (Sevredol®, Napp
Pharmaceuticals Limited, Cambridge, UK)
(10mg)
Pack of 56 5.31 NHS Electronic Drug Tariff127
Celecoxib (100 mg) Pack of 60 2.30 NHS Electronic Drug Tariff127
Gabapentin (600 mg) Pack of 100 12.00 NHS Electronic Drug Tariff127
NSAIDs
Ibuprofen (200 mg) Pack of 16 2.67 NHS Electronic Drug Tariff127
Ibuprofen gel Each 2.10 NHS Electronic Drug Tariff127
Meloxicam (15 mg) Pack of 30 1.77 NHS Electronic Drug Tariff127
Naproxen (500 mg) Pack of 56 4.14 NHS Electronic Drug Tariff127
Diclofenac (25 mg) Pack of 28 3.86 NHS Electronic Drug Tariff127
Other medication usage
Phorpain Each 2.72 NHS Electronic Drug Tariff127
Temazepam (20 mg) Pack of 28 1.60 NHS Electronic Drug Tariff127
Vitamin D Pack of 30 4.93 NHS Electronic Drug Tariff127
Voltarol emulgel Each 2.04 NHS Electronic Drug Tariff127
Zapain (30 mg) Pack of 100 4.77 NHS Electronic Drug Tariff127
Diazepan (2 mg) Pack of 28 0.76 NHS Electronic Drug Tariff127
Movelat gel Each 8.49 NHS Electronic Drug Tariff127
Adcal (750 mg) Pack of 112 2.95 NHS Electronic Drug Tariff127
Alendronic (10 mg) Pack of 28 2.63 NHS Electronic Drug Tariff127
Prednisolone (1 mg) Pack of 28 0.85 NHS Electronic Drug Tariff127
Feldene gel (60 g) Each 6.00 NHS Electronic Drug Tariff127
Sertraline (100 mg) Pack of 28 3.82 NHS Electronic Drug Tariff127
continued
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TABLE 43 Summary of prescribed medication unit cost (in 2019 £) (continued )
Medication Unit type Unit cost (£) Source
Docycycline (50 mg) Pack of eight 2.25 NHS Electronic Drug Tariff127
Butrans patch (5 µg) Pack of four 17.60 NHS Electronic Drug Tariff127
Corticosteroid injections
Kenalog (40 mg) Each 7.45 NHS Electronic Drug Tariff127
Depomedrone (40 mg) Each 7.13 NHS Electronic Drug Tariff127
Local anaesthetic
Lidocaine (50 mg/5 ml) (1%) Pack of 20 6.50 NHS Electronic Drug Tariff127
Bupivacaine hydrochloride (50mg/10ml) (0.5%) Pack of 10 7.56 NHS Electronic Drug Tariff127
NSAID, non-steroidal anti-inflammatory drug.
Notes
Source of unit cost data: NHS Electronic Drug Tariff.127 Costs for smallest appropriate pack size, non-proprietary (unless
brand is stated). Individual recorded doses were used where possible, otherwise average daily doses were assumed.
TABLE 44 Unit costs of health and social care items and additional financial cost due to rotator cuff disorder
Resource item Unit Unit cost (£)a Source
Inpatient stay (because of shoulder)
Surgery to repair rotator cuff tear Episode 3711.07 NHS Reference Costs 2017:92
elective HRG HN53A,
HN53B, HN53C
Frozen shoulder surgery Episode 3064.07 NHS Reference Costs 2017:92
elective HRG HN54A,
HN54B, HN54C




Orthopaedic clinic (shoulder) Visit 120.00 NHS Reference Costs 2019:128
110
Physiotherapy Visit 38.88 PSSRU 2019:89 p. 68
Radiology (X-rays) Test 31.00 NHS Reference Costs 2017:92
DAPF
Radiology (ultrasound) Test 39.00 NHS Reference Costs 2019:128
RD40Z
Radiology (MRI) Test 108.00 NHS Reference Costs 2019:128
RD01A
Emergency department Visit 106.00 NHS Reference Costs 2019:128
VB09Z
Community care (NHS)
GP (surgery) 9.22-minute visit 39.23 PSSRU 2019:89 p. 120
GP (home) Per minute 5.32 PSSRU 2010:129 p. 167
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Model 1: regression analysis model with interaction term (base-case analysis)
For the 2 × 2 GRASP factorial trial, the regression model predicting costs with an interaction term took
the form:
yi = β0 + βAAi + βBBi + βABAiBi + εi, (2)
where yi represents the outcome measure (cost or QALY), βA represents the coefficient for treatment
effects for exercise, βB represents the coefficient for treatment effects for the corticosteroid injection,
βAB represents the interaction coefficient between exercise and corticosteroid injection and βo represents
the constant term.
Note that the QALY equation included baseline utility.
TABLE 44 Unit costs of health and social care items and additional financial cost due to rotator cuff disorder (continued )
Resource item Unit Unit cost (£)a Source
GP (telephone contact) 7.1 minutes 27.62 PSSRU 2015:130 p. 177
Practice nurse Hour visit 42.00 PSSRU 2019:89 p. 118
111 advice Per call 14.32 Financial Times 2017131
Physiotherapist Session 36.83 PSSRU 2019:89 p. 82
Community care (private)
Orthopaedic clinic (shoulder) Visit 200.00 Orthopaedic Clinics UK132
Physiotherapy Visit 75.00 The Physiotherapy Centre133
Radiology (X-rays) Test 90.00 Orthopaedic Clinics UK132
Radiology (ultrasound) Test 358.00 Private Healthcare UK134
Radiology (MRI) Test 285.00 Orthopaedic Clinics UK132
Chiropractor Visit 35.00 Orthopaedic Clinics UK132
Complementary therapist
(e.g. reflexology, acupuncture)
Visit 65.00 Orthopaedic Clinics UK132
Sports massage therapist Visit 60.00 Orthopaedic Clinics UK132
Direct non-medical cost
Help with housework Trial
Help with childcare Trial
Travel Trial
Lost productivity
Median wage Per week 585.00 Office for National
Statistics135
HRG, Healthcare Resource Group; MRI, magnetic resonance imaging; PSSRU, Personal Social Service Research Unit.
a Unit cost has been inflated to 2018/19 prices.
Note
If more than one code applies, costs are estimated weighted by activity as depicted in annex A (Department of Health
and Social Care).136
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Model 2: regression analysis without interaction term (sensitivity analysis)
This analysis was used as a sensitivity analysis. This analysis was carried out by analysing the same
set of bootstraps, omitting the interaction between injection and progressive exercise, and results were
combined across bootstraps and imputations using the same methods as the base-case analysis. This
approach assumes that interventions are mutually exclusive. In other words, the cost and outcomes of
the individually tailored progressive-exercise programme are assumed to not be affected by whether or
not corticosteroid injection is given (and vice versa). In addition, regression analysis without interaction
term, although similar to the at-the-margins approach, makes the prediction of group means and SEs
easier. As interventions are assumed to be mutually exclusive options, these predictions can help us
identify which of the four treatment options (progressive exercise, best-practice advice, corticosteroid
injection plus progressive exercise or corticosteroid injection plus best-practice advice) maximises NMB
and also estimates the cost and effects of each option separately.
For the 2 × 2 GRASP factorial trial, the regression model for this sensitivity analysis took the form:
yi = βo + βAAi + βBBi + εi, (3)
where yi represents the outcome measure (cost, QALY or NMB), βA represents the coefficient for
treatment effects for exercise, βB represents the coefficient for treatment effects for the corticosteroid
injection and βo represents the constant term.
Note that the QALY equation included baseline utility.
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TABLE 45 Mean health resource utilisation: baseline to 8 weeks (available-case analysis, excluding patients with missing data on that resource)
Type of care
Best-practice advice (N= 150)
Injection plus best-practice





rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD)
Primary care (NHS community-
based services)
129 150 146 162
GP visit 127 98.45 0.15 (0.47) 149 99.33 0.06 (0.29) 138 94.52 0.13 (0.42) 157 96.91 0.04 (0.19)
GP telephone contact 117 90.7 0.04 (0.24) 143 95.33 0.01 (0.08) 125 85.62 0.02 (0.18) 154 95.06 0.05 (0.50)
GP home visit 113 87.6 0 142 94.67 0 124 84.93 0 152 93.83 0
Practice nurse 114 88.37 0.02 (0.19) 142 94.67 0 125 85.62 0.04 (0.45) 154 95.06 0.01 (0.11)
Physiotherapy (not as part
of the GRASP trial)
114 88.37 0.05 (0.56) 143 95.33 0.001 (0.08) 132 90.41 0.121 (0.51) 154 95.06 0.02 (0.14)
Other NHS community
services
114 88.37 0 143 95.33 0 126 86.3 0.03 (0.28) 152 93.83 0.01 (0.08)
Secondary care (NHS
outpatient services)
129 150 146 163
Orthopaedic clinic
(for shoulder)
124 96.12 0.01 (0.09) 145 96.67 0.01 (0.16) 136 93.15 0 160 98.16 0
Physiotherapy department
(not as part of the
GRASP trial)
123 95.35 0 145 96.67 0.03 (0.42) 138 94.52 0.03 (0.27) 161 98.77 0.02 (0.32)
Radiology: X-ray 125 99.21 0.02 (0.13) 147 98.66 0.02 (0.14) 144 100 0.08 (0.34) 160 98.77 0
Radiology: ultrasound 124 98.41 0.01 (0.09) 147 98.66 0.02 (0.14) 136 94.44 0 162 100 0.01 (0.11)
Radiology: MRI 123 97.62 0 144 96.64 0 136 94.44 0 160 98.77 0
Accident and emergency 125 96.9 0.02 (0.13) 147 98 0.02 (0.14) 136 100 0 160 98.16 0
Other outpatient services 123 95.35 0 146 97.33 0.01 (0.12) 136 100 0 160 98.16 0
Secondary care (NHS inpatient
services)
129 150 145 162



































































































































































































































































































TABLE 45 Mean health resource utilisation: baseline to 8 weeks (available-case analysis, excluding patients with missing data on that resource) (continued )
Type of care
Best-practice advice (N= 150)
Injection plus best-practice





rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD)
Private care 129 151 146 162
Orthopaedic clinic
(for shoulder)
127 98.45 0 150 100 0 144 98.63 0.01 (0.08) 162 100 0
Physiotherapy department 128 73.56 0.03 (0.35) 150 100 0 143 97.95 0 162 100 0
Radiology: X-ray 127 100 0 150 99.34 0 143 100 0 162 100 0
Radiology: ultrasound 127 100 0 151 100 0 143 100 0 162 100 0
Radiology: MRI 127 100 0 150 99.34 0 143 100 0 162 100 0
Chiropractor 127 98.45 0 150 99.34 0 144 98.63 0.01 (0.08) 162 100 0
Complementary therapist 128 99.22 0.05 (0.53) 150 99.34 0 144 98.63 0.01 (0.17) 162 100 0
Injection utilisation 130 151 147 163
Injections 130 0.02 (0.18) 151 147 0.02 (0.14) 163 0.06 (0.24)
Non-medical expenses 129 150 146 162
MRI, magnetic resonance imaging.
a Relates to the number of participants for whom follow-up data were available.
b Completion rate of the corresponding question related to usage or not of resource utilisation.
































TABLE 46 Mean health resource utilisation: 8 weeks to 6 months (available-case analysis, excluding patients with missing data on that resource)
Type of care
Best-practice advice (N= 144)
Injection plus best-practice





rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD)
Primary care (NHS community-
based services)
127 147 140 150
GP visit 123 96.85 0.15 (0.59) 142 96.6 0.09 (0.36) 135 96.43 0.16 (0.56) 149 99.33 0.14 (0.45)
GP telephone contact 117 92.13 0.08 (0.44) 133 90.48 0.01 (0.09) 123 87.86 0.02 (0.18) 135 90 0.01 (0.09)
GP home visit 112 88.19 0 133 90.48 0 122 87.14 0 134 89.33 0
Practice nurse 113 88.98 0.01 (0.09) 132 89.8 0 122 87.14 0 134 89.33 0
Physiotherapy (not as part
of the GRASP trial)
117 92.13 0.19 (1.13) 138 93.88 0.09 (0.57) 126 90 0.08 (0.52) 136 90.67 0.02 (0.19)
Other NHS community services 113 88.98 0.02 (0.02) 132 89.8 0 123 87.86 0.03 (0.36) 136 90.67 0.01 (0.12)
Secondary care (NHS
outpatient services)
127 146 140 150
Orthopaedic clinic
(for shoulder)
123 96.85 0.03 (0.22) 141 96.58 0.03 (0.17) 135 96.43 0.03 (0.21) 148 98.67 0
Physiotherapy department
(not as part of the
GRASP trial)
122 96.06 0.02 (0.13) 138 94.52 0.04 (0.43) 135 96.43 0.07 (0.49) 150 100 0.03 (0.28)
Radiology: X-ray 121 95.28 0.01 (0.11) 137 93.84 0.02 (0.13) 132 94.29 0.01 (0.11) 148 98.67 0
Radiology: ultrasound 121 95.28 0 137 93.84 0 132 94.29 0 148 98.67 0
Radiology: MRI 121 95.28 0 137 93.84 0 132 94.29 0 148 98.67 0
Accident and emergency 121 95.28 0.01 (0.09) 137 93.84 0 132 94.29 0 148 98.67 0
Other outpatient services 121 95.28 0.01 (0.09) 137 93.84 0 132 94.29 0 148 98.67 0
Secondary care (NHS inpatient
services)
127 147 140 150



































































































































































































































































































TABLE 46 Mean health resource utilisation: 8 weeks to 6 months (available-case analysis, excluding patients with missing data on that resource) (continued )
Type of care
Best-practice advice (N= 144)
Injection plus best-practice





rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD)
Private care 128 147 140 150
Orthopaedic clinic
(for shoulder)
121 94.53 0.02 (0.18) 141 95.92 0 132 94.29 0 147 98 0.01 (0.08)
Physiotherapy department 124 96.88 0.08 (0.45) 143 97.28 0.12 (1.26) 134 95.71 0.01 (0.12) 150 100 0.07 (0.53)
Radiology: X-ray 120 93.75 0 141 95.92 0 132 94.29 0 147 98 0
Radiology: ultrasound 120 93.75 0 141 95.92 0 132 94.29 0 146 97.33 0
Radiology: MRI 120 93.75 0 141 95.92 0 132 94.29 0 146 97.33 0
Chiropractor 122 95.31 0.03 (0.29) 142 96.6 0.04 (0.50) 135 96.43 0.15 (1.19) 147 98 0.01 (0.08)
Complementary therapist 122 95.31 0.05 (0.4) 142 96.6 0.01 (0.17) 133 95 0.02 (0.26) 146 97.33 0
Injection utilisation 130 147 140 149
Injections 130 100 0.07 (0.25) 147 100 0.04 (0.19) 140 100 0.08 (0.32) 149 100 0.06 (0.30)
Non-medical expenses 129 147 140 150
MRI, magnetic resonance imaging.
a Relates to the number of participants for whom follow-up data were available.
b Completion rate of the corresponding question related to usage or not of resource utilisation.
































TABLE 47 Mean health resource utilisation: 6–12 months (available-case analysis, excluding patients with missing data on that resource)
Type of care
Best-practice advice (N= 143)
Injection plus best-practice





rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD)
Primary care (NHS community-
based services)
133 150 140 152
GP visit 129 96.99 0.19 (0.69) 145 96.67 0.21 (0.63) 138 98.57 0.21 (0.84) 147 96.71 0.26 (0.83)
GP telephone contact 118 88.72 0.03 (0.21) 130 86.67 0.02 (0.19) 126 90 0 133 87.5 0.13 (0.92)
GP home visit 116 87.22 0 128 85.33 0 126 90 0 129 84.87 0.01 (0.09)
Practice nurse 116 87.22 0 128 85.33 0 126 90 0 128 84.21 0
Physiotherapy (not as part
of the GRASP trial)
120 90.23 0.1 (0.67) 133 88.67 0.11 (0.71) 130 92.86 0.09 (0.60) 135 88.82 0.16 (0.81)
Other NHS community
services
118 88.72 0.03 (0.21) 131 87.33 0.02 (0.15) 129 92.14 0.02 (0.15) 129 84.87 0.01 (0.09)
Secondary care (NHS
outpatient services)
133 150 141 152
Orthopaedic clinic
(for shoulder)
128 96.24 0.08 (0.45) 140 93.33 0.07 (0.39) 135 95.74 0.04 (0.32) 147 96.71 0.12 (0.47)
Physiotherapy department
(not as part of the
GRASP trial)
126 94.74 0.06 (0.49) 142 94.67 0.13 (0.70) 133 94.33 0.02 (0.17) 140 92.11 0.04 (0.31)
Radiology: X-ray 126 94.74 0.01 (0.11) 142 94.67 0.02 (0.17) 133 94.33 0.02 (0.19) 140 92.11 0.01 (0.11)
Radiology: ultrasound 126 94.74 0.01 (0.07) 142 94.67 0 133 94.33 0 140 92.11 0.01 (0.07)
Radiology: MRI 126 94.74 0.01 (0.07) 142 94.67 0.01 (0.08) 133 94.33 0.01 (0.08) 140 92.11 0.02 (0.13)
Accident and emergency 124 93.23 0.01 (0.08) 137 91.33 0.01 (0.12) 132 93.62 0 137 90.13 0



































































































































































































































































































TABLE 47 Mean health resource utilisation: 6–12 months (available-case analysis, excluding patients with missing data on that resource) (continued )
Type of care
Best-practice advice (N= 143)
Injection plus best-practice





rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD) na
Completion
rateb (%) Meanc (SD)
Secondary care (NHS inpatient
services)
132 150 140 152
Inpatient care 133 150 141 152
Private care 126 94.74 0.02 (0.18) 147 98 0 134 95.04 0.01 (0.17) 145 95.39 0.02 (0.19)
Orthopaedic clinic
(for shoulder)
127 95.49 0.05 (0.37) 148 98.67 0.01 (0.08) 136 96.45 0.05 (0.37) 148 97.37 0.11 (0.66)
Physiotherapy department 126 94.74 0 147 98 0 135 95.74 0 148 97.37 0.01 (0.07)
Radiology: X-ray 126 94.74 0 147 98 0 135 95.74 0 148 97.37 0
Radiology: ultrasound 126 94.74 0 147 98 0 135 95.74 0 148 97.37 0.01 (0.07)
Radiology: MRI 126 94.74 0.01 (0.09) 147 98 0 135 95.74 0.05 (0.42) 145 95.39 0.03 (0.26)
Chiropractor 126 94.74 0.07 (0.80) 148 98.67 0.10 (1.23) 134 95.04 0.02 (0.27) 143 94.08 0
Complementary therapist 133 150 141 150
Injection utilisation 133 0.11 (0.35) 150 0.07 (0.29) 141 0.09 (0.35) 150 0.1 (0.36)
Injections 133 150 141 152
Non-medical expenses 133 150 140 152
MRI, magnetic resonance imaging.
a Relates to the number of participants for whom follow-up data were available.
b Completion rate of the corresponding question related to usage or not of resource utilisation.






















































Primary care (NHS community-based services)
GP visit 5.86 18.54 2.36 11.38 5.11 7.54 3.57 13.87
GP telephone contact 1.18 6.68 0.19 2.31 0.44 4.94 1.43 13.69
Practice nurse 0.74 7.87 0.00 0.00 1.68 18.78 0.55 4.77
Physiotherapy (not as part
of the GRASP trial)
1.93 20.69 0.26 3.08 4.46 18.78 0.72 5.11
Secondary care (NHS outpatient services)
Orthopaedic clinic (for shoulder) 0.97 10.78 1.66 19.93 0.00 0.00 0.00 0.00
Physiotherapy department
(not as part of the
GRASP trial)
0.00 0.00 1.33 16.11 1.12 10.42 0.96 12.23
Radiology: X-ray 0.49 3.91 0.63 4.39 2.36 10.42 0.00 0.00
Radiology: ultrasound 0.31 3.50 0.79 5.53 0.00 0.00 0.48 4.32
Accident and emergency 1.69 13.35 2.16 15.03 0.00 0.00 0.00 0.00
Total 9.31 35.65 7.75 39.2 11.82 35.95 4.85 23.37






















Primary care (NHS community-based services)
GP visit 6.05 23.03 3.59 13.94 6.39 22.07 5.52 17.67
GP telephone contact 2.12 12.11 0.21 2.39 0.45 4.98 0.20 2.38
Practice nurse 0.37 3.95 0.00 0.00 0.00 0.00 0.00 0.00
Physiotherapy (not as part of
the GRASP trial)
6.92 41.01 3.46 21.28 2.92 18.98 0.81 7.04
Secondary care (NHS outpatient services)
Orthopaedic clinic (for shoulder) 3.9 26.32 3.4 19.99 3.55 25.14 0.00 0.00
Physiotherapy department
(not as part of the GRASP trial)
0.64 4.95 1.41 16.52 2.59 19.08 1.03 9.99
Radiology: X-ray 0.36 3.31 0.52 4.00 0.36 3.31 0.00 0.00
Accident and emergency 0.88 9.64 0.00 0.00 0.00 0.00 0.00 0.00
Secondary care (NHS inpatient services)
Inpatient care 0.00 0.00 24.64 298.82 0.00 0.00 0.00 0.00
Total 14.78 59.69 30.37 293.54 12.51 44.02 6.13 20.59
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Primary care (NHS community-based services)
GP visit 7.60 27.33 8.11 24.85 8.24 32.99 10.40 32.57
GP telephone contact 0.70 5.67 0.64 5.39 0.00 0.00 3.53 25.31
GP home visit 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.49
Physiotherapy (not as part of
the GRASP trial)
3.68 24.53 4.15 25.91 3.40 22.21 6.00 29.92
Secondary care (NHS outpatient services)
Orthopaedic clinic (for shoulder) 9.37 53.47 8.57 46.95 5.33 38.41 13.87 57.08
Physiotherapy department
(not as part of the
GRASP trial)
2.46 18.84 4.91 27.28 0.58 6.73 1.66 12.20
Radiology: X-ray 0.36 3.33 0.53 5.21 0.72 5.75 0.35 3.27
Radiology: ultrasound 0.23 2.98 0.00 0.00 0.00 0.00 0.22 2.92
Radiology: MRI 0.63 8.26 0.62 8.16 0.63 8.25 1.80 13.86
Accident and emergency 0.85 9.52 1.55 12.76 0.00 0.00 0.00 0.00
Secondary care (NHS inpatient services)
Inpatient care 22.83 261.35 0.00 0.00 0.00 0.00 23.99 294.84
Total 36.33 293.35 23.16 84.3 14.99 56.62 50.19 309.46
MRI, magnetic resonance imaging.


















Baseline to 8 weeks 150 6.64 (57.73) 165 0.74 (3.32) 157 0.71 (2.70) 169 5.11 (54.02)
8 weeks to 6 months 144 1.94 (8.09) 158 1.74 (6.93) 151 0.75 (3.17) 162 3.28 (11.69)
6–12 months 143 1.65 (5.62) 161 2.57 (11.27) 153 1.17 (6.55) 161 7.87 (34.81)
a Relates to the number of participants for whom follow-up data were available.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
136
TABLE 52 Utilisation of steroid injections outside the GRASP trial
Time point
Best-practice advice Injection plus best-practice advice Progressive exercise Injection plus progressive exercise
n (%)
Privately
paid, % Mean (SD) n (%)
Privately
paid, % Mean (SD) n (%)
Privately
paid, % Mean (SD) n (%)
Privately
paid, % Mean (SD)
Baseline to
8 weeks
1 (0.77) 0 0.81 (9.17) 7 (4.63) 0 2.78 (13.22) 3 (2.04) 33.33 1.07 (7.42) 10 (6.13) 0 3.21 (12.59)
8 weeks to
6 months
9 (6.92) 0.77 3.62 (13.33) 6 (4.08) 0 2.14 (10.38) 9 (6.43) 0.71 4.11 (16.68) 6 (4.03) 0.67 2.81 (15.84)







































































































































































































































































































best-practice advice Progressive exercise
Injection plus
progressive exercise
na Mean (SE) na Mean (SE) na Mean (SE) na Mean (SE)
Baseline 174 74.68 (1.42) 178 77.34 (1.16) 172 77.25 (1.17) 181 75.55 (1.31)
8 weeks 132 77.04 (1.24) 151 79.95 (1.11) 147 78.89 (1.17) 165 76.78 (1.38)
6 months 134 78.49 (1.44) 151 80.68 (1.20) 143 81.36 (1.29) 154 78.33 (1.50)




107 4.65 (18.27) 133 1.22 (12.53) 123 1.70 (11.47) 139 1.26 (15.53)
QALYs 107 0.73 (0.17) 132 0.75 (0.12) 124 0.76 (0.12) 137 0.72 (0.18)
a Relates to the number of participants for whom follow-up data were available.
TABLE 54 Regression analysis without interaction term, including imputation of missing values and adjustment for
baseline utility, sex and age
Total costs (£), mean (SE) QALYs, mean (SE) NMB (£),a mean (SE)
Injection 256 (17) 0.749 (0.009) 14,729 (185)
No injection 221 (35) 0.747 (0.010) 14,715 (221)
Injection main effect 35 (31) (p = 0.239) 0.003 (0.011) (p = 0.818) 15 (233) (p = 0.947)
Progressive exercise 277 (18) 0.748 (0.010) 14,685 (201)
No progressive exercise 199 (34) 0.748 (0.010) 14,758 (201)
Progressive exercise main effect 78 (30) (p = 0.012) 0.00 (0.011) (p = 0.984) –73 (231) (p = 0.753)
a NMB calculated at a ceiling ratio of £20,000 per QALY.
Notes
Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there
was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment
and the interaction between treatments are assumed to be the same for all participant subgroups, although the
absolute costs and absolute QALYs may vary, depending on participants’ sex, age and baseline utility.
TABLE 55 Regression analysis with an interaction term, including both NHS and broader societal perspective
Total societal costs (£),
mean (SE) QALYs, mean (SE) NMB (£),a mean (SE)
Best-practice advice 396 (159) 0.737 (0.014) 14,340 (344)
Injection plus best-practice advice 362 (118) 0.757 (0.011) 14,783 (266)
Progressive exercise 336 (108) 0.756 (0.012) 14,778 (285)
Injection plus progressive exercise 710 (247) 0.741 (0.012) 14,118 (366)
Injection simple effect –34 (137) (p = 0.813) 0.020 (0.015) (p = 0.183) 443 (359) (p = 0.218)
Exercise simple effect –60 (113) (p = 0.604) 0.019 (0.016) (p = 0.229) 438 (352) (p = 0.215)
Interaction: exercise by injection 408 (343) (p = 0.194) –0.035 (0.022) (p = 0.106) –1103 (583) (p = 0.049)
a NMB calculated at a ceiling ratio of £20,000 per QALY.
Notes
Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there
was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment
and the interaction between treatments are assumed to be the same for all patient subgroups, although the absolute
costs and absolute QALYs may vary, depending on patients’ sex, age and baseline utility.
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TABLE 56 Results of the worst-case scenario for training costs: regression analysis with an interaction term, including
imputation of missing values and adjustment for baseline utility, sex and age
Total costs (£),
mean (SE) QALYs, mean (SE) NMB (£),a mean (SE)
Best-practice advice 295 (69) 0.738 (0.018) 14,469 (384)
Injection plus best-practice advice 303 (28) 0.760 (0.016) 14,905 (327)
Progressive exercise 388 (29) 0.757 (0.019) 14,754 (383)
Injection plus progressive exercise 449 (45) 0.745 (0.016) 14,441 (327)
Injection simple effect 8 (58) (p = 0.737) 0.022 (0.022) (p = 0.301) 436 (449) (p = 0.326)
Exercise simple effect 92 (55) (p = 0.138) 0.019 (0.022) (p = 0.368) 285 (460) (p = 0.504)
Interaction: exercise by injection 53 (72) (p = 0.495) –0.035 (0.033) (p = 0.285) –749 (678) (p = 0.259)
a NMB calculated at a ceiling ratio of £20,000 per QALY.
Notes
Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there
was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment
and the interaction between treatments are assumed to be the same for all patient subgroups, although the absolute
costs and absolute QALYs may vary, depending on patients’ sex, age and baseline utility.
TABLE 57 Results of the best-case scenario: regression analysis with an interaction term, including imputation of missing
values and adjustment for baseline utility, sex and age
Total costs (£),
mean (SE) QALYs, mean (SE) NMB (£),a mean (SE)
Best-practice advice 149 (54) 0.737 (0.013) 14,584 (291)
Injection plus best-practice advice 160 (20) 0.757 (0.011) 14,986 (229)
Progressive exercise 195 (22) 0.756 (0.013) 14,920 (257)
Injection plus progressive exercise 255 (30) 0.741 (0.012) 14,572 (262)
Injection simple effect 11 (44) (p = 0.722) 0.021 (0.015) (p = 176) 403 (320) (p = 0.206)
Exercise simple effect 46 (44) (p = 0.299) 0.019 (0.016) (p = 0.217) 337 (325) (p = 0.297)
Interaction: exercise by injection 49 (57) (p = 0.399) –0.035 (0.022) (p = 0.108) –751 (457) (p = 0.100)
a NMB calculated at a ceiling ratio of £20,000 per QALY.
Notes
Values represent the mean (SE) for each group for males of age 55.46 years and a baseline utility of 0.653. As there
was assumed to be no interaction between baseline variables and treatments, the simple effects for each treatment
and the interaction between treatments are assumed to be the same for all patient subgroups, although the absolute
costs and absolute QALYs may vary, depending on patients’ sex, age and baseline utility.
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TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions











verified by MRI (usual
physiotherapy, n=23;
home exercise, n=20);
14 females : 24 males;























taught how to perform
exercises correctly
Exercises were aimed at
restoring neuromuscular
control at the shoulder,
as well as strength and
ROM. Contents of booklet
instructed patients on
the type of exercises,
repetitions, intensity,
training and rest phases,
and included a diary-type
weekly plan
Primary outcome
Average change in pain














Baseline: HEP mean 5.2 (2.9
SD), physiotherapy 5.0 (1.4)
2 months: HEP mean 3.5

















Baseline: HEP 53.8 (SD 19),
physiotherapy 58.6 (SD 21.8)




programme on the basis
of an illustrated booklet
with independent

















































in each group); 22
females : 24 males; mean
age 47.9 (9.9 SD) years
Supervised exercise
Up to 10 supervised
exercise treatments in
addition to home





exercises at home for
6 weeks
Primary outcome
SPADI [0 (best) to
100 (worse)]
Secondary outcomes
Average pain in the past
week (VAS 0–10), FABQ
physical activity scale
[0 (best) to 24 (worse)],
FABQ work scale [0




















mean 49 (SD 12), supervised
exercise mean 48 (SD 19)
6 weeks: home exercise
mean 32 (SD 15), supervised
exercise mean 32 (SD 20)
26 weeks: home exercise
mean 24 (SD 24), supervised
exercise mean 21 (SD18)
Average pain VAS
Baseline: home exercise
mean 6.3 (SD 1.3),
supervised exercise mean
5.9 (SD 2.2)
6 weeks: home exercise mean
4.3 (SD 2.2), supervised
exercise mean 4.1 (SD 2.1)
FABQ physical activity
Baseline: home exercise
mean 14 (SD 4), supervised
exercise mean 14.4 (SD 5)
6 weeks: home exercise





mean 20.6 (SD 7.1),
supervised exercise mean
19.3 (SD 12.4)
6 weeks: home exercise
mean 17.4 (SD 7.6),
supervised exercise mean
16.2 (SD 13.1)
Supervision of more than
the first session of a
6-week exercise regimen
did not cause significant
differences in pain and
disability in people with
subacromial impingement
No differences were













































































































































































































































































































TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions (continued )
Study Design/follow-up Participants Intervention Comparator Outcomes Number analysed Results Conclusion
Work status (on sick leave)
6 weeks: home exercise
7/21, supervised exercise
10/23
26 weeks: home exercise 4/18,
supervised exercise 3/21
No significant differences
between groups for work








No change: home exercise




Much worse: home exercise








Neither: home exercise 19%,
supervised exercise 9%
Dissatisfied: home exercise









































A total of 256 patients
with subacromial
impingement randomised
(n= 64 to each
treatment group, i.e. 128
to each exercise group);
52% female : 48% male;
mean age 54 years;

















Six to eight sessions
over 12 weeks plus daily
home exercise: stage 1,
hourly; stage 2, three or
four times per day; and










SIS, plus simple self-help
messages about pain
relief (including the
application of cold packs)
and activities. It includes

























Superior pain and function
scores for physiotherapist-
led exercise than exercise
leaflet at 6 months (adjusted
mean SPADI difference
between groups −8.23,
95% CI −14.14 to −2.32;
p< 0.001), but not at





than exercise leaflet at
6 weeks (odds ratio 15.81;
p< 0.001) and 6 months




than exercise leaflet at
6 weeks (odds ratio 7.56;
p= 0.001) and 6 months
(odds ratio 6.09; p= 0.002)
Physiotherapist-led
exercise for patients
with SIS leads to greater
improvements in pain
and function at 6 months,






































































































































































































































































































TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions (continued )















n= 42); 50% female;
mean age 55 years;
mean SPADI score 49
Usual physiotherapy





















hand weight over three
sets of 10–15 repetitions










SPADI at 3 months
Secondary outcomes
SPADI at 6 and 12months,
health-related quality of
life (SF-36)



















Mean SPADI score at
3 months 32.4 (SD 20.2) for
the self-managed group,
30.7 (SD 19.7) for usual
physiotherapy treatment
group; adjusted MD 3.2
(95% CI –6.0 to 12.4;
p= 0.49)
Adjusted MD at 6 months:
–6.2 (95% CI –16.1 to 3.6)
Adjusted MD at 12 months:
–6.0 (95% CI –19.7 to 7.6)
For the primary outcome
(i.e. the mean SPADI
score at 3 months),




treatment group. At 6














































control, n= 38); 58%
























no attendance at five
group sessions. In
interim, exercises to be
performed at home only
(unsupervised)
Follow-up at 5 weeks
only: shoulder pain VAS
(0–10), Constant–Murley










–0.1 (95% CI –1.0 to 0.7;
p= 0.723)
Intervention group, mean
change 3.0 (1.4 SD)




4.1 (95% CI –8.8 to 0.6;
p= 0.085)
Intervention group, mean
change –15.7 (SD 6.8)




14.7 (95% CI 7.7 to 21.7;
p< 0.001)
Intervention group, mean
change 26.3 (SD 14.3)






There were no differences,
however, in theVAS and
Constant–Murley scores



































































































































































































































































































TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions (continued )













n= 138); 75% female :
25% male; mean age 56
(12 SD) years
Standard physiotherapy
Ten exercise sessions in
6-week blocks (i.e.
minimum of 10 sessions

























recovery at 6 weeks
Secondary outcomes
Patient-perceived









test, DASH score and






7.2 (SD 1.8), supervised
mean 7.4 (SD 2)
6 weeks: unsupervised mean
5.3 (SD 2.7), supervised
mean 4.6 (SD 2.9)
12 weeks: unsupervised
mean 4.7 (SD 2.9),
supervised mean 4.3 (SD 3.1)
24 weeks: unsupervised
mean 4.9 (SD 3.4),
supervised mean 4.5 (SD 3.0)
Constant–Murley scale
Baseline: unsupervised mean
63.2 (SD 15.2), supervised
mean 60.9 (SD 17.2)
6 weeks: unsupervised mean
70.9 (SD 18.5), supervised
mean 71.8 (SD 19.1)
12 weeks: unsupervised








with a painful shoulder is
no different with regard
to function, quality of
life or disability in short
and medium term.
Similarly, it is not worse
with regard to patient
perceived recovery in
the short term, but in
the medium term (i.e.




































Study Design/follow-up Participants Intervention Comparator Outcomes Number analysed Results Conclusion
24 weeks: unsupervised





50.3 (SD 23.1), supervised
mean 53.8 (SD 19.7)
6 weeks: unsupervised mean
38.8 (SD 21.2), supervised
mean 39.8 (SD 23)
12 weeks: unsupervised

















































































































































































































































































































TABLE 58 Summary of trials comparing the effects of supervised vs. unsupervised exercise interventions (continued )








randomised (VBR, n= 16;
physiotherapy, n= 17);
10 females : 20 males;










group three sets of
10 repetitions per day







participation of a patient.
Exercises performed three
sets of 10 repetitions per
day for 6 weeks. Patients
attended two sessions
with the physiotherapist
during the 6-week period
to observe ‘condition of
the patients, accuracy
of the exercises given,
and the clarity of the
commands...but no
feedback was given to
not interfere with the
effectiveness of the
program’114 (unsupervised)





[0 (worst) to 100 (best)];
participant global rating
of change [one (worst) to
five (best) on a Likert
scale]; shoulder ROM
30 patients
analysed (n= 15 in
each group)
Rest pain VAS
Baseline: VBR mean 1.13
(SD 1.8), physiotherapy
mean 3.47 (SD 2.74)
6 weeks: VBR mean 0
(SD 0), physiotherapy mean
0.13 (SD 0.35)
Activity pain VAS:
Baseline: VBR mean 6.47
(SD 1.18), physiotherapy
mean 6.87 (SD 1.72)
6 weeks: VBR mean 1.47
(SD 0.99), physiotherapy
mean 1.27 (SD 0.79)
Night pain VAS
Baseline: VBR mean 5.13
(SD 2.56), physiotherapy
mean 5.6 (SD 2.06)
6 weeks: VBR mean 0.27
(SD 0.79), physiotherapy
mean 0.07 (SD 0.25)
DASH
Baseline: VBR mean 32.68
(SD 14.48), physiotherapy
mean 37.45 (SD 18.25)
6 weeks: VBR mean 5.39
(SD 5.67), physiotherapy





and quality of life for the
conservative treatment
of partial rotator cuff
tears. In addition, there


































Study Design/follow-up Participants Intervention Comparator Outcomes Number analysed Results Conclusion
ASES
Baseline: VBR mean 64.51
(SD 11.47), physiotherapy
mean 54.18 (SD 15.2)
6 weeks: VBR mean 95.3
(SD 4.51), physiotherapy





6 weeks: VBR 51.64
(SD 3.49), physiotherapy
mean 52.04 (SD 3.61)
SF-12 mental
Baseline: VBR mean 33.2
(SD 4.79), physiotherapy
mean 32.71 (SD 5.81)
6 weeks: VBR mean 38.06
(SD 3.49), physiotherapy
mean 38.28 (SD 3.38)
Global rating of change
Much better: VBR 10/15
(66.7%), physiotherapy 9/15
(60%)
Better: VBR 5/15 (33.3%),
physiotherapy 6/15 (40%)
ADL, activities of daily living; AROM, active range of shoulder movement; ASES, American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form; DASH, Disabilities of the Arm, Shoulder and Hand;
HEP, home exercise programme; MRI, magnetic resonance imaging; QuickDASH, Disabilities of the Arm, Shoulder and Hand, abbreviated version; RCT, randomised controlled trial; ROM, range of shoulder movement;


































































































































































































































































































TABLE 59 Studies comparing subacromial corticosteroid injection with no injection or placebo injection








Mean age: one CSI –
79 years; no injection–










(2) No injection (n = 20)
No treatment
(3) Two unguided CSIs
(n = 20)
Triamcinolone
acetonide (40 mg) at
baseline and 21 days
later




CSI, n = 20; no
CSI, n = 20
Intra-articular injection
of triamcinolone
improved pain relief at
3 months. There was
no difference between












Mean age: CSI – 51 years;
placebo – 55 years;




DoS: CSI = 8.6;
placebo = 8.5;
NSAID – 7.7
Unguided CSI (n = 20)
1 ml of 80 mg/ml
triamcinolone with
















injection of 3 ml of
0.5% lignocaine








at 4 weeks compared
with placebo injection.







2 weeks, 6 weeks,
3 months and
6 months
Mean age: CSI – 50 years;




DoS: CSI = 3.8 (years);
placebo = 2.5 (years)
Unguided CSI (n = 31)
4 ml of 2% xylocaine
without adrenaline
combined with




5 ml of 2% xylocaine
without adrenaline
(1) Shoulder pain and
function (ASES score)
(2) Shoulder pain VAS
score (0–100)
(3) Disease-specific
quality of life (WORC)


















































DoS: CSI = 8.1;
placebo = 3.1








3 ml of lidocaine 1%








study groups in the
change in the range of
shoulder movement at
3 and 6 months of
follow-up. Subacromial
injection of a mixture
of methylprednisolone








CSI – 33 weeks;
placebo –
28 weeks
Mean age: CSI – 56 years;






Unguided CSI (n = 19)
2 ml of 40 mg/ml
triamcinolone





6 ml of 1% lidocaine
without adrenaline




NR The mean pain score
after the injection was
1.2 points for the
corticosteroid group
and 2.0 points for the
control group. This
difference was significant
(p< 0.005).The use of
such injections can
substantially decrease
pain and increase the









Mean age: CSI – 62 years;





DoS: CSI = 15.9;
placebo = 10




1% in 1 ml
Placebo injection
(n = 21)




This pilot trial showed
that it is feasible to
recruit participants
with shoulder pain in
the primary care








































































































































































































































































































TABLE 59 Studies comparing subacromial corticosteroid injection with no injection or placebo injection (continued )







Mean age: CSI 40 mg –
51 years; placebo –





DoS: CSI 40 mg = 8.9;
placebo = 8.6;
CSI 20 mg = 13
(1) Guided CSI 40 mg
(n = 30)





4 ml of 1% lidocaine




and 2ml of 1% lidocaine




CSI 40 mg, n = 27;
placebo, n= 27
In groups 1 (40 mg
of triamcinolone
acetonide) and 2
(20 mg of triamcinolone
acetonide) there were
significant differences
in mean changes post
treatment at weeks 2, 4
and 8 compared with
pre treatment (paired
t-test, all p=0.001),
whereas in group 3
(placebo) there was no
significant difference post
treatment at weeks 2, 4










Mean age: CSI – 52 years;





DoS: 62% of CSI group
mean > 26 weeks; 71%




2 ml of triamcinolone
acetonide 10mg/ml




2 ml of NaCl 0.9% with
8 ml of lidocaine 1%
(3) HA injection (n= 51)






(2) Shoulder pain VAS
scale
(3) Shoulder function





in terms of pain reduction,

















































1 cc of 40 mg/ml
triamcinolone with 3 cc
of 1% lidocaine plus
placebo naproxen pill




4 cc of 1% lidocaine
plus placebo naproxen
pill two times per day
for 30 days
(3) Unguided CSI plus
NSAID (n = 25)
1 cc of 40 mg/ml
triamcinolone with 3 cc
of 1% lidocaine plus
naproxen pill (500 mg)
two times per day for
30 days
(4) Placebo injection
plus NSAID (n= 25)
4 cc of 1% lidocaine
plus naproxen (500 mg)






CSI, n = 25;
placebo, n= 25
Both triamcinolone
(p = 0.00005) and
naproxen (p = 0.02) are
superior to placebo in




































































































































































































































































































TABLE 59 Studies comparing subacromial corticosteroid injection with no injection or placebo injection (continued )







Mean age: CSI – 56 years;




DoS: CSI = 5 weeks;
placebo = 4 weeks
Unguided CSI (n = 29)
40 mg of
methylprednisolone




Lignocaine 1% (1 ml)
(1) Shoulder pain NR Although steroid-
treated patients seem
to have improved to a
greater extent than
lignocaine-treated
patients at 2 weeks,
this was not statistically
significant. This small
improvement was not







Mean age: CSI – 61 years;




DoS: CSI = 4.1;
placebo = 4.6
Unguided CSI (n = 12)
80 mg of
methylprednisolone




4 ml of saline (0.9%)
(1) Shoulder pain VAS
(0–10)
CSI, n = 12;
placebo, n= 13
The VAS score in group
1 (steroid) improved
by a mean of 2.72
between weeks 0 and
8, whereas group 2
(placebo) showed a
mean improvement
of 1.16 in the same
period. This difference
was not statistically
significant (p > 0.05)
ASES, American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form; CSI, corticosteroid injection; DoS, duration of symptoms; HA, hyaluronic acid; NaCl, sodium
chloride; NR, not reported; NSAID, non-steroidal anti-inflammatory drug; OSS, Oxford Shoulder Score; RCT, randomised controlled trial; SDQ, Strengths and Difficulties
Questionnaire; VAS, visual analogue scale; WORC, Western Ontario Rotator Cuff.
Note

































Medline (Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Ovid MEDLINE® Daily and Ovid MEDLINE®)
Date range searched: 1946 to present.
Date searched: June 2020.
Search strategy
1. Shoulder Pain/ (4378)
2. Shoulder Impingement Syndrome/ (1655)
3. Rotator Cuff/and Tendinopathy/ (477)
4. Shoulder/and Bursitis/or Tendinopathy/) (438)
5. ((shoulder* or rotator cuff or subacromial or sub-acromial) adj5 (bursitis or impinge* or tendinitis
or tendonitis or tendinopathy or pain*)).ti,ab. (12,483)
6. 1 or 2 or 3 or 4 or 5 (14,765)
7. (Cortisone/or Glucocorticoids/) and Injections/ (1354)
8. ((subacromial or sub-acromial or corticosteroid* or cortisone or glucocorticoid*) adj5 inject*).ti,ab.
(5093)
9. CSI.ti,ab. (3029)
10. 7 or 8 or 9 (9227)
11. 6 and 10 (480)
12. randomized controlled trial.pt. (477,274)
13. controlled clinical trial.pt. (92,948)
14. (randomized or randomised).ab. (522,076)
15. placebo.ab. (195,900)




20. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (4,404,372)
21. exp animals/not humans.sh. (4,554,611)
22. 20 not 21 (3,810,278)
23. 11 and 22 (320).
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